<html lang="en" class="pb-page js" data-request-id="94d6468482d1decb-SJC"><head data-pb-dropzone="head"><style type="text/css" nonce="94d6468482d1decb-SJC">@font-face {font-family: "Source Sans Pro";src: url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.ttf) format("truetype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.woff) format("woff"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.otf) format("opentype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.eot) format("embedded-opentype");}.truste_cursor_pointer {cursor: pointer;}.truste_border_none {border: none;}.truste_accessible_link {font-family: "Source Sans Pro", sans-serif;color: #1D4ED8;font-size: 14px;font-weight: 600;text-decoration: underline;}.truste_accessible_link:hover {color: #1D4ED8;text-decoration: none !important;}.truste_accessible_link:focus-visible {outline: none;border-radius: 4px;box-shadow: 0 0 0 1px #FFFFFF, 0 0 0 4px #3699F1;}</style><script src="https://ssl-cdn.janraincapture.com/widget_data/flow.js:7h8bznq6j7bvyvzqcrwvyp8dfb:en-US:20240514181256512029:standard" type="text/javascript"></script><script src="https://cssjs.nejm.org/akamai/capture:login" type="text/javascript"></script><script src="https://ssl-widget-cdn.rpxnow.com/translations/login/en-US" type="text/javascript"></script><script type="text/javascript" id="janrainAuthWidget" src="https://cssjs.nejm.org/akamai/mms-prod.js"></script><script type="text/javascript" src="https://www.nejm.org/ZumhSdRI8Nv2sVcBSEV4arhUMY5Tc6vfFyRvEs1z2ZKnSn4I-vFiMZAZ4VRyUvTqlxMfyF_OaVHJOhwXNSwO2w=="></script>
            

<meta charset="UTF-8">






    
        
            
        
    
        
            
        
    
        
            
        
    
        
            
        
    
        
    
        
    
        
            
                
                
<title>Capmatinib in MET Exon 14–Mutated or MET-Amplified Non–Small-Cell Lung Cancer | New England Journal of Medicine</title>





                
            
        
    







    
        
            
        
    
        
            
        
    
        
            
                
                



                
            
        
    
        
            
        
    
        
    
        
    
        
            
        
    











    








    

    
    

    
    
    
    
        
            
                <link rel="stylesheet" type="text/css" href="/wro/1125813~article-metrics.css">
            
            
            
        
    

    
    
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_nejm_1-994b0160d1eb33dc79517ef0295aab1b.ico" type="image/x-icon">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_16-4aa032aa775940f725817b7ff42f0e2c.png" type="image/png" sizes="16x16">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_32-0a94fa44823476ffa0bb15bdb320fb34.png" type="image/png" sizes="32x32">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_152-d6c3522864a8e483996b7e9c132c901a.png" sizes="152x152">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_180-f2538afc53a365d4cd3f10ab73c56aad.png" sizes="180x180">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_167-8e888012bbdd31a00c3e54bc5b8ca5b6.png" sizes="167x167">
        
    

    
    
            <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-5b89b331018866a4a965.css" media="all">
        <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/print-5b89b331018866a4a965.css" media="print">
           <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css" media="all" id="article-style-sheet">
    
        <script nonce="94d6468482d1decb-SJC">
        try {
            document.documentElement.classList.add('js');
        } catch (e) {
        }
    </script>
     
    

















    
        
            
                
                
                
                    
                    <!-- TrustArc Scripts -->
<script async="async" src="https://consent.trustarc.com/notice?domain=nejm.com&amp;c=teconsent&amp;js=nj&amp;noticeType=bb&amp;gtm=1&amp;text=true&amp;pcookie" crossorigin="" id="truste_0.09206752390956252"></script>
<script src="https://consent.trustarc.com/autoblockasset/core.min.js?domain=nejm.com"></script>
<script src="https://consent.trustarc.com/autoblockoptout?domain=nejm.com"></script>
<!-- /TrustArc Scripts -->
<!-- BlueConic Scripts -->
<script src="https://bc.nejm.org/script.js"></script>
    <!-- /BlueConic Scripts -->
<!-- Printing Meta Tags -->
    <meta name="articleType" content="Original Article">
<meta name="Specialties" content="Hematology/Oncology">
<meta name="topics" content="Treatments in Oncology|Lung Cancer">
<meta name="articleCategory" content="Research"><script type="text/javascript">var mmsData = {"access":{"isFreeCountry":"n"},"ad":{"category":"article"},"imageChallenge":{"id":null},"article":{"doi":"10.1056/NEJMoa2002787","title":"Capmatinib in MET Exon 14–Mutated or MET-Amplified Non–Small-Cell Lung Cancer","category":"Research","type":"Original Article","topics":"Treatments in Oncology|Lung Cancer","specialties":"Hematology/Oncology","seriesTitle":"","viewType":"Full","age":"2Years-1990","issueDate":"2020-09-03T00:00Z","isFree":"y","broadTopics":"","perspectiveTopics":"","granularTopics":"","methodologicalArea":"","isOnlineFirst":"n","isCurrentIssue":"n","metaTags":"\u003cmeta name\u003d\"articleType\" content\u003d\"Original Article\"/\u003e\n\u003cmeta name\u003d\"Specialties\" content\u003d\"Hematology/Oncology\"/\u003e\n\u003cmeta name\u003d\"topics\" content\u003d\"Treatments in Oncology|Lung Cancer\"/\u003e\n\u003cmeta name\u003d\"articleCategory\" content\u003d\"Research\"/\u003e"},"page":{"activity":"showFullText","url":"www.nejm.org/doi/full/10.1056/NEJMoa2002787","viewType":"desktop","journal":"NEJM"},"user":{"ucid":null,"audienceSegment":null,"specialtyGroupCode":null,"meterCountRemaining":null,"totalMeterCount":null},"object":[]};</script>
    <script type="text/javascript">var mmsDataAdd = {"user":{"customerType":"null","accessInstitutionID":"null"}};</script>
    <!-- Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- placeholder id=null, description=Adobe-Target-Prehiding-Snippet --><!--
  Adobe Target - Prehiding Snippet
  v2.0.0
-->
<script nonce="94d6468482d1decb-SJC">
function tgtNoFlicker(e,n,t,o,i,c,l,r){function d(){return n.getElementsByTagName("head")[0]}function a(e,t){if(e){var o=n.getElementById(t);o&&e.removeChild(o)}}function f(e,o){!function(e,t,o){if(e){var i=n.createElement("style");i.id=t,i.innerHTML=o,e.appendChild(i)}}(d(),t,e),setTimeout(function(){a(d(),t)},o)}var m;n.location.href.indexOf(c)>-1?f(l,r):f(o,i),n.location.href.indexOf("mboxDisable")>-1?(a(d(),t),console.log("[TARGET] - Disabled, removing prehiding style")):(m=function(e){e&&(a(d(),t),console.log("[TARGET] - Blocked, removing prehiding style"))},fetch("//cdn.tt.omtrdc.net/cdn/target-vec.js",{method:"HEAD",mode:"no-cors"}).then(e=>m(!1)).catch(e=>m(!0)))}

tgtNoFlicker(window, document, 'at-body-style', 'div[data-location-name="Anonymous Module"], div[data-location-name="Anonymous Banner"], main > div.page-body > div > div > div > div.col-md-2-3.o-col.o-col--primary > div[class*="u-hide"], main > div.page-body > div > div > div > div.col-md-1-3.o-col.o-col--secondary > aside, header > h1#mainContent, a.m-article__link[href*="/10.1056/NEJMoa2116747"] > span.m-article__blurb > p, li.g-nejm-group__user-tool-secondary {opacity: 0 !important}', 3000);

tgtNoFlicker(window, document, 'at-mbox-style', '.N-ad-global-top-right, #N-ad-myNEJM-contextual-top, .N-ad-recentArticles, #N-ad-article-rightRail-1, #N-ad-siteWide-rightRail-1, #N-ad-imageChallenge-rightRail-2 {opacity: 0 !important}', 3000);
</script><!-- /Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- Launch Header Embed Code -->
    <script src="//assets.adobedtm.com/launch-ENcd6450fae3ae4870becbe6a2b01ab2e1.min.js" async="" type="ta-blocked" data-ta-blocked="1"></script>
    <!-- /Launch Header Embed Code -->

                    
                
            
        
    
        
            
                
                
                
                    
                    <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/"><meta name="citation_journal_title" content="New England Journal of Medicine"><meta name="dc.Title" content="Capmatinib in MET Exon 14–Mutated or MET-Amplified Non–Small-Cell Lung Cancer"><meta name="dc.Creator" content="Jürgen Wolf"><meta name="dc.Creator" content="Takashi Seto"><meta name="dc.Creator" content="Ji-Youn Han"><meta name="dc.Creator" content="Noemi Reguart"><meta name="dc.Creator" content="Edward B. Garon"><meta name="dc.Creator" content="Harry J.M. Groen"><meta name="dc.Creator" content="Daniel S.W. Tan"><meta name="dc.Creator" content="Toyoaki Hida"><meta name="dc.Creator" content="Maja de Jonge"><meta name="dc.Creator" content="Sergey V. Orlov"><meta name="dc.Creator" content="Egbert F. Smit"><meta name="dc.Creator" content="Pierre-Jean Souquet"><meta name="dc.Creator" content="Johan Vansteenkiste"><meta name="dc.Creator" content="Maximilian Hochmair"><meta name="dc.Creator" content="Enriqueta Felip"><meta name="dc.Creator" content="Makoto Nishio"><meta name="dc.Creator" content="Michael Thomas"><meta name="dc.Creator" content="Kadoaki Ohashi"><meta name="dc.Creator" content="Ryo Toyozawa"><meta name="dc.Creator" content="Tobias R. Overbeck"><meta name="dc.Creator" content="Filippo de Marinis"><meta name="dc.Creator" content="Tae-Min Kim"><meta name="dc.Creator" content="Eckart Laack"><meta name="dc.Creator" content="Anna Robeva"><meta name="dc.Creator" content="Sylvie Le Mouhaer"><meta name="dc.Creator" content="Maeve Waldron-Lynch"><meta name="dc.Creator" content="Banu Sankaran"><meta name="dc.Creator" content="O. Alejandro Balbin"><meta name="dc.Creator" content="Xiaoming Cui"><meta name="dc.Creator" content="Monica Giovannini"><meta name="dc.Creator" content="Mikhail Akimov"><meta name="dc.Creator" content="Rebecca S. Heist"><meta name="dc.Description" content="Among patients with non–small-cell lung cancer (NSCLC), MET exon 14 skipping mutations occur in 3 to 4% and MET amplifications occur in 1 to 6%. Capmatinib, a selective inhibitor of the MET recepto..."><meta name="Description" content="Among patients with non–small-cell lung cancer (NSCLC), MET exon 14 skipping mutations occur in 3 to 4% and MET amplifications occur in 1 to 6%. Capmatinib, a selective inhibitor of the MET recepto..."><meta name="dc.Publisher" content="Massachusetts Medical Society"><meta name="dc.Date" scheme="WTN8601" content="2020-09-03"><meta name="dc.Type" content="research-article"><meta name="dc.Format" content="text/HTML"><meta name="dc.Identifier" scheme="doi" content="10.1056/NEJMoa2002787"><meta name="dc.Identifier" scheme="publisher-id" content="NJ202009033831011"><meta name="dc.Language" content="EN"><meta name="dc.Relation" content="10.1056/NEJMoa2004407"><meta name="dc.Coverage" content="world"><meta name="dc.Rights" content="Copyright © 2020 Massachusetts Medical Society. All rights reserved.">




<link rel="meta" type="application/atom+xml" href="https://doi.org/10.1056%2FNEJMoa2002787">
<link rel="meta" type="application/rdf+json" href="https://doi.org/10.1056%2FNEJMoa2002787">
<link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1056%2FNEJMoa2002787">


                    
                
            
        
    
        
            
                
                
                
                
                
            
        
    
        
            
                
                
                
                    
                    





<meta name="robots" content="noarchive">





    





    
    
        
        <meta name="twitter:title" content="Capmatinib in MET Exon 14–Mutated or MET-Amplified Non–Small-Cell Lung Cancer | NEJM">
        <meta property="og:title" content="Capmatinib in MET Exon 14–Mutated or MET-Amplified Non–Small-Cell Lung Cancer | NEJM">
    


    <meta property="og:type" content="article">


    
    
        <meta property="og:url" content="https://www.nejm.org/doi/full/10.1056/NEJMoa2002787">
    
    


    
    
        <meta property="og:image" content="https://www.nejm.org/cms/asset/6bdb0b9c-7e03-4610-a745-acef42916681/nejmoa2002787_f1.jpg">
        <meta name="twitter:image" content="https://www.nejm.org/cms/asset/6bdb0b9c-7e03-4610-a745-acef42916681/nejmoa2002787_f1.jpg">
    



    <meta property="og:site_name" content="The New England Journal of Medicine">


    
    
        
        <meta property="og:description" content="Among patients with non–small-cell lung cancer (NSCLC), MET exon 14 skipping mutations
occur in 3 to 4% and MET amplifications occur in 1 to 6%. Capmatinib, a selective
inhibitor of the MET recepto...">
        <meta name="twitter:description" content="Among patients with non–small-cell lung cancer (NSCLC), MET exon 14 skipping mutations
occur in 3 to 4% and MET amplifications occur in 1 to 6%. Capmatinib, a selective
inhibitor of the MET recepto...">
    


    
    
        <meta property="og:image:width" content="2180">
    


    
    
        <meta property="og:image:height" content="3438">
    


    <meta name="twitter:card" content="summary">


    <meta name="twitter:site" content="@NEJM">


<meta name="viewport" content="width=device-width,initial-scale=1"><meta name="publication_doi" content="10.1056/NEJMoa2002787">


    















                    
                
            
        
    
        
    
        
    
        
            
                
                
                
                
                
            
        
    




<meta name="format-detection" content="telephone=no">

<meta http-equiv="X-UA-Compatible" content="IE=edge">
    




    
        
        
        <link rel="canonical" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2002787">
    
    







<meta name="pbContext" content=";issue:issue:doi\:10.1056/nejm_2020.383.issue-10;requestedJournal:journal:nejm;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:MMS NextGen Website Group;pageGroup:string:Publication Pages;article:article:doi\:10.1056/NEJMoa2002787;subPage:string:Full Text;website:website:mms-site;journal:journal:nejms">
        <link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-933-8e181dff8b36ea01dc4c.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-34-6ea546d794fb7a1cea52.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-743-ddd329e1530654ec0846.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-305-9eee37798fdfe5196307.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-388-bb098c62445f518c0b46.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-556-8e58ca05fb5497e541ef.css"><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/0-dfd243c732a07d3608f6.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/7-10d355ba95f7ec1fddf2.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/11-04bf2a0da30146b4a5d0.js"></script><script src="https://static.addtoany.com/menu/modules/core.pt5ow5lr.js" type="module"></script><link rel="preconnect" href="https://use.typekit.net"><meta http-equiv="P3P" content="CP=&quot;NOI DSP ADM OUR IND OTC&quot;"><style type="text/css">.a2a_hide{display:none}.a2a_logo_color{background-color:#0166ff}.a2a_menu,.a2a_menu *{-moz-box-sizing:content-box;-webkit-box-sizing:content-box;box-sizing:content-box;float:none;margin:0;padding:0;position:static;height:auto;width:auto}.a2a_menu{border-radius:6px;display:none;direction:ltr;background:#FFF;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;color:#000;line-height:12px;border:1px solid #CCC;vertical-align:baseline;overflow:hidden}.a2a_mini{min-width:200px;position:absolute;width:300px;z-index:9999997}.a2a_overlay{display:none;background:#616c7deb;backdrop-filter:blur(4px);-webkit-backdrop-filter:blur(4px);position:fixed;top:0;right:0;left:0;bottom:0;z-index:9999998;-webkit-tap-highlight-color:transparent;transition:opacity .14s,backdrop-filter .14s}.a2a_full{background:#FFF;border:1px solid #FFF;box-shadow:#2a2a2a1a 0 0 20px 10px;height:auto;height:calc(320px);top:15%;left:50%;margin-left:-320px;position:fixed;text-align:center;width:640px;z-index:9999999;transition:transform .14s,opacity .14s}.a2a_full_footer,.a2a_full_header,.a2a_full_services{border:0;margin:0;padding:12px;box-sizing:border-box}.a2a_full_header{padding-bottom:8px}.a2a_full_services{height:280px;overflow-y:scroll;padding:0 12px;-webkit-overflow-scrolling:touch}.a2a_full_services .a2a_i{display:inline-block;float:none;width:181px;width:calc(33.334% - 18px)}div.a2a_full_footer{font-size:12px;text-align:center;padding:8px 14px}div.a2a_full_footer a,div.a2a_full_footer a:visited{display:inline;font-size:12px;line-height:14px;padding:8px 14px}div.a2a_full_footer a:focus,div.a2a_full_footer a:hover{background:0 0;border:0;color:#0166FF}div.a2a_full_footer a span.a2a_s_a2a,div.a2a_full_footer a span.a2a_w_a2a{background-size:14px;border-radius:3px;display:inline-block;height:14px;line-height:14px;margin:0 3px 0 0;vertical-align:top;width:14px}.a2a_modal{height:0;left:50%;margin-left:-320px;position:fixed;text-align:center;top:15%;width:640px;z-index:9999999;transition:transform .14s,opacity .14s;-webkit-tap-highlight-color:transparent}.a2a_modal_body{background:0 0;border:0;font:24px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;position:relative;height:auto;width:auto}.a2a_thanks{color:#fff;height:auto;margin-top:20px;width:auto}.a2a_thanks>div:first-child{margin:0 0 40px 0}.a2a_thanks div *{height:inherit}#a2a_copy_link{background:#FFF;border:1px solid #FFF;cursor:pointer;margin-top:15%}label.a2a_s_link#a2a_copy_link_icon,label.a2a_w_link#a2a_copy_link_icon{background-size:48px;border-radius:0;display:inline-block;height:48px;left:0;line-height:48px;margin:0 3px 0 0;position:absolute;vertical-align:top;width:48px}#a2a_modal input#a2a_copy_link_text{background-color:transparent;border:0;color:#2A2A2A;cursor:pointer;font:inherit;height:48px;left:62px;max-width:initial;min-height:auto;padding:0;position:relative;width:564px;width:calc(100% - 76px)}#a2a_copy_link_copied{background-color:#0166ff;color:#fff;display:none;font:inherit;font-size:16px;margin-top:1px;padding:3px 8px}@media (forced-colors:active){.a2a_color_buttons a,.a2a_svg{forced-color-adjust:none}}@media (prefers-color-scheme:dark){.a2a_menu a,.a2a_menu a.a2a_i,.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more,i.a2a_i{border-color:#2a2a2a!important;color:#fff!important}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover,.a2a_menu_find_container{border-color:#444!important;background-color:#444!important}.a2a_menu:not(.a2a_thanks){background-color:#2a2a2a;border-color:#2a2a2a}.a2a_menu_find{color:#fff!important}.a2a_menu label.a2a_s_find svg{background-color:transparent!important}.a2a_menu label.a2a_s_find svg path{fill:#fff!important}.a2a_full{box-shadow:#00000066 0 0 20px 10px}.a2a_overlay{background-color:#373737eb}}@media print{.a2a_floating_style,.a2a_menu,.a2a_overlay{visibility:hidden}}@keyframes a2aFadeIn{from{opacity:0}to{opacity:1}}.a2a_starting{opacity:0}.a2a_starting.a2a_full,.a2a_starting.a2a_modal{transform:scale(.8)}@media (max-width:639px){.a2a_full{border-radius:0;top:15%;left:0;margin-left:auto;width:100%}.a2a_modal{left:0;margin-left:10px;width:calc(100% - 20px)}}@media (min-width:318px) and (max-width:437px){.a2a_full .a2a_full_services .a2a_i{width:calc(50% - 18px)}}@media (max-width:317px){.a2a_full .a2a_full_services .a2a_i{width:calc(100% - 18px)}}@media (max-height:436px){.a2a_full{bottom:40px;height:auto;top:40px}}@media (max-height:550px){.a2a_modal{top:30px}}@media (max-height:360px){.a2a_modal{top:20px}.a2a_thanks>div:first-child{margin-bottom:20px}}.a2a_menu a{color:#0166FF;text-decoration:none;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;line-height:14px;height:auto;width:auto;outline:0}.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more{color:#0166FF}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover{color:#2A2A2A;border-color:#EEE;border-style:solid;background-color:#EEE;text-decoration:none}.a2a_menu label.a2a_s_find{background-size:24px;height:24px;left:8px;pointer-events:auto;position:absolute;top:7px;width:24px}.a2a_menu label.a2a_s_find svg{background-color:#FFF}.a2a_menu label.a2a_s_find svg path{fill:#CCC}#a2a_menu_container{display:inline-block}.a2a_menu_find_container{border:1px solid #CCC;border-radius:6px;padding:2px 24px 2px 0;position:relative;text-align:left}.a2a_cols_container .a2a_col1{overflow-x:hidden;overflow-y:auto;-webkit-overflow-scrolling:touch}#a2a_modal input,#a2a_modal input[type=text],.a2a_menu input,.a2a_menu input[type=text]{display:block;background-image:none;box-shadow:none;line-height:100%;margin:0;outline:0;overflow:hidden;padding:0;-moz-box-shadow:none;-webkit-box-shadow:none;-webkit-appearance:none}#a2afeed_find_container input,#a2afeed_find_container input[type=text],#a2apage_find_container input,#a2apage_find_container input[type=text]{background-color:transparent;border:0;box-sizing:content-box;color:#2A2A2A;float:none;font:inherit;font-size:16px;height:28px;line-height:20px;left:38px;outline:0;margin:0;max-width:initial;min-height:initial;padding:2px 0;position:relative;width:99%}.a2a_clear{clear:both}.a2a_svg{background-repeat:no-repeat;display:block;overflow:hidden;height:32px;line-height:32px;padding:0;pointer-events:none;width:32px}.a2a_svg svg{background-repeat:no-repeat;background-position:50% 50%;border:none;display:block;left:0;margin:0 auto;overflow:hidden;padding:0;position:relative;top:0;width:auto;height:auto}a.a2a_i,i.a2a_i{display:block;float:left;border:1px solid #FFF;line-height:24px;padding:6px 8px;text-align:left;white-space:nowrap;overflow:hidden;text-overflow:ellipsis;width:132px}a.a2a_i span,a.a2a_more span{display:inline-block;overflow:hidden;vertical-align:top}a.a2a_i .a2a_svg{margin:0 6px 0 0}a.a2a_i .a2a_svg,a.a2a_more .a2a_svg{background-size:24px;height:24px;line-height:24px;width:24px}a.a2a_sss:hover{border-left:1px solid #CCC}a.a2a_more{border-bottom:1px solid #FFF;border-left:0;border-right:0;line-height:24px;margin:6px 0 0;padding:6px;-webkit-touch-callout:none}a.a2a_more span{height:24px;margin:0 6px 0 0}.a2a_kit .a2a_svg{background-repeat:repeat}.a2a_default_style a:empty,.a2a_flex_style a:empty,.a2a_floating_style a:empty,.a2a_overlay_style a:empty{display:none}.a2a_color_buttons a,.a2a_floating_style a{text-decoration:none}.a2a_default_style:not(.a2a_flex_style) a{float:left;line-height:16px;padding:0 2px}.a2a_default_style a:hover .a2a_svg,.a2a_floating_style a:hover .a2a_svg,.a2a_overlay_style a:hover .a2a_svg svg{opacity:.7}.a2a_overlay_style.a2a_default_style a:hover .a2a_svg{opacity:1}.a2a_default_style .a2a_count,.a2a_default_style .a2a_svg,.a2a_floating_style .a2a_svg,.a2a_menu .a2a_svg,.a2a_vertical_style .a2a_count,.a2a_vertical_style .a2a_svg{border-radius:4px}.a2a_default_style .a2a_counter img,.a2a_default_style .a2a_dd,.a2a_default_style .a2a_svg{float:left}.a2a_default_style .a2a_img_text{margin-right:4px}.a2a_default_style .a2a_divider{border-left:1px solid #000;display:inline;float:left;height:16px;line-height:16px;margin:0 5px}.a2a_kit a{cursor:pointer;transition:none}.a2a_floating_style{background-color:#fff;border-radius:6px;position:fixed;z-index:9999995}.a2a_overlay_style{z-index:2147483647}.a2a_floating_style,.a2a_overlay_style{animation:a2aFadeIn .2s ease-in;padding:4px}.a2a_vertical_style:not(.a2a_flex_style) a{clear:left;display:block;overflow:hidden;padding:4px}.a2a_floating_style.a2a_default_style{bottom:0}.a2a_floating_style.a2a_default_style a,.a2a_overlay_style.a2a_default_style a{padding:4px}.a2a_count{background-color:#fff;border:1px solid #ccc;box-sizing:border-box;color:#2a2a2a;display:block;float:left;font:12px Arial,Helvetica,sans-serif;height:16px;margin-left:4px;position:relative;text-align:center;width:50px}.a2a_count:after,.a2a_count:before{border:solid transparent;border-width:4px 4px 4px 0;content:"";height:0;left:0;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:50%;width:0}.a2a_count:before{border-right-color:#ccc}.a2a_count:after{border-right-color:#fff;margin-left:-3px}.a2a_count span{animation:a2aFadeIn .14s ease-in}.a2a_vertical_style .a2a_counter img{display:block}.a2a_vertical_style .a2a_count{float:none;margin-left:0;margin-top:6px}.a2a_vertical_style .a2a_count:after,.a2a_vertical_style .a2a_count:before{border:solid transparent;border-width:0 4px 4px 4px;content:"";height:0;left:50%;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:0;width:0}.a2a_vertical_style .a2a_count:before{border-bottom-color:#ccc}.a2a_vertical_style .a2a_count:after{border-bottom-color:#fff;margin-top:-3px}.a2a_color_buttons .a2a_count,.a2a_color_buttons .a2a_count:after,.a2a_color_buttons .a2a_count:before,.a2a_color_buttons.a2a_vertical_style .a2a_count:after,.a2a_color_buttons.a2a_vertical_style .a2a_count:before{background-color:transparent;border:none;color:#fff;float:none;width:auto}.a2a_color_buttons.a2a_vertical_style .a2a_count{margin-top:0}.a2a_flex_style{display:flex;align-items:flex-start;gap:0}.a2a_default_style.a2a_flex_style{left:0;right:0;width:100%}.a2a_vertical_style.a2a_flex_style{flex-direction:column;top:0;bottom:0}.a2a_flex_style a{display:flex;justify-content:center;flex:1;padding:4px}.a2a_flex_style.a2a_vertical_style a{flex-direction:column}.a2a_floating_style.a2a_color_buttons,.a2a_floating_style.a2a_flex_style{border-radius:0;padding:0}.a2a_floating_style.a2a_default_style.a2a_flex_style{bottom:0}.a2a_kit.a2a_flex_style .a2a_counter img,.a2a_kit.a2a_flex_style .a2a_dd,.a2a_kit.a2a_flex_style .a2a_svg{float:none}.a2a_nowrap{white-space:nowrap}.a2a_note{margin:0 auto;padding:9px;font-size:12px;text-align:center}.a2a_note .a2a_note_note{margin:0;color:#2A2A2A}.a2a_wide a{display:block;margin-top:3px;border-top:1px solid #EEE;text-align:center}.a2a_label{position:absolute!important;clip-path:polygon(0px 0px,0px 0px,0px 0px);-webkit-clip-path:polygon(0px 0px,0px 0px,0px 0px);overflow:hidden;height:1px;width:1px}.a2a_kit,.a2a_menu,.a2a_modal,.a2a_overlay{-ms-touch-action:manipulation;touch-action:manipulation;outline:0}.a2a_dd{-webkit-user-drag:none}.a2a_dd img{border:0}.a2a_button_facebook_like iframe{max-width:none}</style><link rel="stylesheet" href="https://quilt-cdn.janrain.com/HEAD/providers.css" type="text/css"><script id="altmetric-embed-js" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/altmetric_badges-288192a491f0ad9cc434f05ea175659426f5ab0cfd6befb3f3592f96bb90b0d1.js"></script><link id="altmetric-embed-css" rel="stylesheet" type="text/css" href="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed-59614f5c46b49b21eeef3bb28c4fb38d1e7069e8d014752fcb66e84942556802.css"></head>
    

    



    
        
        
        
            <body class="pb-ui website-mms-site loaded">
            






    
    
        





    
    
        
        
    
    
    







<input type="hidden" id="isRoMode" name="isRoMode" value="false">

        <div id="pb-page-content" data-ng-non-bindable="">
                
            <div data-pb-dropzone="main" data-pb-dropzone-name="Main">
                
                    
                        



        
        <header data-sticky="false" class="ng-header js_stickyAd"><a href="#mainContent" class="ng-skipToMainContent">Skip to main content</a><div class="ng-header_topAd"><div class="ng-header_topAd-content d-flex justify-content-center align-items-center">



        
        <div id="DTM_Position_Topbanner" class="ad">
 <!--emptycomment-->
</div>
</div></div><div class="ng-header_journal-navbar"><div class="ng-header_journal-navbar-content"><div class="container-fluid"><div class="row"><div class="ng-header_journal-navbar_left col-lg-8 col-sm-12 pr-lg-0 d-flex align-items-center"><div data-location="nejm_group_product_nav" class="ng-header_journalNavMenu">



        
        <nav data-location="nejm_group_product_nav" role="navigation" class="ng-journalNavMenu">
<ul class="ng-journalNavMenu_list">
<li class="ng-journalNavMenu_list-item"><a href="/" class="ng-journalNavMenu_mainLink active" aria-current="page" aria-label="The New England Journal of Medicine selected item"><span class="ng-journalNavMenu_mainLink-text d-lg-block d-none">The New England Journal of Medicine</span><span class="ng-journalNavMenu_mainLink-text d-lg-none d-block">NEJM</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://evidence.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Evidence</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://ai.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> AI</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://catalyst.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Catalyst</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://www.jwatch.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Journal Watch</span></a></li>
</ul>
</nav>

</div></div><div class="ng-header_journal-navbar_right col-lg-4 pl-lg-0 d-none d-xl-flex align-items-center justify-content-end"><div class="ng-header_loginBar d-xl-flex align-items-lg-center">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2002787" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div></div><div class="ng-header_instBanner d-none d-lg-block"></div><div class="ng-header_logoBar"><div class="container-fluid"><div class="row"><div data-location="logo" class="ng-header_logoBar_left col-lg-4 col-6 d-flex align-items-center justify-content-start"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-logo-166667e91992a5212bc723b03e45d39f.svg" alt="The New England Journal of Medicine homepage" width="366" height="58" class="ng-header_logo-image"></a></div><div class="ng-header_logoBar_right ng-header_navBar col-lg-8 col-sm-12 p-lg-0 align-items-center justify-content-end"><div class="ng-header_navBar-content"><div class="container-fluid"><div class="row"><div class="ng-header_instBanner-md col-12 d-block d-lg-none"></div><div class="ng-header_loginBar-md col-12 d-block d-xl-none">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2002787" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div><div class="ng-header_navBar_left col-lg-8 col-sm-12 d-flex align-items-center"><div class="ng-header_stickyLogo mr-32"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-small-logo-070df7a3f4d8cfa2e71c3c45bb4b172f.svg" alt="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-image"></a></div><div class="ng-header_mainMenu">









    
    
        <div data-widget-def="menuWidget" data-widget-id="97fb3983-db63-4b0b-97dd-d9bb7929fce1" data-location="main_nav">
        



        
        <nav class="ng-menu"><ul class="ng-menu_list ng-simple-menu"><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/toc/nejm/current" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">current issue</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/toc/nejm/current" class="ng-simple-menu_list-link">VIEW CURRENT ISSUE</a></li><li class="ng-simple-menu_list-item"><a href="/toc/nejm/recently-published" class="ng-simple-menu_list-link">BROWSE RECENTLY PUBLISHED</a></li><li class="ng-simple-menu_list-item"><a href="/loi/nejm" class="ng-simple-menu_list-link">BROWSE ALL ISSUES</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/medical-specialties" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">SPECIALTIES</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/browse/specialty/cardiology" class="ng-simple-menu_list-link">Cardiology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/clinical-medicine" class="ng-simple-menu_list-link">Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/endocrinology" class="ng-simple-menu_list-link">Endocrinology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/gastroenterology" class="ng-simple-menu_list-link">Gastroenterology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/hematology-oncology" class="ng-simple-menu_list-link">Hematology/Oncology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/infectious-disease" class="ng-simple-menu_list-link">Infectious Disease</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/nephrology" class="ng-simple-menu_list-link">Nephrology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/neurology-neurosurgery" class="ng-simple-menu_list-link">Neurology/Neurosurgery</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/obstetrics-gynecology" class="ng-simple-menu_list-link">Obstetrics/Gynecology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pediatrics" class="ng-simple-menu_list-link">Pediatrics</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pulmonary-critical-care" class="ng-simple-menu_list-link">Pulmonary/Critical Care</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/surgery" class="ng-simple-menu_list-link">Surgery</a></li><li class="ng-simple-menu_list-item"><a href="/medical-specialties" class="ng-simple-menu_list-link">View All Specialties</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/topics" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">TOPICS</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/ai-in-medicine" class="ng-simple-menu_list-link">AI in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/climate-change" class="ng-simple-menu_list-link">Climate Change</a></li><li class="ng-simple-menu_list-item"><a href="/coronavirus" class="ng-simple-menu_list-link">Coronavirus</a></li><li class="ng-simple-menu_list-item"><a href="/equity" class="ng-simple-menu_list-link">Efforts toward Equity</a></li><li class="ng-simple-menu_list-item"><a href="/firearm-injury-prevention" class="ng-simple-menu_list-link">Firearm Injury Prevention</a></li><li class="ng-simple-menu_list-item"><a href="/nam" class="ng-simple-menu_list-link">From the National Academy of Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/fundamentals-of-medical-ethics" class="ng-simple-menu_list-link">Fundamentals of Medical Ethics</a></li><li class="ng-simple-menu_list-item"><a href="/gray-matters" class="ng-simple-menu_list-link">Gray Matters</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/health-policy" class="ng-simple-menu_list-link">Health Policy</a></li><li class="ng-simple-menu_list-item"><a href="/medicine-and-society" class="ng-simple-menu_list-link">Medicine and Society</a></li><li class="ng-simple-menu_list-item"><a href="/nutrition-in-medicine" class="ng-simple-menu_list-link">Nutrition in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/outbreaks" class="ng-simple-menu_list-link">Outbreaks Center</a></li><li class="ng-simple-menu_list-item"><a href="/race-and-medicine" class="ng-simple-menu_list-link">Race and Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/recognizing-historical-injustices" class="ng-simple-menu_list-link">Recognizing Historical Injustices and the Journal</a></li><li class="ng-simple-menu_list-item"><a href="/tobacco-use-reduction" class="ng-simple-menu_list-link">Tobacco Use Reduction</a></li><li class="ng-simple-menu_list-item"><a href="/topics" class="ng-simple-menu_list-link">View All Topics</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/multimedia" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">MULTIMEDIA</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/rss-feed" class="ng-simple-menu_list-link">Podcasts</a></li><li class="ng-simple-menu_list-item"><a href="/double-take" class="ng-simple-menu_list-link">Double Takes</a></li><li class="ng-simple-menu_list-item"><a href="https://illustrated-glossary.nejm.org/" class="ng-simple-menu_list-link">Illustrated Glossary</a></li><li class="ng-simple-menu_list-item"><a href="/image-challenge" class="ng-simple-menu_list-link">Image Challenge</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/images-in-clinical-medicine" class="ng-simple-menu_list-link">Images in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/interactive-medical-case" class="ng-simple-menu_list-link">Interactive Medical Cases</a></li><li class="ng-simple-menu_list-item"><a href="/plain-language-research-summaries" class="ng-simple-menu_list-link">Plain Language/Research Summaries</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia/quick-take-video" class="ng-simple-menu_list-link">Quick Takes</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/videos-in-clinical-medicine" class="ng-simple-menu_list-link">Videos in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia" class="ng-simple-menu_list-link">View All Multimedia</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/learning" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">LEARNING/CME</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/continuing-medical-education" class="ng-simple-menu_list-link">Weekly CME</a></li><li class="ng-simple-menu_list-item"><a href="/cme-ce/obesity" class="ng-simple-menu_list-link">Obesity CME/CE</a></li><li class="ng-simple-menu_list-item"><a href="/learning" class="ng-simple-menu_list-link">VIEW ALL LEARNING/CME</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item"><a href="/author-center/home" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">AUTHOR CENTER</span></a></li></ul></nav>

        </div>
    

</div><button aria-label="Search" class="ng-header_searchBtn searchBtnNav d-block ml-24"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button></div><div class="ng-header_loginBar ng-header_loginBar-sticky col-4">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2002787" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div><div class="ng-header_logoBar_right-lg col-lg-8 col-6 d-flex align-items-center justify-content-end d-xl-none"><button aria-label="Search" class="ng-header_searchBtn d-flex justify-content-end"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><div class="ng-header_openCloseBtns d-flex align-items-center justify-content-end"><button aria-label="Open" class="ng-header_openBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#burger"></use></svg></span></button><button aria-label="Close" class="ng-header_closeBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></button></div></div><div class="ng-header_quickSearch col-12"><div class="ng-header_quickSearch-content">



        
        <div class="ng-quick-search js-ng-quick-search"><form action="/search" method="get" class="ng-quick-search_form js-form"><div class="ng-quick-search_inputArea js-inputArea"><input type="search" name="q" placeholder="Enter keyword, author, title or citation" autocomplete="off" value="" required="required" class="ng-quick-search_allField ng-large-text-input js-allField js-allField-def-tmpl ui-autocomplete-input"><button type="submit" aria-label="Search Button" class="ng-quick-search_iconBtn d-xl-none d-block js-submitBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><ul id="ui-id-1" tabindex="0" class="ui-menu ui-widget ui-widget-content ui-autocomplete ui-front" style="display: none;"></ul></div><div class="ng-quick-search_btnsArea d-none d-xl-flex align-items-center justify-content-end"><a href="/search/advanced" class="ng-quick-search_advSearchLink ng-btn_link js-advancedSearchLink">Advanced Search</a><button type="submit" class="ng-quick-search_textBtn ng-btn_secondary ng-btn_iconRight js-submitBtn"><span class="ng-btn_text">SEARCH</span><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-right"></use></svg></span></button></div></form></div>
</div></div></div></div></div></header><div class="ng-header_overlay"></div><div class="ng-header_after">









    
    
        <div data-widget-def="literatumAd" data-widget-id="4931ddbd-d46e-4597-b4fd-92549e9847ca" id="ad-global-banner-FULLx64-1">
        



        
        



    

    

    
        
    



        </div>
    

</div>

                    
                        



        
        <div>









    
    
        <main data-widget-def="axelPublicationContent" data-widget-id="fcdb5261-d6a2-4a9c-81d5-3a3e2304e9c1" id="mainContent">
        



        
        <div class="article-tools__savePopup"><div class="ng-save"><input type="hidden" value="/action/getSavedTags" class="getKeywordsServiceUrl"><input type="hidden" value="/action/mmsSaveItemsService?itemType=article" class="saveServiceUrl"><input type="hidden" value="article" class="saveType"><input type="hidden" value="10.1056/NEJMoa2002787" class="inputDoi"><input type="hidden" value="J. Wolf and Others" class="inputAuthor"><input type="hidden" value="N Engl J Med 2020;383:944-957" class="inputCitation"><input type="hidden" value="09-02-2020" class="inputEPubDate"><input type="hidden" value="September 2020" class="inputCoverDate"><input type="hidden" value="Original Article" class="inputContentType"><input type="hidden" value="Capmatinib in <i>MET</i> Exon 14–Mutated or <i>MET</i>-Amplified Non–Small-Cell Lung Cancer" class="inputArticleTitle"><input type="hidden" value="/browse/nejm-article-type/original-article" class="inputContentTypeUrl"><button type="button" id="saveArticleShowPopupBtn" aria-hidden="true" tabindex="-1" class="ng-save-btn ng-btn_secondary isLoggedOut">Save</button></div></div><div class="article-tools__articleAlertPopup"><div id="articleAlertModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="articleAlertModalTitle" class="ng-modal_title modal-title">Create an E-mail Alert for This Article</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><div class="ng-do-media_popup"><div id="doPopup" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><link id="build-style-article" rel="stylesheet" type="text/css" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css"><article xmlns="http://www.w3.org/1999/xhtml" data-design="pill" data-has="right-rail" data-type="research-article" vocab="http://schema.org/" typeof="ScholarlyArticle" lang="en" dir="ltr"><header data-extent="frontmatter" data-location="header_article"><div class="core-container"><div data-article-access="free" data-article-access-type="free" class="meta-panel"><div class="meta-panel__left-content"><div class="meta-panel__type"><a href="/browse/nejm-article-type/original-article">Original Article</a></div></div><div class="meta-panel__right-content"><div class="meta-panel__share">









    
    
        <div data-widget-def="UX3share" data-widget-id="eee5f139-16f2-48f8-97ea-1b114367da16" data-location="share_tools_article">
        



        
        <!-- Go to https://www.addtoany.com/buttons/customize/ to customize your tools --><script type="text/javascript" defer="defer" src="https://static.addtoany.com/menu/page.js" nonce="94d6468482d1decb-SJC"></script><div class="share"><div class="share__block share__inline-links"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="d-flex list-unstyled a2a a2a_kit a2a_default_style mb-0 a2a_kit_size_32" style="line-height: 32px;"><li class="a2a_listitem_custom"><a role="link" title="Facebook" data-interactiontype="social" class="share__link a2a_button_facebook" target="_blank" rel="nofollow noopener" href="/#facebook"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-facebook"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="X (formerly Twitter)" data-interactiontype="social" class="share__link a2a_button_twitter" target="_blank" rel="nofollow noopener" href="/#twitter"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-twitter"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Linked In" data-interactiontype="social" class="share__link a2a_button_linkedin" target="_blank" rel="nofollow noopener" href="/#linkedin"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-linkedin"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Email" data-interactiontype="content_email_click" class="share__link a2a_button_email" target="_blank" rel="nofollow noopener" href="/#email"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-email"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Bluesky" data-interactiontype="social" class="share__link a2a_button_bluesky" target="_blank" rel="nofollow noopener" href="/#bluesky"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-bluesky"></use></svg></span></a></li></ul></div></div>

        </div>
    

</div></div></div><h1 property="name">Capmatinib in <i>MET</i> Exon 14–Mutated or <i>MET</i>-Amplified Non–Small-Cell Lung Cancer</h1><div class="core-relations my-3"></div><div class="contributors"><span class="authors"><span class="heading">Authors</span>: <span role="list"><span property="author" typeof="Person" role="listitem"><span property="givenName">Jürgen</span> <span property="familyName">Wolf</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Takashi</span> <span property="familyName">Seto</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Ji-Youn</span> <span property="familyName">Han</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Noemi</span> <span property="familyName">Reguart</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Edward B.</span> <span property="familyName">Garon</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Harry J.M.</span> <span property="familyName">Groen</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Daniel S.W.</span> <span property="familyName">Tan</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span><span data-displayed-on="all">, <span data-action="reveal" tabindex="0" role="listitem">+25</span> </span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Toyoaki</span> <span property="familyName">Hida</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Maja</span> <span property="familyName">de Jonge</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Sergey V.</span> <span property="familyName">Orlov</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Egbert F.</span> <span property="familyName">Smit</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Pierre-Jean</span> <span property="familyName">Souquet</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Johan</span> <span property="familyName">Vansteenkiste</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Maximilian</span> <span property="familyName">Hochmair</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Enriqueta</span> <span property="familyName">Felip</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Makoto</span> <span property="familyName">Nishio</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Michael</span> <span property="familyName">Thomas</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Kadoaki</span> <span property="familyName">Ohashi</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Ryo</span> <span property="familyName">Toyozawa</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Tobias R.</span> <span property="familyName">Overbeck</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Filippo</span> <span property="familyName">de Marinis</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Tae-Min</span> <span property="familyName">Kim</span>, <span property="honorificSuffix">M.D., Ph.D.</span> <a class="orcid-id" href="https://orcid.org/0000-0001-6145-4426" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0001-6145-4426</a></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Eckart</span> <span property="familyName">Laack</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Anna</span> <span property="familyName">Robeva</span>, <span property="honorificSuffix">M.S.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Sylvie</span> <span property="familyName">Le Mouhaer</span>, <span property="honorificSuffix">M.Sc.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Maeve</span> <span property="familyName">Waldron-Lynch</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Banu</span> <span property="familyName">Sankaran</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">O. Alejandro</span> <span property="familyName">Balbin</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Xiaoming</span> <span property="familyName">Cui</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Monica</span> <span property="familyName">Giovannini</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Mikhail</span> <span property="familyName">Akimov</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span><span data-hidden-on="all">, and <span property="author" typeof="Person" role="listitem"><span property="givenName">Rebecca S.</span> <span property="familyName">Heist</span>, <span property="honorificSuffix">M.D., M.P.H.</span></span></span>, for <span property="author" typeof="Person" role="listitem">the GEOMETRY mono-1 Investigators<sup><a href="#fn1" role="doc-noteref">*</a></sup></span><span data-displayed-on="none" data-on-display="all" aria-hidden="true"> <span data-action="hide" tabindex="0" role="listitem">-25</span></span></span></span><a href="#tab-contributors" class="to-authors-affiliations" data-id="article-authors-viewall">Author Info &amp; Affiliations</a></div><div class="core-self-citation"><div class="core-date-published">Published <span property="datePublished">September 2, 2020</span></div><div property="isPartOf" typeof="Periodical"><span property="name">N Engl J Med</span> 2020<span property="isPartOf" typeof="PublicationVolume">;<span property="volumeNumber">383</span></span>:<span property="pageStart">944</span>-<span property="pageEnd">957</span></div><div class="doi">DOI: 10.1056/NEJMoa2002787</div><div class="core-enumeration"><a href="/toc/nejm/383/10"><span property="isPartOf" typeof="PublicationVolume">VOL. <span property="volumeNumber">383</span></span> <span property="isPartOf" typeof="PublicationIssue">NO. <span property="issueNumber">10</span></span></a></div><div><a href="#tab-information">Copyright © 2020</a></div></div><div class="info-panel"><div class="info-panel__left-content"><div class="info-panel__metrics info-panel__item"></div></div><div data-location="tools_article" class="info-panel__right-content"><div class="info-panel__article_tools info-panel__item">



        
        <div data-permission="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3DJ%25C3%25BCrgen%2BWolf%252C%2BTakashi%2BSeto%252C%2BJi-Youn%2BHan%252C%2Bet%2Bal%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D383%26issueNum%3D10%26contentID%3D10.1056%252FNEJMoa2002787%26title%3DCapmatinib%2Bin%2B%253Ci%253EMET%253C%252Fi%253E%2BExon%2B14%2526%2523x2013%253BMutated%2Bor%2B%253Ci%253EMET%253C%252Fi%253E-Amplified%2BNon%2526%2523x2013%253BSmall-Cell%2BLung%2BCancer%26publicationDate%3D09%252F03%252F2020" class="article-tools"><button id="articleToolsAlertBtn" data-url="/action/addCitationAlert?doi=10.1056%2FNEJMoa2002787" data-toggle="" data-target="#articleAlertModal" aria-label="Sign in or create account to add an article alert" data-interactiontype="article_alert" class="article-tools__citation btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to add an article alert"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#alerts"></use></svg></span></span></button><button id="articleToolsSaveBtn" data-toggle="modal" data-target="#saveArticle" aria-label="Sign in or create account to save this article" data-interactiontype="article_tools_save_click" class="article-tools__favorite btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to save this article"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#bookmarkFilled"></use></svg></span></span></button><a href="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3DJ%25C3%25BCrgen%2BWolf%252C%2BTakashi%2BSeto%252C%2BJi-Youn%2BHan%252C%2Bet%2Bal%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D383%26issueNum%3D10%26contentID%3D10.1056%252FNEJMoa2002787%26title%3DCapmatinib%2Bin%2B%253Ci%253EMET%253C%252Fi%253E%2BExon%2B14%2526%2523x2013%253BMutated%2Bor%2B%253Ci%253EMET%253C%252Fi%253E-Amplified%2BNon%2526%2523x2013%253BSmall-Cell%2BLung%2BCancer%26publicationDate%3D09%252F03%252F2020" target="_blank" title="" data-toggle="tooltip" aria-label="Permissions" data-interactiontype="article_tools_permissions_click" class="article-tools__permissions btn btn--slim" data-original-title="Permissions"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#permissions"></use></svg></span></a><a href="/about-nejm/reprints" title="" data-toggle="tooltip" aria-label="Reprints" data-interactiontype="article_tools_reprints_click" class="article-tools__reprints btn btn--slim" data-original-title="Reprints"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#reprints"></use></svg></span></a><a href="/cms/asset/7ebccb84-97fb-4ecf-b8f5-383d9c6e41be/nejmoa2002787.pptx" target="_blank" title="" data-toggle="tooltip" aria-label="Download Slides" data-interactiontype="article_tools_slide_set_download" data-multimedia-type="Article Slideset" data-multimedia-filename="nejmoa2002787.pptx" class="article-tools__downloadSlides btn btn--slim" data-original-title="Download Slides"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#download"></use></svg></span></a><div class="article-tools__permissionsPopup"><div id="permissionsModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="permissionsModalTitle" class="ng-modal_title modal-title">Permissions</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body">For permission requests, please contact NEJM Reprints at <a href="mailto:reprints@nejm.org">reprints@nejm.org</a></div></div></div></div></div></div>
</div><div class="info-panel__citations info-panel__item"><a href="#tab-citations" class="btn btn--slim" aria-label="View Citations" data-toggle="tooltip" data-original-title="View Citations" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><i aria-hidden="true" class="icon-format_quote"></i></a></div><div class="info-panel__formats info-panel__item"><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa2002787" class="btn btn--pdf btn--slim" aria-label="View PDF" data-toggle="tooltip" data-original-title="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa2002787" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2002787.pdf"><i aria-hidden="true" class="icon-PDF"></i></a></div></div></div></div></header><div data-core-nav="header" data-extent="frontmatter"><div class="core-nav-wrapper core-container" aria-label="Article navigation"><div class="core-sections-menu"><button data-id="article-toolbar-showhide" aria-controls="article_sections_menu" aria-expanded="false" aria-label="Toggle section navigation menu" style="margin-top: 0px;"><i class="icon-list" aria-hidden="true"></i><span>Contents</span></button><nav id="article_sections_menu" aria-label="Contents" data-core-nav="article" style="margin-top: 0px;"><ul><li><a href="#summary-abstract" aria-current="true">Abstract</a></li><li><a href="#sec-1" aria-current="false">Methods</a></li><li><a href="#sec-2" aria-current="false">Results</a></li><li><a href="#sec-3" aria-current="false">Discussion</a></li><li class="bordered"><a href="#backnotes" aria-current="false">Notes</a></li><li><a href="#supplementary-materials" aria-current="false">Supplementary Material</a></li><li><a href="#bibliography" aria-current="false">References</a></li></ul></nav></div><nav id="article_collateral_menu"><ul data-core-nav="collateral" class="collateral-pill" style="margin-top: 0px;"><li><a href="#core-collateral-info" data-id="article-nav-menubar-info" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Information &amp; Authors"><i aria-hidden="true" class="icon-info"></i><span class="sr-only">Information &amp; Authors</span></a></li><li><a href="#core-collateral-metrics" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Metrics &amp; Citations"><i aria-hidden="true" class="icon-timeline"></i><span class="sr-only">Metrics &amp; Citations</span></a></li><li><a href="#core-collateral-fulltext-options" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="View Options"><i aria-hidden="true" class="icon-eye"></i><span class="sr-only">View Options</span></a></li><li><a href="#core-collateral-references" data-id="article-nav-menubar-references" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="References"><i aria-hidden="true" class="icon-references"></i><span class="sr-only">References</span></a></li><li><a href="#core-collateral-media" data-id="article-nav-menubar-media" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Media"><i aria-hidden="true" class="icon-photo"></i><span class="sr-only">Media</span></a></li><li><a href="#core-collateral-tables" data-id="article-nav-menubar-tables" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Tables"><i aria-hidden="true" class="icon-tables"></i><span class="sr-only">Tables</span></a></li><li><a href="#core-collateral-share" data-id="article-nav-menubar-share" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Share"><i aria-hidden="true" class="icon-share"></i><span class="sr-only">Share</span></a></li></ul></nav></div></div><div data-core-wrapper="content"><div id="abstracts" data-extent="frontmatter" data-location="articleTab_article"><div class="core-container"><section id="summary-abstract" property="abstract" typeof="Text" role="doc-abstract"><h2 property="name">Abstract</h2><section id="abs-sec-1"><h3>Background</h3><div role="paragraph">Among patients with non–small-cell lung cancer (NSCLC), <i>MET</i> exon 14 skipping mutations occur in 3 to 4% and <i>MET</i> amplifications occur in 1 to 6%. Capmatinib, a selective inhibitor of the MET receptor, has shown activity in cancer models with various types of MET activation.</div></section><section id="abs-sec-2"><h3>Methods</h3><div role="paragraph">We conducted a multiple-cohort, phase 2 study evaluating capmatinib in patients with <i>MET</i>-dysregulated advanced NSCLC. Patients were assigned to cohorts on the basis of previous lines of therapy and <i>MET</i> status (<i>MET</i> exon 14 skipping mutation or <i>MET</i> amplification according to gene copy number in tumor tissue). Patients received capmatinib (400-mg tablet) twice daily. The primary end point was overall response (complete or partial response), and the key secondary end point was response duration; both end points were assessed by an independent review committee whose members were unaware of the cohort assignments.</div></section><section id="abs-sec-3"><h3>Results</h3><div role="paragraph">A total of 364 patients were assigned to the cohorts. Among patients with NSCLC with a <i>MET</i> exon 14 skipping mutation, overall response was observed in 41% (95% confidence interval [CI], 29 to 53) of 69 patients who had received one or two lines of therapy previously and in 68% (95% CI, 48 to 84) of 28 patients who had not received treatment previously; the median duration of response was 9.7 months (95% CI, 5.6 to 13.0) and 12.6 months (95% CI, 5.6 to could not be estimated), respectively. Limited efficacy was observed in previously treated patients with <i>MET</i> amplification who had a gene copy number of less than 10 (overall response in 7 to 12% of patients). Among patients with <i>MET</i> amplification and a gene copy number of 10 or higher, overall response was observed in 29% (95% CI, 19 to 41) of previously treated patients and in 40% (95% CI, 16 to 68) of those who had not received treatment previously. The most frequently reported adverse events were peripheral edema (in 51%) and nausea (in 45%); these events were mostly of grade 1 or 2.</div></section><section id="abs-sec-4"><h3>Conclusions</h3><div role="paragraph">Capmatinib showed substantial antitumor activity in patients with advanced NSCLC with a <i>MET</i> exon 14 skipping mutation, particularly in those not treated previously. The efficacy in <i>MET</i>-amplified advanced NSCLC was higher in tumors with a high gene copy number than in those with a low gene copy number. Low-grade peripheral edema and nausea were the main toxic effects. (Funded by Novartis Pharmaceuticals; GEOMETRY mono-1 ClinicalTrials.gov number, <a href="http://clinicaltrials.gov/show/NCT02414139" target="_blank">NCT02414139</a>.)</div></section></section></div></div><section id="bodymatter" data-extent="bodymatter" property="articleBody" typeof="Text" data-location="articleTab_article"><div class="core-container"><div role="paragraph">Activation of the MET pathway is associated with many cancers and can be caused by overexpression, gene amplification, and <i>MET</i> exon 14 skipping mutations, which can result from point mutations or from insertions or deletions.<sup><a href="#core-r1" role="doc-biblioref" data-xml-rid="r1 r2 r3 r4 r5 r6 r7" id="body-ref-r7-1" href-manipulated="true">1-7</a></sup> The shorter exon 14–spliced protein has increased stability, which increases MET signaling.<sup><a href="#core-r8" role="doc-biblioref" data-xml-rid="r8" id="body-ref-r8" href-manipulated="true" aria-label="Reference 8">8</a></sup> <i>MET</i> exon 14 skipping mutations occur in approximately 3 to 4% of patients with non–small-cell lung cancer (NSCLC), typically in the absence of other driver mutations,<sup><a href="#core-r3" role="doc-biblioref" data-xml-rid="r3 r4 r5 r7" id="body-ref-r7-2" href-manipulated="true">3–5,7</a></sup> and are associated with a poor prognosis.<sup><a href="#core-r7" role="doc-biblioref" data-xml-rid="r7 r9" id="body-ref-r9" href-manipulated="true">7,9</a></sup> <i>MET</i> amplification occurs in 1 to 6% of patients with NSCLC.<sup><a href="#core-r10" role="doc-biblioref" data-xml-rid="r10 r11 r12 r13" id="body-ref-r13" href-manipulated="true">10-13</a></sup> Historically, the lack of clear biomarkers has made it difficult to select patients who will benefit the most from targeting MET with MET-specific therapy. In patients with NSCLC, selection of treatment on the basis of MET overexpression has not shown significant benefit.<sup><a href="#core-r14" role="doc-biblioref" data-xml-rid="r14" id="body-ref-r14" href-manipulated="true" aria-label="Reference 14">14</a></sup> However, <i>MET</i> exon 14 skipping mutations and high-level <i>MET</i> amplification have emerged as potential predictive biomarkers.<sup><a href="#core-r4" role="doc-biblioref" data-xml-rid="r4 r6 r15 r16 r17 r18" id="body-ref-r18-1" href-manipulated="true">4,6,15–18</a></sup></div><div role="paragraph">Capmatinib (INC280), a highly potent and selective inhibitor of the MET receptor, has shown in vitro and in vivo activity in cancer models with various types of MET activation.<sup><a href="#core-r19" role="doc-biblioref" data-xml-rid="r19 r20 r21" id="body-ref-r21" href-manipulated="true">19-21</a></sup> In addition, capmatinib crosses the blood–brain barrier.<sup><a href="#core-r22" role="doc-biblioref" data-xml-rid="r22 r23" id="body-ref-r23" href-manipulated="true">22,23</a></sup> Preliminary clinical data showed low-grade toxic effects and a promising efficacy of capmatinib monotherapy in patients with <i>MET</i>-dysregulated NSCLC.<sup><a href="#core-r17" role="doc-biblioref" data-xml-rid="r17 r24" id="body-ref-r24" href-manipulated="true">17,24</a></sup></div><div role="paragraph">We report the results of the GEOMETRY mono-1 study, which investigated the activity of capmatinib in patients with advanced NSCLC with a <i>MET</i> exon 14 skipping mutation or <i>MET</i> amplification. The study included patients who had received treatment previously and patients who had not.</div><section id="sec-1" data-type="methods"><h2>Methods</h2><section id="sec-1-1"><h3>Patients and Study Design</h3><div role="paragraph">We conducted a prospective, international, open-label, multiple-cohort, phase 2 study to evaluate the safety and efficacy of capmatinib in patients with advanced NSCLC with a <i>MET</i> exon 14 skipping mutation or <i>MET</i> amplification. Eligible patients were adults (≥18 years of age) with stage IIIB or IV NSCLC with any histologic features, without an activating epidermal growth factor receptor mutation or anaplastic lymphoma kinase fusion, and with at least one measurable lesion, defined according to the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1. <i>MET</i> status was determined by a central laboratory (see the Supplementary Methods section in the <a href="#ap2">Supplementary Appendix</a>, available with the full text of this article at NEJM.org).</div><div role="paragraph">Patients were assigned to cohorts on the basis of <i>MET</i> status and previous lines of therapy. In cohorts of patients with a <i>MET</i> exon 14 skipping mutation, enrollment was allowed regardless of concurrent <i>MET</i> amplification; however, no concurrent <i>MET</i> exon 14 skipping mutation was permitted in cohorts of patients with <i>MET</i> amplification. The study included five cohorts (with cohorts 1 and 5 having subcohorts) for the assessment of efficacy on the basis of prespecified statistical hypotheses; two expansion cohorts (6 and 7) were added to generate supportive clinical evidence.</div><div role="paragraph">Patients with brain metastases who had had no increase in glucocorticoid dose within the 2 weeks before enrollment were eligible for enrollment if their condition was judged by the investigator to be neurologically stable. The complete eligibility criteria are provided in the <a href="#ap1">protocol</a>, available at NEJM.org. Oral capmatinib at a dose of 400 mg twice daily was administered under fasting conditions in cohorts 1 through 5 and was administered without fasting restrictions in cohorts 6 and 7.</div></section><section id="sec-1-2"><h3>Study End Points</h3><div role="paragraph">The primary end point was overall response (complete or partial response), as assessed under blinded conditions by an independent review committee according to RECIST, version 1.1.<sup><a href="#core-r25" role="doc-biblioref" data-xml-rid="r25" id="body-ref-r25" href-manipulated="true" aria-label="Reference 25">25</a></sup> The key secondary end point was the duration of response, as assessed under blinded conditions by the independent review committee. Other secondary end points included investigator-assessed response and duration of response, investigator-evaluated and independent review committee–evaluated time to response, disease control (defined as a best overall response of complete response, partial response, or stable disease according to RECIST, version 1.1), progression-free survival, and the safety profile and pharmacokinetics of capmatinib.</div><div role="paragraph">An ad hoc blinded review (by an independent neuroradiologic review committee) involving patients with a <i>MET</i> exon 14 skipping mutation and brain metastases at baseline was conducted after reports of responses in the brain in some patients. Prespecified exploratory analyses of baseline tumor-biopsy samples obtained from patients with NSCLC with a <i>MET</i> exon 14 skipping mutation were performed in order to determine the type of <i>MET</i> alteration leading to exon 14 skipping, the presence or absence of concurrent <i>MET</i> amplification, and a correlation between reverse-transcriptase–polymerase-chain-reaction (RT-PCR) analyses and next-generation sequencing with the use of the FoundationOne CDx panel (Foundation Medicine).</div></section><section id="sec-1-3"><h3>Study Oversight</h3><div role="paragraph">This study was conducted in accordance with the principles of the Declaration of Helsinki and the Good Clinical Practice guidelines of the International Council for Harmonisation. The study protocol and all amendments were reviewed by the independent ethics committee or institutional review board at each center. All the patients provided written informed consent.</div><div role="paragraph">The study was sponsored by Novartis Pharmaceuticals and was designed by the sponsor and the authors in conjunction with an independent steering committee. The sponsor conducted all the statistical analyses. All the authors agreed to submit the manuscript for publication and vouch for the accuracy of the data and for the adherence of the study to the protocol. The manuscript was developed with medical writing assistance, funded by the sponsor in accordance with Good Publication Practice guidelines (<a href="http://www.ismpp.org/gpp3" target="_blank">www.ismpp.org/gpp3</a>).</div></section><section id="sec-1-4"><h3>Statistical Analysis</h3><div role="paragraph">Cohorts 1 through 5 were analyzed separately with independent statistical hypotheses. In the cohorts involving previously treated patients, on the basis of historical data,<sup><a href="#core-r26" role="doc-biblioref" data-xml-rid="r26 r27" id="body-ref-r27" href-manipulated="true">26,27</a></sup> capmatinib was considered to have clinically relevant efficacy if a response was observed in at least 35% of the patients, with a lower boundary of the 95% confidence interval of more than 25%, as assessed by the independent review committee. For the cohorts involving patients who had not received treatment previously, capmatinib was considered to have clinically relevant efficacy if a response was observed in at least 55% of the patients, with a lower boundary of the 95% confidence interval of more than 35%, as assessed by the independent review committee.<sup><a href="#core-r28" role="doc-biblioref" data-xml-rid="r28 r29" id="body-ref-r29" href-manipulated="true">28,29</a></sup></div><div role="paragraph">No efficacy hypothesis was planned for cohort 6, which was intended to provide supportive analyses of efficacy and safety in patients who had received one previous line of treatment for NSCLC with a <i>MET</i> exon 14 skipping mutation or <i>MET</i> amplification with a gene copy number of at least 10 in tumor tissue. The efficacy hypotheses for cohort 7 were the same as those used for the cohorts involving patients who had not received treatment previously.</div><div role="paragraph">All the tests were performed on the basis of the exact 95% confidence interval for response in each cohort, with the use of a one-sided alpha level of 0.025. No adjustment for multiplicity was made because each cohort was independent; therefore, the reported confidence intervals have not been adjusted for multiplicity.</div><div role="paragraph">An interim analysis for futility was planned to involve previously treated patients with NSCLC with a <i>MET</i> exon 14 skipping mutation or <i>MET</i> amplification when at least 28 patients (≥20 patients in cohort 3) had completed at least six cycles of treatment or had discontinued treatment. Small sample sizes precluded interim futility analyses in cohorts involving patients who had not received treatment previously, and no interim analysis was planned for cohort 6.</div><div role="paragraph">The primary analysis was to be performed when all treated patients in their respective cohort (if the study was not stopped for futility at the interim analysis) had completed at least six cycles of treatment or had discontinued treatment. Confirmed partial responses or complete responses that were reported before the receipt of any additional anticancer therapy were included in the calculation of response. Patients with a best overall response of “unknown” according to RECIST, version 1.1, or with no blinded assessment of data by the independent review committee were considered to not have had a response when the percentages of patients with a response were estimated (as a worst-case scenario). Multiple imputation analysis was also performed and is described in the <a href="#ap2">Supplementary Appendix</a>. The consistency in the treatment effect (response) was explored according to subgroup, including prespecified analyses (age, sex, race, and Eastern Cooperative Oncology Group performance-status score) and post hoc analyses (smoking status, histologic features, and receipt of previous immunotherapy).</div><div role="paragraph">Safety analyses included all the patients in cohorts 1 through 7 who had received at least one dose of capmatinib. The pharmacokinetics of capmatinib were characterized under fasting conditions in cohorts 1 through 5 and were characterized without regard to food intake in cohorts 6 and 7.</div><div role="paragraph">The statistical analysis plan is provided with the study protocol. Additional details of the study end points and methods are described in the <a href="#ap2">Supplementary Appendix</a>.</div></section></section><section id="sec-2" data-type="results"><h2>Results</h2><section id="sec-2-1"><h3>Patients</h3><div role="paragraph">A total of 364 patients with advanced NSCLC were enrolled in the study (<a href="#f1">Figure 1</a>). Across cohorts 1 through 5, a total of 97 patients had a <i>MET</i> exon 14 skipping mutation and 210 had <i>MET</i> amplification. The characteristics of these patients at baseline are described in <a href="#t1">Table 1</a>. Previously treated patients who were enrolled in cohorts 1 through 4 had received one or two lines of therapy previously (Table S1), and patients in cohorts 5a and 5b had not received treatment previously. The median age of the patients was slightly higher in cohorts involving patients with a <i>MET</i> exon 14 skipping mutation (71 years) than in most of the cohorts involving patients with <i>MET</i> amplification (60 to 70 years). Patients with a <i>MET</i> exon 14 skipping mutation were more likely to be women and were more likely to have never smoked than were patients with <i>MET</i> amplification.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 1</div><nav><a href="#f1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2002787_f1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f1" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2002787_f1.jpg"><img src="/cms/10.1056/NEJMoa2002787/asset/6bdb0b9c-7e03-4610-a745-acef42916681/assets/images/large/nejmoa2002787_f1.jpg" height="3438" width="2180" aria-labelledby="f1" loading="lazy"></a><figcaption><div class="caption">Study Design.</div><div class="notes"><div role="doc-footnote">Eligible patients with non–small-cell lung cancer (NSCLC) had to have an Eastern Cooperative Oncology Group (ECOG) performance-status score of 0 or 1 (on a scale from 0 [fully active] to 5 [death]; a score of 1 indicates that the patient is ambulatory but restricted from strenuous activity) and to have at least one measurable tumor, according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1. Patients were assigned to cohorts on the basis of <i>MET</i> status (<i>MET</i> exon 14 skipping mutation or <i>MET</i> amplification, as measured by gene copy number [GCN]) and previous lines of therapy. Enrollment in cohorts with a <i>MET</i> exon 14 skipping mutation was allowed regardless of concurrent <i>MET</i> amplification, but no concurrent <i>MET</i> exon 14 skipping mutation was permitted in cohorts with <i>MET</i> amplification. Previously treated patients had received systemic antineoplastic therapy for advanced NSCLC. Enrollment in cohort 5a was stopped early because of slow enrollment. Each cohort of the study, except the expansion cohorts, enrolled patients in parallel. Enrollment in cohort 6 was to be initiated only on completion of enrollments in cohort 1a or cohort 4 and included only patients who had received one line of therapy previously. Cohort 7 was added in a protocol amendment (on February 28, 2019); enrollment was ongoing at the data-cutoff date (January 6, 2020). The expansion cohorts allowed further data collection in the specified patient populations. <i>ALK</i> denotes anaplastic lymphoma kinase, and <i>EGFR</i> epidermal growth factor receptor.</div></div></figcaption></figure></div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 1</div><nav><a href="#t1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2002787_t1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t1" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2002787_t1.jpg"><img src="/cms/10.1056/NEJMoa2002787/asset/300b4740-aa3a-4dc7-8a38-d5d592183ef3/assets/images/large/nejmoa2002787_t1.jpg" height="2067" width="2615" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Characteristic</th><th class="txxx-borders" colspan="2"><span>NSCLC with <i>MET</i> Exon 14<br>Skipping Mutation</span></th><th class="txxr-borders" colspan="5"><span>NSCLC with <i>MET</i> Amplification</span></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">Cohort 4<br>(N=69)</th><th class="xxxx-borders">Cohort 5b<br>(N=28)</th><th class="xxxx-borders">Cohort 1a<br>(N=69)</th><th class="xxxx-borders">Cohort 5a<br>(N=15)</th><th class="xxxx-borders">Cohort 1b<br>(N=42)</th><th class="xxxx-borders">Cohort 2<br>(N=54)</th><th class="xxxr-borders">Cohort 3<br>(N=30)</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging02 shading">Age</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Median (range) — yr</td><td class="xxxx-borders">71 (49–90)</td><td class="xxxx-borders">71 (57–86)</td><td class="xxxx-borders">61 (33–76)</td><td class="xxxx-borders">70 (49–86)</td><td class="xxxx-borders">60 (36–76)</td><td class="xxxx-borders">64 (39–84)</td><td class="xxxr-borders">63 (38–78)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">≥65 yr — no. (%)</td><td class="xxxx-borders shading">55 (80)</td><td class="xxxx-borders shading">25 (89)</td><td class="xxxx-borders shading">28 (41)</td><td class="xxxx-borders shading">10 (67)</td><td class="xxxx-borders shading">13 (31)</td><td class="xxxx-borders shading">24 (44)</td><td class="xxxr-borders shading">14 (47)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Female sex — no. (%)</td><td class="xxxx-borders">40 (58)</td><td class="xxxx-borders">18 (64)</td><td class="xxxx-borders">15 (22)</td><td class="xxxx-borders">4 (27)</td><td class="xxxx-borders">21 (50)</td><td class="xxxx-borders">15 (28)</td><td class="xxxr-borders">11 (37)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">ECOG performance-status score — no. (%)<a href="#t1fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">0</td><td class="xxxx-borders">16 (23)</td><td class="xxxx-borders">7 (25)</td><td class="xxxx-borders">17 (25)</td><td class="xxxx-borders">4 (27)</td><td class="xxxx-borders">14 (33)</td><td class="xxxx-borders">23 (43)</td><td class="xxxr-borders">9 (30)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">≥1</td><td class="xxxx-borders shading">53 (77)</td><td class="xxxx-borders shading">21 (75)</td><td class="xxxx-borders shading">52 (75)</td><td class="xxxx-borders shading">11 (73)</td><td class="xxxx-borders shading">28 (67)</td><td class="xxxx-borders shading">31 (57)</td><td class="xxxr-borders shading">21 (70)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Smoking history — no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Never smoked</td><td class="xxxx-borders shading">40 (58)</td><td class="xxxx-borders shading">18 (64)</td><td class="xxxx-borders shading">5 (7)</td><td class="xxxx-borders shading">2 (13)</td><td class="xxxx-borders shading">7 (17)</td><td class="xxxx-borders shading">11 (20)</td><td class="xxxr-borders shading">7 (23)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Former smoking</td><td class="xxxx-borders">27 (39)</td><td class="xxxx-borders">9 (32)</td><td class="xxxx-borders">54 (78)</td><td class="xxxx-borders">8 (53)</td><td class="xxxx-borders">29 (69)</td><td class="xxxx-borders">34 (63)</td><td class="xxxr-borders">20 (67)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Current smoking</td><td class="xxxx-borders shading">2 (3)</td><td class="xxxx-borders shading">1 (4)</td><td class="xxxx-borders shading">10 (14)</td><td class="xxxx-borders shading">5 (33)</td><td class="xxxx-borders shading">6 (14)</td><td class="xxxx-borders shading">9 (17)</td><td class="xxxr-borders shading">3 (10)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Histologic findings — no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Adenocarcinoma</td><td class="xxxx-borders shading">53 (77)</td><td class="xxxx-borders shading">25 (89)</td><td class="xxxx-borders shading">57 (83)</td><td class="xxxx-borders shading">11 (73)</td><td class="xxxx-borders shading">35 (83)</td><td class="xxxx-borders shading">48 (89)</td><td class="xxxr-borders shading">22 (73)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Squamous-cell carcinoma</td><td class="xxxx-borders">6 (9)</td><td class="xxxx-borders">2 (7)</td><td class="xxxx-borders">7 (10)</td><td class="xxxx-borders">2 (13)</td><td class="xxxx-borders">2 (5)</td><td class="xxxx-borders">4 (7)</td><td class="xxxr-borders">5 (17)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Large-cell carcinoma</td><td class="xxxx-borders shading">1 (1)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">2 (3)</td><td class="xxxx-borders shading">1 (7)</td><td class="xxxx-borders shading">1 (2)</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">1 (3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Other</td><td class="xxxx-borders">9 (13)</td><td class="xxxx-borders">1 (4)</td><td class="xxxx-borders">3 (4)</td><td class="xxxx-borders">1 (7)</td><td class="xxxx-borders">4 (10)</td><td class="xxxx-borders">2 (4)</td><td class="xxxr-borders">2 (7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Brain metastases at baseline — no. (%)<a href="#t1fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders shading">11 (16)</td><td class="xxxx-borders shading">3 (11)</td><td class="xxxx-borders shading">26 (38)</td><td class="xxxx-borders shading">7 (47)</td><td class="xxxx-borders shading">14 (33)</td><td class="xxxx-borders shading">18 (33)</td><td class="xxxr-borders shading">6 (20)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">No. of previous lines of antineoplastic therapy — no. (%)<a href="#t1fn4" role="doc-noteref">§</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">1</td><td class="xxxx-borders shading">51 (74)</td><td class="xxxx-borders shading">NA</td><td class="xxxx-borders shading">41 (59)</td><td class="xxxx-borders shading">NA</td><td class="xxxx-borders shading">27 (64)</td><td class="xxxx-borders shading">28 (52)</td><td class="xxxr-borders shading">9 (30)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">2</td><td class="xxxx-borders">16 (23)</td><td class="xxxx-borders">NA</td><td class="xxxx-borders">27 (39)</td><td class="xxxx-borders">NA</td><td class="xxxx-borders">15 (36)</td><td class="xxxx-borders">26 (48)</td><td class="xxxr-borders">21 (70)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging12 shading" data-xml-align="left">3</td><td class="xbxx-borders shading">2 (3)</td><td class="xbxx-borders shading">NA</td><td class="xbxx-borders shading">1 (1)</td><td class="xbxx-borders shading">NA</td><td class="xbxx-borders shading">0</td><td class="xbxx-borders shading">0</td><td class="xbxr-borders shading">0</td></tr></tbody></table></div><figcaption><div class="caption">Characteristics of the Patients at Baseline.<a href="#t1fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t1fn1" role="paragraph">Patients with non–small-cell lung cancer (NSCLC) with a <i>MET</i> exon 14 skipping mutation were assigned to study cohorts on the basis of receipt of previous treatment: cohort 4 included patients who had received treatment previously, and cohort 5b included those who had not received treatment previously. Patients with NSCLC with <i>MET</i> amplification were assigned to study cohorts on the basis of gene copy number (≥10, 6 to 9, 4 or 5, or &lt;4) and receipt of previous treatment (yes or no): among patients with a copy number of at least 10, cohort 1a included previously treated patients and cohort 5a included patients who had not received treatment previously; cohort 1b included patients with a gene copy number of 6 to 9, cohort 2 those with a gene copy number of 4 or 5, and cohort 3 those with a gene copy number of less than 4. All the patients with a gene copy number of less than 10 had received treatment previously. The data-cutoff date was January 6, 2020. Percentages may not total 100 because of rounding. NA denotes not applicable.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t1fn2" role="paragraph">Eastern Cooperative Oncology Group (ECOG) performance-status scores are assessed on a scale from 0 (fully active) to 5 (death); a score of 1 indicates that the patient is ambulatory but restricted from strenuous activity. One patient in cohort 4, who had undergone randomization in error (protocol deviation), had an ECOG performance-status score of 2 (indicating that the patient was ambulatory and capable of self-care but unable to carry out any work activities).</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="t1fn3" role="paragraph">Among patients with NSCLC with a <i>MET</i> exon 14 skipping mutation, 12 were identified from their medical history and 2 were identified on the basis of the baseline computed tomographic scan.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="t1fn4" role="paragraph">The types of antineoplastic therapy that had been received by patients in the previously treated cohorts are shown in Table S1.</div></div></div></figcaption></figure></div><div role="paragraph">Cohort 6 comprised 34 patients: 3 patients with <i>MET</i>-amplified NSCLC with a gene copy number of at least 10 and 31 patients with NSCLC with a <i>MET</i> exon 14 skipping mutation who had received one previous line of therapy (Table S2). As of the data-cutoff point (January 6, 2020), a total of 23 patients, all of whom had NSCLC with a <i>MET</i> exon 14 skipping mutation and had not received treatment previously, had been enrolled in cohort 7; no efficacy data were available for this cohort.</div><div role="paragraph">The cutoff date for the efficacy analyses was January 6, 2020, except in the three cohorts in which patients had a gene copy number of less than 10 (cohorts 1b, 2, and 3); these cohorts had been closed earlier for futility (cutoff date, April 15, 2019). The cutoff date for the safety analyses in all the cohorts was January 6, 2020.</div></section><section id="sec-2-2"><h3>Efficacy</h3><section id="sec-2-2-1"><h4>Advanced NSCLC with <i>MET</i> Exon 14 Skipping Mutation</h4><div role="paragraph">Among patients with advanced NSCLC with a <i>MET</i> exon 14 skipping mutation, the primary end point of overall response, as assessed by the independent review committee, was observed in 41% (95% confidence interval [CI], 29 to 53) of 69 previously treated patients and in 68% (95% CI, 48 to 84) of 28 patients who had not received treatment previously (<a href="#t2">Table 2</a> and <a href="#f2">Figure 2A</a> and Fig. S1). The median duration of response, as assessed by the independent review committee, was 9.7 months (95% CI, 5.6 to 13.0) among previously treated patients and 12.6 months (95% CI, 5.6 to could not be estimated) among patients who had not received treatment previously (<a href="#t2">Table 2</a>).</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 2</div><nav><a href="#f2" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2002787_f2.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f2" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f2" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2002787_f2.jpg"><img src="/cms/10.1056/NEJMoa2002787/asset/69aa6840-a5e0-4ba5-ab13-693005a1f5c5/assets/images/large/nejmoa2002787_f2.jpg" height="1674" width="2640" aria-labelledby="f2" loading="lazy"></a><figcaption><div class="caption">Tumor Responses to Capmatinib.</div><div class="notes"><div role="doc-footnote">Assessments were conducted by an independent review committee whose members were unaware of the cohort assignments. Panel A shows the best percentage change from baseline in the sum of the longest diameters in patients with NSCLC with a <i>MET</i> exon 14 skipping mutation who had measurable disease at baseline and at least one valid postbaseline assessment; the analysis included 60 previously treated patients and 26 patients who had not received treatment previously. The line at 20% corresponds to a change indicating progressive disease; the line at −30% corresponds to a change indicating a partial response. Circles at the end of the bars indicate patients receiving ongoing treatment. Panel B shows the best percentage change from baseline in the sum of the longest diameters in patients with <i>MET</i>-amplified NSCLC (tumor tissue with a gene copy number [GCN] ≥10) who had measurable disease at baseline and at least one valid postbaseline assessment; the analysis included 55 previously treated patients and 14 patients who had not received treatment previously. Panel C shows progression-free survival among patients with NSCLC with a <i>MET</i> exon 14 skipping mutation; the analysis included 69 previously treated patients and 28 patients who had not received treatment previously. Diamonds at the end of the bars indicate censored data because the patient was still followed for efficacy and had not had disease progression or died, triangles indicate censored data because the patient was no longer followed for efficacy and had not had disease progression or died, and squares indicate death. Patients with no symbol at the end of the bar had progressive disease at the data-cutoff date (January 6, 2020). Panel D shows progression-free survival among patients with <i>MET</i>-amplified NSCLC (tumor tissue with a GCN ≥10); the analysis included 69 previously treated patients and 15 patients who had not received treatment previously.</div></div></figcaption></figure></div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 2</div><nav><a href="#t2" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2002787_t2.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t2" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t2" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2002787_t2.jpg"><img src="/cms/10.1056/NEJMoa2002787/asset/ebe1f72a-2669-4427-ae61-505f115b7a31/assets/images/large/nejmoa2002787_t2.jpg" height="1951" width="2615" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Response</th><th class="txxx-borders" colspan="2"><span>NSCLC with <i>MET</i> Exon 14<br>Skipping Mutation</span></th><th class="txxr-borders" colspan="5"><span>NSCLC with <i>MET</i> Amplification</span></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">Cohort 4<br>(N=69)</th><th class="xxxx-borders">Cohort 5b<br>(N=28)</th><th class="xxxx-borders">Cohort 1a<br>(N=69)</th><th class="xxxx-borders">Cohort 5a<br>(N=15)</th><th class="xxxx-borders">Cohort 1b<br>(N=42)</th><th class="xxxx-borders">Cohort 2<br>(N=54)</th><th class="xxxr-borders">Cohort 3<br>(N=30)</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging02 shading">Best response — no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Complete response</td><td class="xxxx-borders">0</td><td class="xxxx-borders">1 (4)</td><td class="xxxx-borders">1 (1)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Partial response</td><td class="xxxx-borders shading">28 (41)</td><td class="xxxx-borders shading">18 (64)</td><td class="xxxx-borders shading">19 (28)</td><td class="xxxx-borders shading">6 (40)</td><td class="xxxx-borders shading">5 (12)</td><td class="xxxx-borders shading">5 (9)</td><td class="xxxr-borders shading">2 (7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Stable disease</td><td class="xxxx-borders">25 (36)</td><td class="xxxx-borders">7 (25)</td><td class="xxxx-borders">28 (41)</td><td class="xxxx-borders">4 (27)</td><td class="xxxx-borders">17 (40)</td><td class="xxxx-borders">20 (37)</td><td class="xxxr-borders">14 (47)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Noncomplete response or nonprogressive disease</td><td class="xxxx-borders shading">1 (1)</td><td class="xxxx-borders shading">1 (4)</td><td class="xxxx-borders shading">1 (1)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">1 (2)</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Progressive disease</td><td class="xxxx-borders">6 (9)</td><td class="xxxx-borders">1 (4)</td><td class="xxxx-borders">12 (17)</td><td class="xxxx-borders">4 (27)</td><td class="xxxx-borders">15 (36)</td><td class="xxxx-borders">21 (39)</td><td class="xxxr-borders">6 (20)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Unknown or could not be evaluated</td><td class="xxxx-borders shading">9 (13)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">8 (12)</td><td class="xxxx-borders shading">1 (7)</td><td class="xxxx-borders shading">4 (10)</td><td class="xxxx-borders shading">8 (15)</td><td class="xxxr-borders shading">8 (27)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Overall response<a href="#t2fn2" role="doc-noteref">†</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">No. of patients with overall response</td><td class="xxxx-borders shading">28</td><td class="xxxx-borders shading">19</td><td class="xxxx-borders shading">20</td><td class="xxxx-borders shading">6</td><td class="xxxx-borders shading">5</td><td class="xxxx-borders shading">5</td><td class="xxxr-borders shading">2</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Percent of patients (95% CI)</td><td class="xxxx-borders">41 (29–53)</td><td class="xxxx-borders">68 (48–84)</td><td class="xxxx-borders">29 (19–41)</td><td class="xxxx-borders">40 (16–68)</td><td class="xxxx-borders">12 (4–26)</td><td class="xxxx-borders">9 (3–20)</td><td class="xxxr-borders">7 (1–22)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Disease control<a href="#t2fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">No. of patients with disease control</td><td class="xxxx-borders">54</td><td class="xxxx-borders">27</td><td class="xxxx-borders">49</td><td class="xxxx-borders">10</td><td class="xxxx-borders">23</td><td class="xxxx-borders">25</td><td class="xxxr-borders">16</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Percent of patients (95% CI)</td><td class="xxxx-borders shading">78 (67–87)</td><td class="xxxx-borders shading">96 (82–100)</td><td class="xxxx-borders shading">71 (59–81)</td><td class="xxxx-borders shading">67 (38–88)</td><td class="xxxx-borders shading">55 (39–70)</td><td class="xxxx-borders shading">46 (33–60)</td><td class="xxxr-borders shading">53 (34–72)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Duration of response</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">No. of events/no. of patients with response</td><td class="xxxx-borders shading">23/28</td><td class="xxxx-borders shading">11/19</td><td class="xxxx-borders shading">15/20</td><td class="xxxx-borders shading">6/6</td><td class="xxxx-borders shading">3/5</td><td class="xxxx-borders shading">4/5</td><td class="xxxr-borders shading">2/2</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Median duration of response (95% CI) — mo</td><td class="xxxx-borders">9.7<br>(5.6–13.0)</td><td class="xxxx-borders">12.6<br>(5.6–NE)</td><td class="xxxx-borders">8.3<br>(4.2–15.4)</td><td class="xxxx-borders">7.5<br>(2.6–14.3)</td><td class="xxxx-borders">24.9<br>(2.7–24.9)</td><td class="xxxx-borders">9.7<br>(4.2–NE)</td><td class="xxxr-borders">4.2<br>(4.2–4.2)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Progression-free survival</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Progression or death — no. of patients</td><td class="xxxx-borders">60</td><td class="xxxx-borders">17</td><td class="xxxx-borders">58</td><td class="xxxx-borders">15</td><td class="xxxx-borders">34</td><td class="xxxx-borders">50</td><td class="xxxr-borders">22</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging12 shading" data-xml-align="left">Median progression-free survival (95% CI) — mo</td><td class="xbxx-borders shading">5.4<br>(4.2–7.0)</td><td class="xbxx-borders shading">12.4<br>(8.2–NE)</td><td class="xbxx-borders shading">4.1<br>(2.9–4.8)</td><td class="xbxx-borders shading">4.2<br>(1.4–6.9)</td><td class="xbxx-borders shading">2.7<br>(1.4–3.1)</td><td class="xbxx-borders shading">2.7<br>(1.4–4.1)</td><td class="xbxr-borders shading">3.6<br>(2.2–4.2)</td></tr></tbody></table></div><figcaption><div class="caption">Responses to Capmatinib Treatment, as Assessed by the Independent Review Committee.<a href="#t2fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t2fn1" role="paragraph">The data-cutoff date was January 6, 2020, for cohorts 4, 5b, 1a, and 5a and April 15, 2019, for cohorts 1b, 2, and 3. Complete response required at least two determinations of complete response (according to the Response Evaluation Criteria in Solid Tumors, version 1.1) that were made at least 4 weeks apart before progression. Partial response required at least two determinations of partial response or better (not qualifying for complete response) that were made at least 4 weeks apart before progression. Stable disease required at least one assessment of stable disease or better (not qualifying for complete response) that was made more than 6 weeks after the start of capmatinib. A noncomplete response or nonprogressive disease was noted when neither complete response nor progressive disease was observed (for patients with nontarget lesions only at baseline). Progressive disease was noted when progression occurred 12 weeks or less after the start of capmatinib (and when the criteria for complete response, partial response, or stable disease were not met). Unknown status indicates all other cases (i.e., those not qualifying as a confirmed complete response or partial response and that did not involve stable disease after &gt;6 weeks after the start of capmatinib or progression within the first 12 weeks of therapy). Percentages may not total 100 because of rounding. NE denotes could not be estimated.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t2fn2" role="paragraph">Overall response was defined as a complete response or partial response.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="t2fn3" role="paragraph">Disease control was defined as a complete response, partial response, stable disease, or noncomplete response or nonprogressive disease.</div></div></div></figcaption></figure></div><div role="paragraph">Responses to capmatinib were rapid, with the majority of patients (82% of the previously treated patients and 68% of those who had not received treatment previously) having a tumor response at the first tumor evaluation after the initiation of capmatinib therapy. Within the limitation of the small sample size of each subgroup, clinical benefit was noted across all the subgroups analyzed (Table S3).</div><div role="paragraph">In an analysis involving 73 patients (53 of whom had been previously treated and 20 of whom had not received treatment previously), a 99% concordance between next-generation sequencing and RT-PCR analyses was observed and there were no considerable differences in response to capmatinib according to the type of genetic alteration causing <i>MET</i> exon 14 skipping mutations or the co-occurrence of <i>MET</i> amplification (see the Supplementary Results section and Figs. S2, S3, and S4). The tumor mutational burden was low in patients with NSCLC with a <i>MET</i> exon 14 skipping mutation (Fig. S5).</div><div role="paragraph">The median progression-free survival, as assessed by the independent review committee, was 5.4 months (95% CI, 4.2 to 7.0) among previously treated patients and 12.4 months (95% CI, 8.2 to could not be estimated) among patients who had not received treatment previously (Figs. S6 and S7). Results according to investigator assessment were similar to those of the independent review committee (Table S4).</div><div role="paragraph">A total of 14 patients with NSCLC with a <i>MET</i> exon 14 skipping mutation had brain metastases at baseline, of whom 13 (10 patients who had been previously treated and 3 who had not received treatment previously) had data that could be evaluated by the independent neuroradiologic review committee. A total of 12 of the 13 patients had intracranial disease control according to neuroradiologic assessment. Seven patients had an intracranial response, including 4 who had a complete response. (Computed tomographic scans in a patient with a response are shown in Fig. S8.) Three of the 7 patients who had a response had received brain radiotherapy previously. Intracranial responses were observed at the first assessment.</div><div role="paragraph">At time of the analyses, 63 previously treated patients (91%) and 23 patients who had not received treatment previously (82%) had discontinued treatment (Table S5). The primary reason for discontinuation was progressive disease (in 58% of the previously treated patients and in 46% of those who had not received treatment previously).</div><div role="paragraph">Results from the expansion cohort 6, which included 31 patients with NSCLC with <i>MET</i> exon 14 skipping mutation who had received one line of therapy previously, were in line with the efficacy of capmatinib as observed in cohort 4 (which included previously treated patients with <i>MET</i> exon 14 skipping mutation). Among these 31 patients in cohort 6, an overall response was observed in 48% (95% CI, 30 to 67) (Table S6).</div></section><section id="sec-2-2-2"><h4>Advanced NSCLC with <i>MET</i> Amplification</h4><div role="paragraph">Among patients with advanced NSCLC with <i>MET</i> amplification, the primary end point of overall response, as assessed by the independent review committee, was observed in 12% of those (95% CI, 4 to 26) who had tumor tissue with a gene copy number of 6 to 9, in 9% of those (95% CI, 3 to 20) who had tumor tissue with a gene copy number of 4 or 5, and in 7% of those (95% CI, 1 to 22) who had tumor tissue with a gene copy number of less than 4 (<a href="#t2">Table 2</a>). Therefore, these cohorts were closed for futility at the interim analysis. The median progression-free survival, as assessed by the independent review committee, was as follows: among patients who had tumor tissue with a gene copy number of 6 to 9, the median progression-free survival was 2.7 months (95% CI, 1.4 to 3.1); among those who had tumor tissue with a gene copy number of 4 or 5, it was 2.7 months (95% CI, 1.4 to 4.1); and among those who had tumor tissue with a gene copy number of less than 4, it was 3.6 months (95% CI, 2.2 to 4.2).</div><div role="paragraph">Capmatinib showed activity in patients who had tumor tissue with a gene copy number of at least 10; however, the overall response was lower than the prespecified threshold for clinically relevant activity. An overall response, as assessed by the independent review committee, was observed in 29% (95% CI, 19 to 41) of 69 previously treated patients and in 40% (95% CI, 16 to 68) of 15 patients who had not received treatment previously (<a href="#t2">Table 2</a> and <a href="#f2">Figure 2B</a>). With the limitation of small sample size in the subgroups involving patients who had not received treatment previously, the results regarding response appeared to be consistent across subgroups (Table S3).</div><div role="paragraph">The median duration of response was 8.3 months (95% CI, 4.2 to 15.4) among 20 previously treated patients and 7.5 months (95% CI, 2.6 to 14.3) among 6 patients who had not received treatment previously (<a href="#f2">Figure 2D</a>); the median progression-free survival was 4.1 months (95% CI, 2.9 to 4.8) and 4.2 months (95% CI, 1.4 to 6.9), respectively. The results according to investigator assessment were similar to those of the independent committee (Table S4).</div><div role="paragraph">Among patients who had NSCLC with <i>MET</i> amplification and tumor tissue with a gene copy number of at least 10, a total of 66 previously treated patients (96%; cohort 1a) and all 15 patients who had not received treatment previously (cohort 5a) had discontinued treatment as of the data-cutoff date (Table S5). Discontinuation was due primarily to progressive disease. Results regarding the 3 patients who had NSCLC with <i>MET</i> amplification and tumor tissue with a gene copy number of at least 10 who had been enrolled in cohort 6 are shown in Table S6.</div></section></section><section id="sec-2-3"><h3>Adverse Events</h3><div role="paragraph">The median duration of exposure to capmatinib varied across the cohorts, with values ranging from 6.6 weeks to 48.2 weeks (<a href="#t3">Table 3</a>). Across all the cohorts (364 patients), the most commonly reported adverse events regardless of causality were peripheral edema, nausea, and vomiting, and adverse events of grade 3 or 4 regardless of causality were reported in 67% of the patients (<a href="#t3">Table 3</a>). The most common treatment-related adverse events (those occurring in ≥10% of the patients) are listed in Table S7; the most frequent of these were peripheral edema, nausea, vomiting, and increased blood creatinine level. Treatment-related serious adverse events occurred in 48 of 364 patients (13%); the incidence was lower in cohorts 1b, 2, and 3, which had shorter durations of exposure to capmatinib (Table S7). Treatment-related adverse events leading to discontinuation of treatment occurred in 39 patients (11%); the results were generally consistent across the cohorts (Table S7). Treatment-related peripheral edema led to discontinuation in 6 patients (2%), with an event of grade 3 or 4 occurring in 2 patients (1%). In total, 83 patients (23%) had at least one adverse event (regardless of causality) that led to dose reduction.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 3</div><nav><a href="#t3" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2002787_t3.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t3" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t3" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2002787_t3.jpg"><img src="/cms/10.1056/NEJMoa2002787/asset/2fdac451-dafe-4867-98a3-df0979b5b06d/assets/images/large/nejmoa2002787_t3.jpg" height="2409" width="2615" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Variable</th><th class="txxx-borders" colspan="4"><span>NSCLC with <i>MET</i> Exon 14<br>Skipping Mutation</span></th><th class="txxx-borders" colspan="10"><span>NSCLC with <i>MET</i> Amplification</span></th><th class="txxr-borders" colspan="2"><span>All Cohorts<br>(N=364)</span></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders" colspan="2"><span>Cohort 4<br>(N=69)</span></th><th class="xxxx-borders" colspan="2"><span>Cohort 5b<br>(N=28)</span></th><th class="xxxx-borders" colspan="2"><span>Cohort 1a<br>(N=69)</span></th><th class="xxxx-borders" colspan="2"><span>Cohort 5a<br>(N=15)</span></th><th class="xxxx-borders" colspan="2"><span>Cohort 1b<br>(N=42)</span></th><th class="xxxx-borders" colspan="2"><span>Cohort 2<br>(N=54)</span></th><th class="xxxx-borders" colspan="2"><span>Cohort 3<br>(N=30)</span></th><th class="xxxx-borders">Total</th><th class="xxxr-borders">Grade<br>3 or 4</th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">Total</th><th class="xxxx-borders">Grade<br>3 or 4</th><th class="xxxx-borders">Total</th><th class="xxxx-borders">Grade<br>3 or 4</th><th class="xxxx-borders">Total</th><th class="xxxx-borders">Grade<br>3 or 4</th><th class="xxxx-borders">Total</th><th class="xxxx-borders">Grade<br>3 or 4</th><th class="xxxx-borders">Total</th><th class="xxxx-borders">Grade<br>3 or 4</th><th class="xxxx-borders">Total</th><th class="xxxx-borders">Grade<br>3 or 4</th><th class="xxxx-borders">Total</th><th class="xxxx-borders">Grade<br>3 or 4</th><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging02 shading"><b>Adverse events</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Any event — no. (%)</td><td class="xxxx-borders">68 (99)</td><td class="xxxx-borders">52 (75)</td><td class="xxxx-borders">28 (100)</td><td class="xxxx-borders">21 (75)</td><td class="xxxx-borders">67 (97)</td><td class="xxxx-borders">48 (70)</td><td class="xxxx-borders">15 (100)</td><td class="xxxx-borders">10 (67)</td><td class="xxxx-borders">42 (100)</td><td class="xxxx-borders">27 (64)</td><td class="xxxx-borders">54 (100)</td><td class="xxxx-borders">35 (65)</td><td class="xxxx-borders">28 (93)</td><td class="xxxx-borders">22 (73)</td><td class="xxxx-borders">355 (98)</td><td class="xxxr-borders">244 (67)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Most common events — no. (%)<a href="#t3fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Peripheral edema</td><td class="xxxx-borders">37 (54)</td><td class="xxxx-borders">10 (14)</td><td class="xxxx-borders">21 (75)</td><td class="xxxx-borders">3 (11)</td><td class="xxxx-borders">34 (49)</td><td class="xxxx-borders">5 (7)</td><td class="xxxx-borders">11 (73)</td><td class="xxxx-borders">3 (20)</td><td class="xxxx-borders">18 (43)</td><td class="xxxx-borders">3 (7)</td><td class="xxxx-borders">24 (44)</td><td class="xxxx-borders">3 (6)</td><td class="xxxx-borders">11 (37)</td><td class="xxxx-borders">1 (3)</td><td class="xxxx-borders">186 (51)</td><td class="xxxr-borders">33 (9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Nausea<a href="#t3fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders shading">32 (46)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">13 (46)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">32 (46)</td><td class="xxxx-borders shading">5 (7)</td><td class="xxxx-borders shading">9 (60)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">17 (40)</td><td class="xxxx-borders shading">3 (7)</td><td class="xxxx-borders shading">24 (44)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">15 (50)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">163 (45)</td><td class="xxxr-borders shading">9 (2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Vomiting<a href="#t3fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders">18 (26)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">7 (25)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">24 (35)</td><td class="xxxx-borders">5 (7)</td><td class="xxxx-borders">4 (27)</td><td class="xxxx-borders">1 (7)</td><td class="xxxx-borders">16 (38)</td><td class="xxxx-borders">1 (2)</td><td class="xxxx-borders">12 (22)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">9 (30)</td><td class="xxxx-borders">1 (3)</td><td class="xxxx-borders">102 (28)</td><td class="xxxr-borders">9 (2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Blood creatinine increased</td><td class="xxxx-borders shading">23 (33)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">10 (36)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">16 (23)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">3 (20)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">8 (19)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">14 (26)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">5 (17)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">89 (24)</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Dyspnea</td><td class="xxxx-borders">19 (28)</td><td class="xxxx-borders">7 (10)</td><td class="xxxx-borders">6 (21)</td><td class="xxxx-borders">2 (7)</td><td class="xxxx-borders">13 (19)</td><td class="xxxx-borders">4 (6)</td><td class="xxxx-borders">5 (33)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">16 (38)</td><td class="xxxx-borders">5 (12)</td><td class="xxxx-borders">14 (26)</td><td class="xxxx-borders">4 (7)</td><td class="xxxx-borders">7 (23)</td><td class="xxxx-borders">1 (3)</td><td class="xxxx-borders">84 (23)</td><td class="xxxr-borders">24 (7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Fatigue</td><td class="xxxx-borders shading">18 (26)</td><td class="xxxx-borders shading">6 (9)</td><td class="xxxx-borders shading">4 (14)</td><td class="xxxx-borders shading">1 (4)</td><td class="xxxx-borders shading">11 (16)</td><td class="xxxx-borders shading">1 (1)</td><td class="xxxx-borders shading">2 (13)</td><td class="xxxx-borders shading">1 (7)</td><td class="xxxx-borders shading">10 (24)</td><td class="xxxx-borders shading">2 (5)</td><td class="xxxx-borders shading">16 (30)</td><td class="xxxx-borders shading">2 (4)</td><td class="xxxx-borders shading">6 (20)</td><td class="xxxx-borders shading">3 (10)</td><td class="xxxx-borders shading">80 (22)</td><td class="xxxr-borders shading">16 (4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Decreased appetite<a href="#t3fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders">15 (22)</td><td class="xxxx-borders">1 (1)</td><td class="xxxx-borders">8 (29)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">15 (22)</td><td class="xxxx-borders">1 (1)</td><td class="xxxx-borders">4 (27)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">7 (17)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">12 (22)</td><td class="xxxx-borders">1 (2)</td><td class="xxxx-borders">8 (27)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">76 (21)</td><td class="xxxr-borders">3 (1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Constipation</td><td class="xxxx-borders shading">10 (14)</td><td class="xxxx-borders shading">2 (3)</td><td class="xxxx-borders shading">4 (14)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">16 (23)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">6 (40)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">9 (21)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">10 (19)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">7 (23)</td><td class="xxxx-borders shading">1 (3)</td><td class="xxxx-borders shading">66 (18)</td><td class="xxxr-borders shading">3 (1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Diarrhea</td><td class="xxxx-borders">12 (17)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">5 (18)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">19 (28)</td><td class="xxxx-borders">1 (1)</td><td class="xxxx-borders">4 (27)</td><td class="xxxx-borders">1 (7)</td><td class="xxxx-borders">6 (14)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">7 (13)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">8 (27)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">64 (18)</td><td class="xxxr-borders">2 (1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Cough</td><td class="xxxx-borders shading">10 (14)</td><td class="xxxx-borders shading">1 (1)</td><td class="xxxx-borders shading">7 (25)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">9 (13)</td><td class="xxxx-borders shading">1 (1)</td><td class="xxxx-borders shading">2 (13)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">9 (21)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">9 (17)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">5 (17)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">58 (16)</td><td class="xxxr-borders shading">2 (1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Back pain</td><td class="xxxx-borders">11 (16)</td><td class="xxxx-borders">2 (3)</td><td class="xxxx-borders">4 (14)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">8 (12)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">2 (13)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">7 (17)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">10 (19)</td><td class="xxxx-borders">1 (2)</td><td class="xxxx-borders">2 (7)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">54 (15)</td><td class="xxxr-borders">3 (1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Pyrexia</td><td class="xxxx-borders shading">9 (13)</td><td class="xxxx-borders shading">1 (1)</td><td class="xxxx-borders shading">2 (7)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">10 (14)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">3 (20)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">8 (19)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">8 (15)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">5 (17)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">50 (14)</td><td class="xxxr-borders shading">3 (1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">ALT increased</td><td class="xxxx-borders">8 (12)</td><td class="xxxx-borders">6 (9)</td><td class="xxxx-borders">4 (14)</td><td class="xxxx-borders">2 (7)</td><td class="xxxx-borders">12 (17)</td><td class="xxxx-borders">7 (10)</td><td class="xxxx-borders">5 (33)</td><td class="xxxx-borders">2 (13)</td><td class="xxxx-borders">4 (10)</td><td class="xxxx-borders">1 (2)</td><td class="xxxx-borders">5 (9)</td><td class="xxxx-borders">2 (4)</td><td class="xxxx-borders">3 (10)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">48 (13)</td><td class="xxxr-borders">23 (6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Asthenia</td><td class="xxxx-borders shading">6 (9)</td><td class="xxxx-borders shading">3 (4)</td><td class="xxxx-borders shading">4 (14)</td><td class="xxxx-borders shading">2 (7)</td><td class="xxxx-borders shading">6 (9)</td><td class="xxxx-borders shading">3 (4)</td><td class="xxxx-borders shading">2 (13)</td><td class="xxxx-borders shading">1 (7)</td><td class="xxxx-borders shading">8 (19)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">11 (20)</td><td class="xxxx-borders shading">3 (6)</td><td class="xxxx-borders shading">3 (10)</td><td class="xxxx-borders shading">1 (3)</td><td class="xxxx-borders shading">42 (12)</td><td class="xxxr-borders shading">13 (4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Pneumonia</td><td class="xxxx-borders">7 (10)</td><td class="xxxx-borders">4 (6)</td><td class="xxxx-borders">2 (7)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">12 (17)</td><td class="xxxx-borders">3 (4)</td><td class="xxxx-borders">1 (7)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">7 (17)</td><td class="xxxx-borders">3 (7)</td><td class="xxxx-borders">3 (6)</td><td class="xxxx-borders">3 (6)</td><td class="xxxx-borders">3 (10)</td><td class="xxxx-borders">1 (3)</td><td class="xxxx-borders">39 (11)</td><td class="xxxr-borders">17 (5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Weight loss</td><td class="xxxx-borders shading">9 (13)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">3 (11)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">7 (10)</td><td class="xxxx-borders shading">1 (1)</td><td class="xxxx-borders shading">3 (20)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">4 (10)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">2 (4)</td><td class="xxxx-borders shading">1 (2)</td><td class="xxxx-borders shading">4 (13)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">36 (10)</td><td class="xxxr-borders shading">2 (1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Noncardiac chest pain</td><td class="xxxx-borders">5 (7)</td><td class="xxxx-borders">1 (1)</td><td class="xxxx-borders">1 (4)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">10 (14)</td><td class="xxxx-borders">2 (3)</td><td class="xxxx-borders">3 (20)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">5 (12)</td><td class="xxxx-borders">1 (2)</td><td class="xxxx-borders">7 (13)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">1 (3)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">35 (10)</td><td class="xxxr-borders">4 (1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Serious adverse event — no. (%)</td><td class="xxxx-borders shading">36 (52)</td><td class="xxxx-borders shading">30 (43)</td><td class="xxxx-borders shading">14 (50)</td><td class="xxxx-borders shading">12 (43)</td><td class="xxxx-borders shading">42 (61)</td><td class="xxxx-borders shading">36 (52)</td><td class="xxxx-borders shading">9 (60)</td><td class="xxxx-borders shading">5 (33)</td><td class="xxxx-borders shading">21 (50)</td><td class="xxxx-borders shading">19 (45)</td><td class="xxxx-borders shading">30 (56)</td><td class="xxxx-borders shading">22 (41)</td><td class="xxxx-borders shading">15 (50)</td><td class="xxxx-borders shading">13 (43)</td><td class="xxxx-borders shading">184 (51)</td><td class="xxxr-borders shading">152 (42)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Event leading to discontinuation — no. (%)</td><td class="xxxx-borders">14 (20)</td><td class="xxxx-borders">8 (12)</td><td class="xxxx-borders">6 (21)</td><td class="xxxx-borders">5 (18)</td><td class="xxxx-borders">11 (16)</td><td class="xxxx-borders">8 (12)</td><td class="xxxx-borders">3 (20)</td><td class="xxxx-borders">2 (13)</td><td class="xxxx-borders">5 (12)</td><td class="xxxx-borders">5 (12)</td><td class="xxxx-borders">8 (15)</td><td class="xxxx-borders">1 (2)</td><td class="xxxx-borders">5 (17)</td><td class="xxxx-borders">2 (7)</td><td class="xxxx-borders">56 (15)</td><td class="xxxr-borders">35 (10)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading"><b>Exposure</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Median duration — wk</td><td class="xxxx-borders">22.1</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">48.2</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">17.6</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">15.3</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">11.8</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">8.8</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">6.6</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">15.3</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-type="row"><td class="xblx-borders hanging02 shading">Range — wk</td><td class="xbxx-borders shading" data-xml-align="center">0.4–<br>136.0</td><td class="xbxx-borders shading">&nbsp;</td><td class="xbxx-borders shading" data-xml-align="center">4.0–<br>117.4</td><td class="xbxx-borders shading">&nbsp;</td><td class="xbxx-borders shading" data-xml-align="center">0.9–<br>201.0</td><td class="xbxx-borders shading">&nbsp;</td><td class="xbxx-borders shading" data-xml-align="center">3.1–<br>61.1</td><td class="xbxx-borders shading">&nbsp;</td><td class="xbxx-borders shading" data-xml-align="center">1.0–<br>215.0</td><td class="xbxx-borders shading">&nbsp;</td><td class="xbxx-borders shading" data-xml-align="center">0.6–<br>195.0</td><td class="xbxx-borders shading">&nbsp;</td><td class="xbxx-borders shading" data-xml-align="center">1.6–<br>73.0</td><td class="xbxx-borders shading">&nbsp;</td><td class="xbxx-borders shading" data-xml-align="center">0.4–<br>215.0</td><td class="xbxr-borders shading">&nbsp;</td></tr></tbody></table></div><figcaption><div class="caption">Adverse Events, According to Grade, Regardless of Causality, and Exposure to Capmatinib.<a href="#t3fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t3fn1" role="paragraph">The data-cutoff date was January 6, 2020. The overall analysis included all patients from cohorts 1 through 7 who received at least one dose of capmatinib. ALT denotes alanine aminotransferase.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t3fn2" role="paragraph">The most common adverse events were those reported in more than 20% of the patients in any cohort.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="t3fn3" role="paragraph">Capmatinib was administered under fasting conditions; food restriction was removed in cohorts 6 (34 patients) and 7 (23 patients). Safety data for cohorts 6 and 7 are shown in Tables S8 and S9, and safety data for cohorts with fasting restrictions, as compared with those without fasting restrictions, are shown in Table S10.</div></div></div></figcaption></figure></div><div role="paragraph">Death from causes other than advanced NSCLC occurred during treatment in 13 patients (4%). The reported causes were atrial fibrillation, hepatitis, pneumonia, organizing pneumonia, bacterial pneumonia, pneumonitis, respiratory distress, sepsis, septic shock, sudden death, and assisted suicide (in 1 patient each) and cardiac arrest (in 2 patients). Only one death (from pneumonitis) was suspected to be related to capmatinib according to review by the investigator and according to medical review by Novartis Pharmaceuticals.</div><div role="paragraph">The safety results in cohorts 6 and 7 are shown in Tables S8 and S9. A lower incidence of gastrointestinal adverse events was observed when capmatinib was administered without fasting restrictions than when it was administered under fasting conditions (Table S10). Results regarding the pharmacokinetics of capmatinib are shown in Table S11.</div></section></section><section id="sec-3" data-type="discussion"><h2>Discussion</h2><div role="paragraph">We evaluated the clinical efficacy of the highly specific MET inhibitor capmatinib in patients with advanced NSCLC with a <i>MET</i> exon 14 skipping mutation or <i>MET</i> amplification. Capmatinib led to clinically meaningful antitumor activity in patients with NSCLC with a <i>MET</i> exon 14 skipping mutation who had not received treatment previously (overall response in 68% of the patients and disease control in 96%); the median duration of response was more than 1 year. Although these efficacy results need confirmation in a larger population, the results are similar to those reported with effective, established targeted therapies for NSCLC.<sup><a href="#core-r30" role="doc-biblioref" data-xml-rid="r30 r31 r32" id="body-ref-r32" href-manipulated="true">30-32</a></sup> Expansion cohort 7 (which includes patients with NSCLC with a <i>MET</i> exon 14 skipping mutation who had not received treatment previously) is ongoing.</div><div role="paragraph">Lower efficacy was observed among patients with NSCLC with a <i>MET</i> exon 14 skipping mutation who had previously received one or two lines of therapy, with an overall response observed in 41% of the patients (and in 48% of patients who had received one previous line of therapy [cohort 6]) and disease control in 78%; the median duration of response was 9.7 months. Nonetheless, these values are higher than those reported for current second- or third-line therapies in patients with advanced NSCLC.<sup><a href="#core-r33" role="doc-biblioref" data-xml-rid="r33 r34 r35 r36 r37 r38" id="body-ref-r38" href-manipulated="true">33-38</a></sup></div><div role="paragraph">In findings that were consistent with evidence that has suggested that the level of gene amplification may dictate whether <i>MET</i> amplification acts as an oncogenic driver in NSCLC,<sup><a href="#core-r39" role="doc-biblioref" data-xml-rid="r39" id="body-ref-r39" href-manipulated="true" aria-label="Reference 39">39</a></sup> capmatinib showed limited activity in patients who had <i>MET</i>-amplified NSCLC and tumor tissue with a gene copy number of less than 10. The frequent coexistence of other known drivers at lower or moderate levels of <i>MET</i> amplification might argue against a true driver function in this context, as compared with high-level <i>MET</i> amplification, in which co-occurring drivers are rare.<sup><a href="#core-r40" role="doc-biblioref" data-xml-rid="r40" id="body-ref-r40" href-manipulated="true" aria-label="Reference 40">40</a></sup> In cohorts involving patients with <i>MET</i> amplification with a gene copy number of at least 10 in tumor tissue, an overall response was observed in 29% of previously treated patients and in 40% of patients who had not received treatment previously; however, the results were lower than the prespecified threshold for significance.</div><div role="paragraph">Our results and those from previous trials confirm that <i>MET</i> exon 14 skipping mutations constitute a valid biomarker for the selection of patients for MET-directed treatment. Crizotinib therapy led to a response in 32% of patients with advanced NSCLC with a <i>MET</i> exon 14 skipping mutation,<sup><a href="#core-r18" role="doc-biblioref" data-xml-rid="r18" id="body-ref-r18-2" href-manipulated="true" aria-label="Reference 18">18</a></sup> and recent results have shown that tepotinib therapy led to a response in 46% of patients.<sup><a href="#core-r41" role="doc-biblioref" data-xml-rid="r41" id="body-ref-r41" href-manipulated="true" aria-label="Reference 41">41</a></sup> Savolitinib has also shown activity in this NSCLC subgroup.<sup><a href="#core-r42" role="doc-biblioref" data-xml-rid="r42" id="body-ref-r42" href-manipulated="true" aria-label="Reference 42">42</a></sup></div><div role="paragraph">Patients who have tumors with a <i>MET</i> exon 14 skipping mutation have a poor prognosis with standard therapies, including immunotherapies.<sup><a href="#core-r43" role="doc-biblioref" data-xml-rid="r43 r44 r45" id="body-ref-r45" href-manipulated="true">43-45</a></sup> The efficacy of capmatinib is noteworthy because these patients are generally elderly<sup><a href="#core-r3" role="doc-biblioref" data-xml-rid="r3 r5" id="body-ref-r5-3" href-manipulated="true">3,5</a></sup> and are thus more challenging to treat owing to a greater risk of toxic effects from first-line multidrug regimens.</div><div role="paragraph">Among the patients with NSCLC with a <i>MET</i> exon 14 skipping mutation in our study, the difference in response between previously treated patients and patients who had not received treatment previously remains unexplained, although it is important to consider the limited number of patients and the overlapping 95% confidence intervals. An overall decline in health during longer durations of disease, as well as the evolution of resistant clones during first-line therapy, might contribute to this observation. On the basis of available data, the antitumor activity and the duration of response that we observed seemed to be independent of the type of <i>MET</i> mutation leading to <i>MET</i> exon 14 skipping and independent of the co-occurrence of <i>MET</i> amplification — findings that suggest that off-target resistance mechanisms may play a role. Molecular characterization of larger cohorts involving patients with tumors with a <i>MET</i> exon 14 skipping mutation might elucidate such mechanisms. These observations support the need for broad molecular profiling before the decision point regarding first-line therapy. The high concordance of detection of <i>MET</i> exon 14 skipping mutations by both RT-PCR testing and next-generation sequencing is particularly important, given the need to test for an increasing number of therapeutically relevant genetic alterations in patients with advanced NSCLC with limited tumor material.</div><div role="paragraph">Brain metastases may develop in up to 20 to 40% of patients with stage IV NSCLC,<sup><a href="#core-r46" role="doc-biblioref" data-xml-rid="r46" id="body-ref-r46" href-manipulated="true" aria-label="Reference 46">46</a></sup> and the incidence among patients with NSCLC with a <i>MET</i> exon 14 skipping mutation is similar<sup><a href="#core-r47" role="doc-biblioref" data-xml-rid="r47" id="body-ref-r47" href-manipulated="true" aria-label="Reference 47">47</a></sup>; the percentage of patients with brain metastases among patients with a <i>MET</i> exon 14 skipping mutation in this study was 11 to 23% (<a href="#t1">Table 1</a> and Table S2). The activity of capmatinib in the brain was encouraging; responses were observed in 7 of 13 patients with NSCLC with a <i>MET</i> exon 14 skipping mutation, including complete resolution of brain metastases in 4 patients. A total of 3 of the 7 patients with a response had received radiotherapy previously, which could have contributed to responses in brain metastases. Given the importance of central nervous system control to maintain best disease response and quality of life, confirmation of these preliminary findings in larger populations of patients will be important.</div><div role="paragraph">Our study confirmed the known safety profile of capmatinib.<sup><a href="#core-r17" role="doc-biblioref" data-xml-rid="r17" id="body-ref-r17-3" href-manipulated="true" aria-label="Reference 17">17</a></sup> The majority of adverse events were of grade 1 or 2, were predictable, and were reversible with dose adjustments. The most frequently reported adverse events related to capmatinib treatment were peripheral edema, nausea, vomiting, and increased blood creatinine level. Peripheral edema and gastrointestinal toxic effects are known side effects of MET inhibitors. The reversible increase in the creatinine level was probably due to inhibition of renal transporters multidrug and toxic extrusion protein 1 and 2-K (MATE1 and MATE2-K), because capmatinib is an inhibitor of these transporters (unpublished data). Approximately 10 to 40% of the serum creatinine is cleared by means of active tubular secretion by renal transporters such as MATE and organic anion transporter, in addition to renal glomerular filtration.<sup><a href="#core-r48" role="doc-biblioref" data-xml-rid="r48" id="body-ref-r48" href-manipulated="true" aria-label="Reference 48">48</a></sup></div><div role="paragraph">Capmatinib therapy showed efficacy in patients with NSCLC with a <i>MET</i> exon 14 skipping mutation. These results and the safety profile, involving mainly low-grade and reversible adverse events, suggest that capmatinib may be a new therapeutic option in patients with advanced NSCLC with a <i>MET</i> exon 14 skipping mutation.</div></section>



        
        
</div></section><section id="backmatter" data-extent="backmatter" data-location="articleTab_article"><div class="core-container"><section id="backnotes" data-location="notes_article"><h2>Notes</h2><div data-type="data-sharing" role="paragraph">A <a href="#ap4">data sharing statement</a> provided by the authors is available with the full text of this article at NEJM.org.</div><div role="paragraph">Supported by <span class="named-content" data-type="funder">Novartis Pharmaceuticals</span>.</div><div role="paragraph"><a href="#ap3">Disclosure forms</a> provided by the authors are available with the full text of this article at NEJM.org.</div><div role="paragraph">We thank our patients, their families and caregivers, and the teams at the participating clinical sites; Pushkar Narvilkar and Aarti Kamaraj, of Novartis Healthcare, and Ana Costa, of Chameleon Communications, for providing medical writing assistance with an earlier version of the manuscript; Lauren Fairchild for performing the biomarker analysis; Bahar Yilmazel and the Foundation Medicine team for assistance with additional biomarker analysis; and Ngozi Nwana, Ming Yan, Shruti Bharadwaj, Agus Darwanto, and Mahtab Marker for providing assistance with the biomarker analysis strategy.</div></section><section id="supplementary-materials" class="core-supplementary-materials"><h2>Supplementary Material</h2><div role="list"><div id="ap1" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Protocol</span> <span class="core-filename">(nejmoa2002787_protocol.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2002787/suppl_file/nejmoa2002787_protocol.pdf" download="nejmoa2002787_protocol.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2002787_protocol.pdf" data-doi="10.1056/NEJMoa2002787">Download</a></li><li>4.07 MB</li></ul></div></div><div id="ap2" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Supplementary Appendix</span> <span class="core-filename">(nejmoa2002787_appendix.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2002787/suppl_file/nejmoa2002787_appendix.pdf" download="nejmoa2002787_appendix.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2002787_appendix.pdf" data-doi="10.1056/NEJMoa2002787">Download</a></li><li>1.66 MB</li></ul></div></div><div id="ap3" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Disclosure Forms</span> <span class="core-filename">(nejmoa2002787_disclosures.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2002787/suppl_file/nejmoa2002787_disclosures.pdf" download="nejmoa2002787_disclosures.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2002787_disclosures.pdf" data-doi="10.1056/NEJMoa2002787">Download</a></li><li>1.54 MB</li></ul></div></div><div id="ap4" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Data Sharing Statement</span> <span class="core-filename">(nejmoa2002787_data-sharing.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2002787/suppl_file/nejmoa2002787_data-sharing.pdf" download="nejmoa2002787_data-sharing.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2002787_data-sharing.pdf" data-doi="10.1056/NEJMoa2002787">Download</a></li><li>85.87 KB</li></ul></div></div></div></section><section id="bibliography" class="core-reference-list" role="doc-bibliography" data-location="references_article"><h2>References</h2><div role="list" data-method="clamp" id="collapsible-text"><div role="listitem" data-has="label"><div class="label">1.</div><div id="r1" class="citations"><div class="citation"><div class="citation-content">Comoglio PM, Trusolino L, Boccaccio C. Known and novel roles of the MET oncogene in cancer: a coherent approach to targeted therapy. <em>Nat Rev Cancer</em> 2018;18:341-358.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r7-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41568-018-0002-y" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29674709/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000432926500005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Known+and+novel+roles+of+the+MET+oncogene+in+cancer%3A+a+coherent+approach+to+targeted+therapy.&amp;publication_year=2018&amp;journal=Nat+Rev+Cancer&amp;pages=341-358&amp;doi=10.1038%2Fs41568-018-0002-y&amp;pmid=29674709" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="r2" class="citations"><div class="citation"><div class="citation-content">Koch JP, Aebersold DM, Zimmer Y, Medová M. MET targeting: time for a rematch. <em>Oncogene</em> 2020;39:2845-2862.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r7-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41388-020-1193-8" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32034310/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000511752600005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=MET+targeting%3A+time+for+a+rematch.&amp;publication_year=2020&amp;journal=Oncogene&amp;pages=2845-2862&amp;doi=10.1038%2Fs41388-020-1193-8&amp;pmid=32034310" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="r3" class="citations"><div class="citation"><div class="citation-content">Awad MM, Oxnard GR, Jackman DM, et al. MET exon 14 mutations in non-small-cell lung cancer are associated with advanced age and stage-dependent MET genomic amplification and c-Met overexpression. <em>J Clin Oncol</em> 2016;34:721-730.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r3" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.2015.63.4600" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26729443/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000374333400018" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=MET+exon+14+mutations+in+non-small-cell+lung+cancer+are+associated+with+advanced+age+and+stage-dependent+MET+genomic+amplification+and+c-Met+overexpression.&amp;publication_year=2016&amp;journal=J+Clin+Oncol&amp;pages=721-730&amp;doi=10.1200%2FJCO.2015.63.4600&amp;pmid=26729443" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r3" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r7-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] mutations or from insertions or deletions. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r7-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] in the absence of other driver mutations, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r5-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] these patients are generally elderly </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="r4" class="citations"><div class="citation"><div class="citation-content">Frampton GM, Ali SM, Rosenzweig M, et al. Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. <em>Cancer Discov</em> 2015;5:850-859.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r4" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1158/2159-8290.CD-15-0285" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25971938/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000359317700018" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Activation+of+MET+via+diverse+exon+14+splicing+alterations+occurs+in+multiple+tumor+types+and+confers+clinical+sensitivity+to+MET+inhibitors.&amp;publication_year=2015&amp;journal=Cancer+Discov&amp;pages=850-859&amp;doi=10.1158%2F2159-8290.CD-15-0285&amp;pmid=25971938" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r4" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r7-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] mutations or from insertions or deletions. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r7-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] in the absence of other driver mutations, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r18-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] emerged as potential predictive biomarkers. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="r5" class="citations"><div class="citation"><div class="citation-content">Schrock AB, Frampton GM, Suh J, et al. Characterization of 298 patients with lung cancer harboring MET exon 14 skipping alterations. <em>J Thorac Oncol</em> 2016;11:1493-1502.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r5" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.jtho.2016.06.004" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27343443/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000382420200015" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Characterization+of+298+patients+with+lung+cancer+harboring+MET+exon+14+skipping+alterations.&amp;publication_year=2016&amp;journal=J+Thorac+Oncol&amp;pages=1493-1502&amp;doi=10.1016%2Fj.jtho.2016.06.004&amp;pmid=27343443" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r5" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r7-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] mutations or from insertions or deletions. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r7-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] in the absence of other driver mutations, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r5-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] these patients are generally elderly </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="r6" class="citations"><div class="citation"><div class="citation-content">Paik PK, Drilon A, Fan P-D, et al. Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping. <em>Cancer Discov</em> 2015;5:842-849.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r6" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1158/2159-8290.CD-14-1467" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25971939/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000359317700017" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Response+to+MET+inhibitors+in+patients+with+stage+IV+lung+adenocarcinomas+harboring+MET+mutations+causing+exon+14+skipping.&amp;publication_year=2015&amp;journal=Cancer+Discov&amp;pages=842-849&amp;doi=10.1158%2F2159-8290.CD-14-1467&amp;pmid=25971939" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r6" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r7-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] mutations or from insertions or deletions. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r18-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] emerged as potential predictive biomarkers. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="r7" class="citations"><div class="citation"><div class="citation-content">Tong JH, Yeung SF, Chan AWH, et al. MET amplification and exon 14 splice site mutation define unique molecular subgroups of non-small cell lung carcinoma with poor prognosis. <em>Clin Cancer Res</em> 2016;22:3048-3056.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r7" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1158/1078-0432.CCR-15-2061" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26847053/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000377958800024" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=MET+amplification+and+exon+14+splice+site+mutation+define+unique+molecular+subgroups+of+non-small+cell+lung+carcinoma+with+poor+prognosis.&amp;publication_year=2016&amp;journal=Clin+Cancer+Res&amp;pages=3048-3056&amp;doi=10.1158%2F1078-0432.CCR-15-2061&amp;pmid=26847053" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r7" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r7-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] mutations or from insertions or deletions. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r7-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] in the absence of other driver mutations, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r9" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] and are associated with a poor prognosis. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="r8" class="citations"><div class="citation"><div class="citation-content">Reungwetwattana T, Liang Y, Zhu V, Ou SI. The race to target MET exon 14 skipping alterations in non-small cell lung cancer: the why, the how, the who, the unknown, and the inevitable. <em>Lung Cancer</em> 2017;103:27-37.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r8"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.lungcan.2016.11.011" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28024693/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000392676900006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+race+to+target+MET+exon+14+skipping+alterations+in+non-small+cell+lung+cancer%3A+the+why%2C+the+how%2C+the+who%2C+the+unknown%2C+and+the+inevitable.&amp;publication_year=2017&amp;journal=Lung+Cancer&amp;pages=27-37&amp;doi=10.1016%2Fj.lungcan.2016.11.011&amp;pmid=28024693" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="r9" class="citations"><div class="citation"><div class="citation-content">Yeung SF, Tong JHM, Law PPW, et al. Profiling of oncogenic driver events in lung adenocarcinoma revealed MET mutation as independent prognostic factor. <em>J Thorac Oncol</em> 2015;10:1292-1300.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r9"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1097/JTO.0000000000000620" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26098749/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000360365400008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Profiling+of+oncogenic+driver+events+in+lung+adenocarcinoma+revealed+MET+mutation+as+independent+prognostic+factor.&amp;publication_year=2015&amp;journal=J+Thorac+Oncol&amp;pages=1292-1300&amp;doi=10.1097%2FJTO.0000000000000620&amp;pmid=26098749" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="r10" class="citations"><div class="citation"><div class="citation-content">Onozato R, Kosaka T, Kuwano H, Sekido Y, Yatabe Y, Mitsudomi T. Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers. <em>J Thorac Oncol</em> 2009;4:5-11.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r13"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1097/JTO.0b013e3181913e0e" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/19096300/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000262196500002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Activation+of+MET+by+gene+amplification+or+by+splice+mutations+deleting+the+juxtamembrane+domain+in+primary+resected+lung+cancers.&amp;publication_year=2009&amp;journal=J+Thorac+Oncol&amp;pages=5-11&amp;doi=10.1097%2FJTO.0b013e3181913e0e&amp;pmid=19096300" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="r11" class="citations"><div class="citation"><div class="citation-content">Okuda K, Sasaki H, Yukiue H, Yano M, Fujii Y. <i>Met</i> gene copy number predicts the prognosis for completely resected non-small cell lung cancer. <em>Cancer Sci</em> 2008;99:2280-2285.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r13"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/j.1349-7006.2008.00916.x" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/19037978/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000260730700025" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Met+gene+copy+number+predicts+the+prognosis+for+completely+resected+non-small+cell+lung+cancer.&amp;publication_year=2008&amp;journal=Cancer+Sci&amp;pages=2280-2285&amp;doi=10.1111%2Fj.1349-7006.2008.00916.x&amp;pmid=19037978" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="r12" class="citations"><div class="citation"><div class="citation-content">Cappuzzo F, Marchetti A, Skokan M, et al. Increased <i>MET</i> gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. <em>J Clin Oncol</em> 2009;27:1667-1674.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r13"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.2008.19.1635" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/19255323/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000266194100023" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Increased+MET+gene+copy+number+negatively+affects+survival+of+surgically+resected+non-small-cell+lung+cancer+patients.&amp;publication_year=2009&amp;journal=J+Clin+Oncol&amp;pages=1667-1674&amp;doi=10.1200%2FJCO.2008.19.1635&amp;pmid=19255323" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">13.</div><div id="r13" class="citations"><div class="citation"><div class="citation-content">Schildhaus HU, Schultheis AM, Rüschoff J, et al. <i>MET</i> amplification status in therapy-naïve adeno- and squamous cell carcinomas of the lung. <em>Clin Cancer Res</em> 2015;21:907-915.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r13"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1158/1078-0432.CCR-14-0450" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25492085/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000349851200029" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=MET+amplification+status+in+therapy-na%C3%AFve+adeno-+and+squamous+cell+carcinomas+of+the+lung.&amp;publication_year=2015&amp;journal=Clin+Cancer+Res&amp;pages=907-915&amp;doi=10.1158%2F1078-0432.CCR-14-0450&amp;pmid=25492085" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">14.</div><div id="r14" class="citations"><div class="citation"><div class="citation-content">Spigel DR, Edelman MJ, O’Byrne K, et al. Results from the phase III randomized trial of onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIB or IV non-small-cell lung cancer: METLung. <em>J Clin Oncol</em> 2017;35:412-420.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r14"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.2016.69.2160" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27937096/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000393182600006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Results+from+the+phase+III+randomized+trial+of+onartuzumab+plus+erlotinib+versus+erlotinib+in+previously+treated+stage+IIIB+or+IV+non-small-cell+lung+cancer%3A+METLung.&amp;publication_year=2017&amp;journal=J+Clin+Oncol&amp;pages=412-420&amp;doi=10.1200%2FJCO.2016.69.2160&amp;pmid=27937096" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">15.</div><div id="r15" class="citations"><div class="citation"><div class="citation-content">Jenkins RW, Oxnard GR, Elkin S, Sullivan EK, Carter JL, Barbie DA. Response to crizotinib in a patient with lung adenocarcinoma harboring a MET splice site mutation. <em>Clin Lung Cancer</em> 2015;16(5):e101-e104.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r18-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.cllc.2015.01.009" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25769807/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000360182100010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Response+to+crizotinib+in+a+patient+with+lung+adenocarcinoma+harboring+a+MET+splice+site+mutation.&amp;publication_year=2015&amp;journal=Clin+Lung+Cancer&amp;pages=e101-e104&amp;doi=10.1016%2Fj.cllc.2015.01.009&amp;pmid=25769807" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">16.</div><div id="r16" class="citations"><div class="citation"><div class="citation-content">Waqar SN, Morgensztern D, Sehn J. MET mutation associated with responsiveness to crizotinib. <em>J Thorac Oncol</em> 2015;10(5):e29-e31.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r18-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1097/JTO.0000000000000478" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25898962/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000354990100004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=MET+mutation+associated+with+responsiveness+to+crizotinib.&amp;publication_year=2015&amp;journal=J+Thorac+Oncol&amp;pages=e29-e31&amp;doi=10.1097%2FJTO.0000000000000478&amp;pmid=25898962" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">17.</div><div id="r17" class="citations"><div class="citation"><div class="citation-content">Schuler M, Berardi R, Lim W-T, et al. Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer: clinical and biomarker results from a phase I trial. <em>Ann Oncol</em> 2020;31:789-797.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r17" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.annonc.2020.03.293" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32240796/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000535705600012" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Molecular+correlates+of+response+to+capmatinib+in+advanced+non-small-cell+lung+cancer%3A+clinical+and+biomarker+results+from+a+phase+I+trial.&amp;publication_year=2020&amp;journal=Ann+Oncol&amp;pages=789-797&amp;doi=10.1016%2Fj.annonc.2020.03.293&amp;pmid=32240796" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r17" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r18-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] emerged as potential predictive biomarkers. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r24" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] -dysregulated NSCLC. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r17-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] the known safety profile of capmatinib. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">18.</div><div id="r18" class="citations"><div class="citation"><div class="citation-content">Drilon A, Clark JW, Weiss J, et al. Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration. <em>Nat Med</em> 2020;26:47-51.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r18" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41591-019-0716-8" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31932802/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000509831900025" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Antitumor+activity+of+crizotinib+in+lung+cancers+harboring+a+MET+exon+14+alteration.&amp;publication_year=2020&amp;journal=Nat+Med&amp;pages=47-51&amp;doi=10.1038%2Fs41591-019-0716-8&amp;pmid=31932802" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r18" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r18-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] emerged as potential predictive biomarkers. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r18-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] exon 14 skipping mutation, </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">19.</div><div id="r19" class="citations"><div class="citation"><div class="citation-content">Liu X, Wang Q, Yang G, et al. A novel kinase inhibitor, INCB28060, blocks c-MET-dependent signaling, neoplastic activities, and cross-talk with EGFR and HER-3. <em>Clin Cancer Res</em> 2011;17:7127-7138.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r21"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1158/1078-0432.CCR-11-1157" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21918175/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000297158500019" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+novel+kinase+inhibitor%2C+INCB28060%2C+blocks+c-MET-dependent+signaling%2C+neoplastic+activities%2C+and+cross-talk+with+EGFR+and+HER-3.&amp;publication_year=2011&amp;journal=Clin+Cancer+Res&amp;pages=7127-7138&amp;doi=10.1158%2F1078-0432.CCR-11-1157&amp;pmid=21918175" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">20.</div><div id="r20" class="citations"><div class="citation"><div class="citation-content">Baltschukat S, Engstler BS, Huang A, et al. Capmatinib (INC280) is active against models of non-small cell lung cancer and other cancer types with defined mechanisms of MET activation. <em>Clin Cancer Res</em> 2019;25:3164-3175.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r21"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1158/1078-0432.CCR-18-2814" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30674502/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000468064200025" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Capmatinib+%28INC280%29+is+active+against+models+of+non-small+cell+lung+cancer+and+other+cancer+types+with+defined+mechanisms+of+MET+activation.&amp;publication_year=2019&amp;journal=Clin+Cancer+Res&amp;pages=3164-3175&amp;doi=10.1158%2F1078-0432.CCR-18-2814&amp;pmid=30674502" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">21.</div><div id="r21" class="citations"><div class="citation"><div class="citation-content">Wolf J, Seto T, Han J-Y, et al. Capmatinib in METΔex14-mutated advanced non-small cell lung cancer (NSCLC): efficacy data from the phase II GEOMETRY mono-1 study. <em>J Clin Oncol.</em> 2019:37:15 Suppl:9004-9004. abstract.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r21"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Capmatinib+in+MET%CE%94ex14-mutated+advanced+non-small+cell+lung+cancer+%28NSCLC%29%3A+efficacy+data+from+the+phase+II+GEOMETRY+mono-1+study&amp;publication_year=2019&amp;pages=9004-9004" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">22.</div><div id="r22" class="citations"><div class="citation"><div class="citation-content">Heist RS, Seto T, Han J-Y, et al. Capmatinib (INC280) in METΔex14-mutated advanced non-small cell lung cancer (NSCLC): efficacy data from the phase 2 GEOMETRY mono-1 study. <em>Neuro Oncol</em> 2019;21:vi56-vi56. abstract.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r23"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/neuonc/noz175.223" target="_blank">Crossref</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000509478701080" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Capmatinib+%28INC280%29+in+MET%CE%94ex14-mutated+advanced+non-small+cell+lung+cancer+%28NSCLC%29%3A+efficacy+data+from+the+phase+2+GEOMETRY+mono-1+study&amp;publication_year=2019&amp;journal=Neuro+Oncol&amp;pages=vi56-vi56&amp;doi=10.1093%2Fneuonc%2Fnoz175.223" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">23.</div><div id="r23" class="citations"><div class="citation"><div class="citation-content">Shih K, Falchook GS, Becker K, et al. A phase Ib study evaluating the c-MET inhibitor INC280 in combination with bevacizumab in glioblastoma multiforme (GBM) patients. <em>Neuro Oncol</em> 2016;18:Suppl 6:vi11-vi12. abstract</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r23"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/neuonc/now212.043" target="_blank">Crossref</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000398604100045" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+phase+Ib+study+evaluating+the+c-MET+inhibitor+INC280+in+combination+with+bevacizumab+in+glioblastoma+multiforme+%28GBM%29+patients&amp;publication_year=2016&amp;journal=Neuro+Oncol&amp;pages=vi11-vi12&amp;doi=10.1093%2Fneuonc%2Fnow212.043" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">24.</div><div id="r24" class="citations"><div class="citation"><div class="citation-content">Wu Y-L, Zhang L, Kim D-W, et al. Phase Ib/II study of capmatinib (INC280) plus gefitinib after failure of epidermal growth factor receptor (EGFR) inhibitor therapy in patients with EGFR-mutated, MET factor-dysregulated non-small-cell lung cancer. <em>J Clin Oncol</em> 2018;36:3101-3109.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r24"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.2018.77.7326" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30156984/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000451439600007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Phase+Ib%2FII+study+of+capmatinib+%28INC280%29+plus+gefitinib+after+failure+of+epidermal+growth+factor+receptor+%28EGFR%29+inhibitor+therapy+in+patients+with+EGFR-mutated%2C+MET+factor-dysregulated+non-small-cell+lung+cancer.&amp;publication_year=2018&amp;journal=J+Clin+Oncol&amp;pages=3101-3109&amp;doi=10.1200%2FJCO.2018.77.7326&amp;pmid=30156984" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">25.</div><div id="r25" class="citations"><div class="citation"><div class="citation-content">Eisenhauer EA, Therasse P, Bogaerts J, et al. New Response Evaluation Criteria in Solid Tumours: revised RECIST guideline (version 1.1). <em>Eur J Cancer</em> 2009;45:228-247.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r25"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.ejca.2008.10.026" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/19097774/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000262948300002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=New+Response+Evaluation+Criteria+in+Solid+Tumours%3A+revised+RECIST+guideline+%28version+1.1%29.&amp;publication_year=2009&amp;journal=Eur+J+Cancer&amp;pages=228-247&amp;doi=10.1016%2Fj.ejca.2008.10.026&amp;pmid=19097774" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">26.</div><div id="r26" class="citations"><div class="citation"><div class="citation-content">de Marinis F, Grossi F. Clinical evidence for second- and third-line treatment options in advanced non-small cell lung cancer. <em>Oncologist</em> 2008;13:Suppl 1:14-20.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r27"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1634/theoncologist.13-S1-14" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/18263770/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000253047500003" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Clinical+evidence+for+second-+and+third-line+treatment+options+in+advanced+non-small+cell+lung+cancer.&amp;publication_year=2008&amp;journal=Oncologist&amp;pages=14-20&amp;doi=10.1634%2Ftheoncologist.13-S1-14&amp;pmid=18263770" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">27.</div><div id="r27" class="citations"><div class="citation"><div class="citation-content">Weiss JM, Stinchcombe TE. Second-line therapy for advanced NSCLC. <em>Oncologist</em> 2013;18:947-953.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r27"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1634/theoncologist.2013-0096" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23918070/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000324101200017" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Second-line+therapy+for+advanced+NSCLC.&amp;publication_year=2013&amp;journal=Oncologist&amp;pages=947-953&amp;doi=10.1634%2Ftheoncologist.2013-0096&amp;pmid=23918070" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">28.</div><div id="r28" class="citations"><div class="citation"><div class="citation-content">Zhou C, Wu Y-L, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. <em>Lancet Oncol</em> 2011;12:735-742.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r29"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S1470-2045(11)70184-X" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21783417/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000293272100024" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Erlotinib+versus+chemotherapy+as+first-line+treatment+for+patients+with+advanced+EGFR+mutation-positive+non-small-cell+lung+cancer+%28OPTIMAL%2C+CTONG-0802%29%3A+a+multicentre%2C+open-label%2C+randomised%2C+phase+3+study.&amp;publication_year=2011&amp;journal=Lancet+Oncol&amp;pages=735-742&amp;doi=10.1016%2FS1470-2045%2811%2970184-X&amp;pmid=21783417" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">29.</div><div id="r29" class="citations"><div class="citation"><div class="citation-content">Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. <em>J Clin Oncol</em> 2008;26:3543-3551.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r29"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.2007.15.0375" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/18506025/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000258050500015" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Phase+III+study+comparing+cisplatin+plus+gemcitabine+with+cisplatin+plus+pemetrexed+in+chemotherapy-naive+patients+with+advanced-stage+non-small-cell+lung+cancer.&amp;publication_year=2008&amp;journal=J+Clin+Oncol&amp;pages=3543-3551&amp;doi=10.1200%2FJCO.2007.15.0375&amp;pmid=18506025" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">30.</div><div id="r30" class="citations"><div class="citation"><div class="citation-content">Mok TS, Wu Y-L, Thongprasert S, et al. Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma. <em>N Engl J Med</em> 2009;361:947-957.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r32"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_31_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2002787&amp;key=10.1056%2FNEJMoa0810699&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/19692680/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000269480400004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Gefitinib+or+carboplatin%E2%80%93paclitaxel+in+pulmonary+adenocarcinoma.&amp;publication_year=2009&amp;journal=N+Engl+J+Med&amp;pages=947-957&amp;doi=10.1056%2FNEJMoa0810699&amp;pmid=19692680" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">31.</div><div id="r31" class="citations"><div class="citation"><div class="citation-content">Solomon BJ, Mok T, Kim D-W, et al. First-line crizotinib versus chemotherapy in <i>ALK</i>-positive lung cancer. <em>N Engl J Med</em> 2014;371:2167-2177.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r32"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_32_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2002787&amp;key=10.1056%2FNEJMoa1408440&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25470694/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000345976700005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=First-line+crizotinib+versus+chemotherapy+in+ALK-positive+lung+cancer.&amp;publication_year=2014&amp;journal=N+Engl+J+Med&amp;pages=2167-2177&amp;doi=10.1056%2FNEJMoa1408440&amp;pmid=25470694" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">32.</div><div id="r32" class="citations"><div class="citation"><div class="citation-content">Shaw AT, Ou S-HI, Bang Y-J, et al. Crizotinib in <i>ROS1</i>-rearranged non–small-cell lung cancer. <em>N Engl J Med</em> 2014;371:1963-1971.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r32"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_33_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2002787&amp;key=10.1056%2FNEJMoa1406766&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25264305/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000345002900005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Crizotinib+in+ROS1-rearranged+non%E2%80%93small-cell+lung+cancer.&amp;publication_year=2014&amp;journal=N+Engl+J+Med&amp;pages=1963-1971&amp;doi=10.1056%2FNEJMoa1406766&amp;pmid=25264305" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">33.</div><div id="r33" class="citations"><div class="citation"><div class="citation-content">Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non–small-cell lung cancer. <em>N Engl J Med</em> 2005;353:123-132.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r38"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_34_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2002787&amp;key=10.1056%2FNEJMoa050753&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/16014882/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000230438800004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Erlotinib+in+previously+treated+non%E2%80%93small-cell+lung+cancer.&amp;publication_year=2005&amp;journal=N+Engl+J+Med&amp;pages=123-132&amp;doi=10.1056%2FNEJMoa050753&amp;pmid=16014882" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">34.</div><div id="r34" class="citations"><div class="citation"><div class="citation-content">Garon EB, Ciuleanu T-E, Arrieta O, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. <em>Lancet</em> 2014;384:665-673.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r38"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(14)60845-X" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24933332/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000341359100024" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Ramucirumab+plus+docetaxel+versus+placebo+plus+docetaxel+for+second-line+treatment+of+stage+IV+non-small-cell+lung+cancer+after+disease+progression+on+platinum-based+therapy+%28REVEL%29%3A+a+multicentre%2C+double-blind%2C+randomised+phase+3+trial.&amp;publication_year=2014&amp;journal=Lancet&amp;pages=665-673&amp;doi=10.1016%2FS0140-6736%2814%2960845-X&amp;pmid=24933332" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">35.</div><div id="r35" class="citations"><div class="citation"><div class="citation-content">Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer. <em>N Engl J Med</em> 2015;373:123-135.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r38"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_36_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2002787&amp;key=10.1056%2FNEJMoa1504627&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26028407/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000357598600005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Nivolumab+versus+docetaxel+in+advanced+squamous-cell+non%E2%80%93small-cell+lung+cancer.&amp;publication_year=2015&amp;journal=N+Engl+J+Med&amp;pages=123-135&amp;doi=10.1056%2FNEJMoa1504627&amp;pmid=26028407" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">36.</div><div id="r36" class="citations"><div class="citation"><div class="citation-content">Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer. <em>N Engl J Med</em> 2015;373:1627-1639.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r38"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_37_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2002787&amp;key=10.1056%2FNEJMoa1507643&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26412456/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000363317800008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Nivolumab+versus+docetaxel+in+advanced+nonsquamous+non%E2%80%93small-cell+lung+cancer.&amp;publication_year=2015&amp;journal=N+Engl+J+Med&amp;pages=1627-1639&amp;doi=10.1056%2FNEJMoa1507643&amp;pmid=26412456" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">37.</div><div id="r37" class="citations"><div class="citation"><div class="citation-content">Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. <em>Lancet</em> 2017;389:255-265.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r38"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(16)32517-X" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27979383/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000392801200027" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Atezolizumab+versus+docetaxel+in+patients+with+previously+treated+non-small-cell+lung+cancer+%28OAK%29%3A+a+phase+3%2C+open-label%2C+multicentre+randomised+controlled+trial.&amp;publication_year=2017&amp;journal=Lancet&amp;pages=255-265&amp;doi=10.1016%2FS0140-6736%2816%2932517-X&amp;pmid=27979383" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">38.</div><div id="r38" class="citations"><div class="citation"><div class="citation-content">Herbst RS, Baas P, Kim D-W, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. <em>Lancet</em> 2016;387:1540-1550.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r38"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(15)01281-7" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26712084/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000373741600030" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Pembrolizumab+versus+docetaxel+for+previously+treated%2C+PD-L1-positive%2C+advanced+non-small-cell+lung+cancer+%28KEYNOTE-010%29%3A+a+randomised+controlled+trial.&amp;publication_year=2016&amp;journal=Lancet&amp;pages=1540-1550&amp;doi=10.1016%2FS0140-6736%2815%2901281-7&amp;pmid=26712084" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">39.</div><div id="r39" class="citations"><div class="citation"><div class="citation-content">Camidge DR, Otterson GA, Clark JW, et al. Crizotinib in patients (pts) with MET-amplified non-small cell lung cancer (NSCLC): updated safety and efficacy findings from a phase 1 trial. <em>J Clin Oncol</em> 2018;36:Suppl:36-36. abstract.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r39"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.2018.36.15_suppl.9062" target="_blank">Crossref</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000442916003235" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Crizotinib+in+patients+%28pts%29+with+MET-amplified+non-small+cell+lung+cancer+%28NSCLC%29%3A+updated+safety+and+efficacy+findings+from+a+phase+1+trial&amp;publication_year=2018&amp;journal=J+Clin+Oncol&amp;pages=36-36&amp;doi=10.1200%2FJCO.2018.36.15_suppl.9062" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">40.</div><div id="r40" class="citations"><div class="citation"><div class="citation-content">Noonan SA, Berry L, Lu X, et al. Identifying the appropriate FISH criteria for defining MET copy number-driven lung adenocarcinoma through oncogene overlap analysis. <em>J Thorac Oncol</em> 2016;11:1293-1304.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r40"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.jtho.2016.04.033" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27262212/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000381067300012" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Identifying+the+appropriate+FISH+criteria+for+defining+MET+copy+number-driven+lung+adenocarcinoma+through+oncogene+overlap+analysis.&amp;publication_year=2016&amp;journal=J+Thorac+Oncol&amp;pages=1293-1304&amp;doi=10.1016%2Fj.jtho.2016.04.033&amp;pmid=27262212" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">41.</div><div id="r41" class="citations"><div class="citation"><div class="citation-content">Paik PK, Felip E, Veillon R, et al. Tepotinib in non–small-cell lung cancer with <i>MET</i> exon 14 skipping mutations. <em>N Engl J Med</em> 2020;383:931-943.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r41"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_42_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2002787&amp;key=10.1056%2FNEJMoa2004407&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32469185/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000569841600013" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Tepotinib+in+non%E2%80%93small-cell+lung+cancer+with+MET+exon+14+skipping+mutations.&amp;publication_year=2020&amp;journal=N+Engl+J+Med&amp;pages=931-943&amp;doi=10.1056%2FNEJMoa2004407&amp;pmid=32469185" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">42.</div><div id="r42" class="citations"><div class="citation"><div class="citation-content">Lu S. Phase II study of savolitinib in patients (pts) with pulmonary sarcomatoid carcinoma (PSC) and other types of non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutations (METex14+). Presented at the 2020 American Society of Clinical Oncology Annual Meeting, Chicago, May 29–31, 2020. abstract.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r42"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Phase+II+study+of+savolitinib+in+patients+%28pts%29+with+pulmonary+sarcomatoid+carcinoma+%28PSC%29+and+other+types+of+non-small+cell+lung+cancer+%28NSCLC%29+harboring+MET+exon+14+skipping+mutations+%28METex14%2B%29&amp;publication_year=2020" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">43.</div><div id="r43" class="citations"><div class="citation"><div class="citation-content">Wolf J, Baik C, Heist RS, et al. Natural history, treatment (tx) patterns, and outcomes in MET dysregulated non-small cell lung cancer (NSCLC) patients (pts). Presented at the EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics, Dublin, November 13–16, 2018. abstract (<a href="https://stanfordhealthcare.org/publications/507/507112.html" target="_blank">https://stanfordhealthcare.org/publications/507/507112.html</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r45"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Natural+history%2C+treatment+%28tx%29+patterns%2C+and+outcomes+in+MET+dysregulated+non-small+cell+lung+cancer+%28NSCLC%29+patients+%28pts%29&amp;publication_year=2018" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">44.</div><div id="r44" class="citations"><div class="citation"><div class="citation-content">Sabari JK, Leonardi GC, Shu CA, et al. PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers. <em>Ann Oncol</em> 2018;29:2085-2091.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r45"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/annonc/mdy334" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30165371/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000455165100011" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=PD-L1+expression%2C+tumor+mutational+burden%2C+and+response+to+immunotherapy+in+patients+with+MET+exon+14+altered+lung+cancers.&amp;publication_year=2018&amp;journal=Ann+Oncol&amp;pages=2085-2091&amp;doi=10.1093%2Fannonc%2Fmdy334&amp;pmid=30165371" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">45.</div><div id="r45" class="citations"><div class="citation"><div class="citation-content">Reis H, Metzenmacher M, Goetz M, et al. MET expression in advanced non-small-cell lung cancer: effect on clinical outcomes of chemotherapy, targeted therapy, and immunotherapy. <em>Clin Lung Cancer</em> 2018;19(4):e441-e463.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r45"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.cllc.2018.03.010" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29631966/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000436644800010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=MET+expression+in+advanced+non-small-cell+lung+cancer%3A+effect+on+clinical+outcomes+of+chemotherapy%2C+targeted+therapy%2C+and+immunotherapy.&amp;publication_year=2018&amp;journal=Clin+Lung+Cancer&amp;pages=e441-e463&amp;doi=10.1016%2Fj.cllc.2018.03.010&amp;pmid=29631966" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">46.</div><div id="r46" class="citations"><div class="citation"><div class="citation-content">Ali A, Goffin JR, Arnold A, Ellis PM. Survival of patients with non-small-cell lung cancer after a diagnosis of brain metastases. <em>Curr Oncol</em> 2013;20(4):e300-e306.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r46"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.3747/co.20.1481" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23904768/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000322782400004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Survival+of+patients+with+non-small-cell+lung+cancer+after+a+diagnosis+of+brain+metastases.&amp;publication_year=2013&amp;journal=Curr+Oncol&amp;pages=e300-e306&amp;doi=10.3747%2Fco.20.1481&amp;pmid=23904768" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">47.</div><div id="r47" class="citations"><div class="citation"><div class="citation-content">Awad MM, Leonardi GC, Kravets S, et al. Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis. <em>Lung Cancer</em> 2019;133:96-102.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r47"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.lungcan.2019.05.011" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31200835/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000474326700016" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Impact+of+MET+inhibitors+on+survival+among+patients+with+non-small+cell+lung+cancer+harboring+MET+exon+14+mutations%3A+a+retrospective+analysis.&amp;publication_year=2019&amp;journal=Lung+Cancer&amp;pages=96-102&amp;doi=10.1016%2Fj.lungcan.2019.05.011&amp;pmid=31200835" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">48.</div><div id="r48" class="citations"><div class="citation"><div class="citation-content">Lepist E-I, Zhang X, Hao J, et al. Contribution of the organic anion transporter OAT2 to the renal active tubular secretion of creatinine and mechanism for serum creatinine elevations caused by cobicistat. <em>Kidney Int</em> 2014;86:350-357.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r48"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/ki.2014.66" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24646860/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000339987700020" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Contribution+of+the+organic+anion+transporter+OAT2+to+the+renal+active+tubular+secretion+of+creatinine+and+mechanism+for+serum+creatinine+elevations+caused+by+cobicistat.&amp;publication_year=2014&amp;journal=Kidney+Int&amp;pages=350-357&amp;doi=10.1038%2Fki.2014.66&amp;pmid=24646860" target="_blank">Google Scholar</a></div></div></div></div></div></div><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary" aria-expanded="false" aria-controls="collapsible-text"><span>Show all references</span></button></div></section></div></section></div><div class="core-collateral"><div id="core-collateral-info" role="tabpanel" data-core-tabs="core-collateral-info" tabindex="-1" aria-labelledby="pane-core-collateral-info"><header><h2 id="pane-core-collateral-info"><i class="icon-info" aria-hidden="true"></i>Information &amp; Authors</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-information" role="tab" id="tab-information-label" aria-selected="true" class="active">Information</button><button aria-controls="tab-contributors" role="tab" id="tab-contributors-label" tabindex="-1" aria-selected="false">Authors</button></div><section id="tab-information" aria-labelledby="tab-information-label" role="tabpanel" tabindex="0"><h3>Information</h3><section class="core-self-citation"><h4>Published In</h4><div class="core-journal-presentation"><div class="core-journal-description"><div property="isPartOf" typeof="Periodical"><span property="name">New England Journal of Medicine</span></div><div class="core-enumeration"><a href="/toc/nejm/383/10"><span property="isPartOf" typeof="PublicationVolume">Volume <span property="volumeNumber">383</span></span> • <span property="isPartOf" typeof="PublicationIssue">Number <span property="issueNumber">10</span></span> • <span property="datePublished">September 3, 2020</span></a></div><div class="core-pagination"><span class="heading">Pages</span>: <span class="content"><span property="pageStart">944</span>-<span property="pageEnd">957</span></span></div></div></div></section><section class="core-copyright"><h4>Copyright</h4><div role="paragraph">Copyright © 2020 Massachusetts Medical Society. All rights reserved.</div><div>For personal use only. Any commercial reuse of NEJM Group content requires <a href="mailto:permissions@nejm.org">permission</a>.</div></section><section class="core-history"><h4>History</h4><div><b class="core-label">Published online</b>: September 2, 2020</div><div><b class="core-label">Published in issue</b>: September 3, 2020</div></section><section data-location="recirc_topics_article" class="core-classifications"><h4>Topics</h4><div class="keywords"><ol><li><a href="/browse/topic/lung-cancer" alt="View article keyword Lung Cancer" data-interactiontype="article_recirculation_click">Lung Cancer</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/treatments-in-oncology" alt="View article keyword Treatments in Oncology" data-interactiontype="article_recirculation_click">Treatments in Oncology</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li></ol></div></section></section><section id="tab-contributors" aria-labelledby="tab-contributors-label" role="tabpanel" tabindex="-1"><h3>Authors</h3><section class="core-authors"><h4>Authors</h4><div role="paragraph"><span property="author" typeof="Person"><span property="givenName">Jürgen</span> <span property="familyName">Wolf</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Takashi</span> <span property="familyName">Seto</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Ji-Youn</span> <span property="familyName">Han</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Noemi</span> <span property="familyName">Reguart</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Edward B.</span> <span property="familyName">Garon</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Harry J.M.</span> <span property="familyName">Groen</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Daniel S.W.</span> <span property="familyName">Tan</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Toyoaki</span> <span property="familyName">Hida</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Maja</span> <span property="familyName">de Jonge</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Sergey V.</span> <span property="familyName">Orlov</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Egbert F.</span> <span property="familyName">Smit</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Pierre-Jean</span> <span property="familyName">Souquet</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Johan</span> <span property="familyName">Vansteenkiste</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Maximilian</span> <span property="familyName">Hochmair</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Enriqueta</span> <span property="familyName">Felip</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Makoto</span> <span property="familyName">Nishio</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Michael</span> <span property="familyName">Thomas</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Kadoaki</span> <span property="familyName">Ohashi</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Ryo</span> <span property="familyName">Toyozawa</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Tobias R.</span> <span property="familyName">Overbeck</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Filippo</span> <span property="familyName">de Marinis</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Tae-Min</span> <span property="familyName">Kim</span>, <span property="honorificSuffix">M.D., Ph.D.</span> <a class="orcid-id" href="https://orcid.org/0000-0001-6145-4426" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0001-6145-4426</a></span>, <span property="author" typeof="Person"><span property="givenName">Eckart</span> <span property="familyName">Laack</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Anna</span> <span property="familyName">Robeva</span>, <span property="honorificSuffix">M.S.</span></span>, <span property="author" typeof="Person"><span property="givenName">Sylvie</span> <span property="familyName">Le Mouhaer</span>, <span property="honorificSuffix">M.Sc.</span></span>, <span property="author" typeof="Person"><span property="givenName">Maeve</span> <span property="familyName">Waldron-Lynch</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Banu</span> <span property="familyName">Sankaran</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">O. Alejandro</span> <span property="familyName">Balbin</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Xiaoming</span> <span property="familyName">Cui</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Monica</span> <span property="familyName">Giovannini</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Mikhail</span> <span property="familyName">Akimov</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, and <span property="author" typeof="Person"><span property="givenName">Rebecca S.</span> <span property="familyName">Heist</span>, <span property="honorificSuffix">M.D., M.P.H.</span></span>, for <span property="author" typeof="Person">the GEOMETRY mono-1 Investigators<sup><a href="#fn1" role="doc-noteref">*</a></sup></span></div></section><section class="core-affiliations"><h4>Affiliations</h4><div property="affiliation" typeof="Organization"><span property="name">From the Department I of Internal Medicine, Center for Integrated Oncology, University Hospital Cologne and University of Cologne, Cologne (J.W.), Internistische Onkologie der Thoraxtumoren, Thoraxklinik im Universitätsklinikum Heidelberg, Translational Lung Research Center Heidelberg, Heidelberg (M.T.), the Department of Hematology and Medical Oncology, University Medical Center Göttingen, Göttingen (T.R.O.), and Hämato-Onkologie Hamburg, Hamburg (E.L.) — all in Germany; the National Hospital Organization Kyushu Cancer Center, Fukuoka (T.S.), Aichi Cancer Center, Nagoya (T.H.), the Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo (M.N.), the Department of Respiratory Medicine, Okayama University Hospital, Okayama (K.O.), and the National Kyushu Cancer Center, Fukuoka (R.T.) — all in Japan; the National Cancer Center, Gyeonggi-do (J.-Y.H.), and the Department of Internal Medicine, Seoul National University Hospital, Seoul (T.-M.K.) — both in South Korea; the Hospital Clinic of Barcelona (N.R.), Translational Genomic and Targeted Therapeutics in Solid Tumors (IDIBAPS) (N.R.), and Vall d’Hebron University Hospital–Vall d’Hebron Institute of Oncology (E.F.), Barcelona; David Geffen School of Medicine at UCLA, Los Angeles (E.B.G.); the University of Groningen and University Medical Center Groningen, Groningen (H.J.M.G.), Erasmus MC Cancer Institute, Rotterdam (M.J.), and the Netherlands Cancer Institute, Amsterdam (E.F.S.) — all in the Netherlands; the National Cancer Centre Singapore, Singapore (D.S.W.T.); St. Petersburg Pavlov State Medical University, St. Petersburg, Russia (S.V.O.); University Hospital of Lyon-Sud, Lyon (P.-J.S.), and Novartis Pharma, Rueil-Malmaison (S.L.M.) — both in France; the Respiratory Oncology Unit, University Hospitals KU Leuven, Leuven, Belgium (J.V.); the Department of Respiratory and Critical Care Medicine, Karl Landsteiner Institute of Lung Research and Pulmonary Oncology, Vienna (M.H.); the Thoracic Oncology Division, European Institute of Oncology, IRCCS, Milan (F.M.); Novartis Pharmaceuticals, East Hanover, NJ (A.R., M.G.); Novartis Pharma, Basel, Switzerland (M.W.-L., M.A.); and Novartis Institutes for BioMedical Research, Cambridge (B.S., O.A.B., X.C.), and Massachusetts General Hospital, Boston (R.S.H.) — both in Massachusetts.</span></div></section><section class="core-authors-notes"><h4>Notes</h4><div role="doc-footnote">Address reprint requests to Dr. Wolf at Department I of Internal Medicine, Center for Integrated Oncology, University Hospital Cologne, D50924 Cologne, Germany, or at <a href="mailto:juergen.wolf@uk-koeln.de">juergen.wolf@uk-koeln.de</a>.</div><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="fn1" role="paragraph">A full list of the GEOMETRY mono-1 Investigators is provided in the <a href="#ap2">Supplementary Appendix</a>, available at NEJM.org.</div></div></section></section></div><div id="core-collateral-metrics" role="tabpanel" data-core-tabs="core-collateral-metrics" tabindex="-1" aria-labelledby="pane-core-collateral-metrics"><header><h2 id="pane-core-collateral-metrics"><i class="icon-timeline" aria-hidden="true"></i>Metrics &amp; Citations</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-metrics-inner" role="tab" id="tab-metrics-inner-label" aria-selected="true" class="active" data-interactiontype="article_tab" data-tabname="metricsWindow">Metrics</button><button aria-controls="tab-citations" role="tab" id="tab-citations-label" tabindex="-1" aria-selected="false" data-interactiontype="article_tab" data-tabname="metricsWindow">Citations<span class="citations-count">700</span></button></div><section id="tab-metrics-inner" aria-labelledby="tab-metrics-inner-label" role="tabpanel" tabindex="0"><h3>Metrics</h3><section>









    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="95ea9f58-ec0e-4db2-b2ab-280fc876af53" data-location="article_metrics_article">
        



        
            <h4 class="">
                Altmetrics
            </h4>
        
        <div data-badge-details="right" data-badge-type="large-donut" data-doi="10.1056/NEJMoa2002787" data-hide-no-mentions="true" data-link-target="_blank" class="altmetric-embed" data-uuid="3b4a0aec-121b-102f-5699-9cb5d60fc758"><div style="overflow:hidden;">
    <div class="altmetric-normal-legend">
        <a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=89353240" style="display:inline-block;">
                <img alt="Article has an altmetric score of 213" src="https://badges.altmetric.com/?size=320&amp;score=213&amp;types=mbvcrttf" width="180" height="180" style="border:0; margin:0; max-width: none;">
        </a>
        <p class="altmetric-see-more-details" style="padding-top: 10px; text-align: center;"><a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=89353240">See more details</a></p>
    </div>
    <div id="_altmetric_popover_el_3b4a0aec-121b-102f-5699-9cb5d60fc758" class="altmetric-embed right" style="margin:0; padding:0; display:inline-block; float:left; position:relative;">
        <div class="altmetric_container">
            <div class="altmetric-embed altmetric-popover-inner right">
                <div style="padding:0; margin: 0;" class="altmetric-embed altmetric-popover-content">
                        <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #FF0000;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=89353240&amp;tab=news">
          Picked up by <b>17</b> news outlets
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #ffd140;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=89353240&amp;tab=blogs">
          Blogged by <b>1</b>
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #74CFED;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=89353240&amp;tab=twitter">
          Posted by <b>128</b> X users
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #2445bd;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=89353240&amp;tab=facebook">
          On <b>4</b> Facebook pages
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #D5E8F0;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=89353240&amp;tab=reddit">
          Reddited by <b>1</b>
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #94DB5E;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=89353240&amp;tab=video">
          On <b>1</b> videos
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #A1E3E4;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=89353240&amp;tab=guidelines">
          Referenced in <b>4</b> clinical guideline sources
      </a>
    </div>

    <div class="altmetric-embed readers" style="margin-top: 10px;">
          <div class="altmetric-embed tip_mendeley" style="padding-left: 10px; line-height:18px; border-left: 16px solid #A60000;">
              <b>483</b> readers on Mendeley
          </div>
    </div>

                </div>
            </div>
        </div>
    </div>
</div></div>
<script async="" type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" nonce="94d6468482d1decb-SJC"></script>

        </div>
    

</section></section><section id="tab-citations" aria-labelledby="tab-citations-label" role="tabpanel" tabindex="-1"><h3>Citations</h3><section>



        
            <h4 class="">
                Export citation
            </h4>
        
        <div class="citation-download cd-sec">
<p class="citation-download_msg">Select the format you want to export the citation of this publication.</p>
<form action="/action/downloadCitation" name="frmCitmgr" method="post" target="_self" class="citation-download_form"><input type="hidden" name="doi" value="10.1056/NEJMoa2002787"> <input type="hidden" name="downloadFileName" value="csp_383_"> <input type="hidden" name="include" value="abs">
<div class="dropdown dropdown-selectable dropdown-selectable--form-control"><input type="hidden" name="format" value=""> <label class="form-label">Format*</label> <button id="slct_format" type="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="btn dropdown-toggle d-flex align-items-center justify-content-between">Please Select </button>
<div aria-labelledby="slct_format" role="listbox" class="dropdown-menu"><a href="#" data-value="ris" class="dropdown-item">RIS (ProCite, Reference Manager)</a><a href="#" data-value="endnote" class="dropdown-item">EndNote</a><a href="#" data-value="bibtex" class="dropdown-item">BibTex</a><a href="#" data-value="medlars" class="dropdown-item">Medlars</a><a href="#" data-value="refworks" class="dropdown-item">RefWorks</a></div>
<div class="invalid-feedback">Please select an item in the list</div>
</div>
<div class="citation-download_checkbox"><label class="checkbox--primary"><input type="checkbox" name="direct" value="true"><span class="checkbox--primary-icons"><span class="checkbox--primary-unchecked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxUnchecked"></use></svg></span></span><span class="checkbox--primary-checked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxChecked"></use></svg></span></span></span><span class="checkbox--primary-label"><span class="checkbox--primary-label-text">Direct Import</span></span></label></div>
<div class="citation-download_btn"><button type="submit" name="submit" value="Download" class="ng-btn_default ng-btn_iconLeft" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#citations"></use></svg></span><span class="ng-btn_text">Export citation</span></button></div>
</form></div>
</section><section>









    
    
        <div data-widget-def="UX3CitedByWidget" data-widget-id="efb4df9a-8e1a-47f9-bfb7-271959277a9f" data-location="citedby_article">
        



        
            <h4 class="">
                Cited by
            </h4>
        
        <section id="cited-by" class="cited-by"><div class="cited-by__wrapper"><div id="cited-by__content" class="cited-by__content"><ol data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2020.383.issue-10%3BrequestedJournal%3Ajournal%3Anejm%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3BpageGroup%3Astring%3APublication+Pages%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa2002787%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Bjournal%3Ajournal%3Anejms" data-lazyload="false" data-total="700" class="cited-by__list list-unstyled"><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Gianluca Russo, </li><li class="list-inline-item cited-by__entry__author">Claudia Scimone, </li><li class="list-inline-item cited-by__entry__author">Lucia Palumbo, </li><li class="list-inline-item cited-by__entry__author">Giuseppina Roscigno, </li><li class="list-inline-item cited-by__entry__author">Claudia Sarracino, </li><li class="list-inline-item cited-by__entry__author">Ilaria Tomaiuolo, </li><li class="list-inline-item cited-by__entry__author">Pasquale Pisapia, </li><li class="list-inline-item cited-by__entry__author">Francesco Pepe, </li><li class="list-inline-item cited-by__entry__author">Danilo Rocco, </li><li class="list-inline-item cited-by__entry__author">Cesare Gridelli, </li><li class="list-inline-item cited-by__entry__author">Giancarlo Troncone, </li><li class="list-inline-item cited-by__entry__author">Umberto Malapelle, </li></ul><span class="cited-by__entry__title">Biologics for novel driver altered non-small cell lung cancer: potential and pitfalls, </span><span class="cited-by__entry__series-title">Critical Reviews in Oncology/Hematology, </span><span class="cited-by__entry__volume"><strong>212</strong>, </span><span class="cited-by__entry__page-range">(104748), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.critrevonc.2025.104748" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.critrevonc.2025.104748</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.critrevonc.2025.104748" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">undefined Shivika, </li><li class="list-inline-item cited-by__entry__author">Mohit Sharma, </li><li class="list-inline-item cited-by__entry__author">Ankit Bajpai, </li><li class="list-inline-item cited-by__entry__author">Zahid Ahmad Dar, </li><li class="list-inline-item cited-by__entry__author">Ranjit Singh, </li><li class="list-inline-item cited-by__entry__author">Ranju Bansal, </li></ul><span class="cited-by__entry__title">Therapeutic dominance of tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC), </span><span class="cited-by__entry__series-title">Bioorganic Chemistry, </span><span class="cited-by__entry__volume"><strong>163</strong>, </span><span class="cited-by__entry__page-range">(108660), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.bioorg.2025.108660" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.bioorg.2025.108660</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.bioorg.2025.108660" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">R. Ben Dhiab, </li><li class="list-inline-item cited-by__entry__author">R. Loyaux, </li><li class="list-inline-item cited-by__entry__author">S. Garinet, </li><li class="list-inline-item cited-by__entry__author">M. Bastide, </li><li class="list-inline-item cited-by__entry__author">S. Léonard-Goyet, </li><li class="list-inline-item cited-by__entry__author">Elizabeth Fabre, </li><li class="list-inline-item cited-by__entry__author">Audrey Mansuet-Lupo, </li><li class="list-inline-item cited-by__entry__author">Laure Gibault, </li><li class="list-inline-item cited-by__entry__author">S. Jouveshomme, </li><li class="list-inline-item cited-by__entry__author">E. Giroux-Leprieur, </li><li class="list-inline-item cited-by__entry__author">K. Leroy, </li><li class="list-inline-item cited-by__entry__author">M. Wislez, </li><li class="list-inline-item cited-by__entry__author">H. Blons, </li></ul><span class="cited-by__entry__title">MET exon 14 skipping mutations in non-small-cell lung cancer a 3&nbsp;years screening experience, </span><span class="cited-by__entry__series-title">Scientific Reports, </span><span class="cited-by__entry__volume"><strong>15</strong>, </span><span class="cited-by__entry__issue">1, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1038/s41598-025-99541-4" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1038/s41598-025-99541-4</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1038/s41598-025-99541-4" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Michelle C. Salazar, </li><li class="list-inline-item cited-by__entry__author">Aki Katarina Kobayashi, </li></ul><span class="cited-by__entry__title">Lung Cancers in Never-Smokers, </span><span class="cited-by__entry__series-title">Surgical Oncology Clinics of North America, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.soc.2025.05.001" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.soc.2025.05.001</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.soc.2025.05.001" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Jia-Jun Wu, </li><li class="list-inline-item cited-by__entry__author">Zhe-Rong Zheng, </li><li class="list-inline-item cited-by__entry__author">Tse-Hsien Lo, </li><li class="list-inline-item cited-by__entry__author">Cheng-Hsiang Chu, </li><li class="list-inline-item cited-by__entry__author">Kun-Chieh Chen, </li><li class="list-inline-item cited-by__entry__author">Gee-Chen Chang, </li></ul><span class="cited-by__entry__title">Combination Therapy With MET Tyrosine Kinase Inhibitor and EGFR Tyrosine Kinase Inhibitor in Patients With MET-Overexpressed EGFR-Mutant Lung Adenocarcinoma, </span><span class="cited-by__entry__series-title">JTO Clinical and Research Reports, </span><span class="cited-by__entry__volume"><strong>6</strong>, </span><span class="cited-by__entry__issue">6, </span><span class="cited-by__entry__page-range">(100832), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.jtocrr.2025.100832" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.jtocrr.2025.100832</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.jtocrr.2025.100832" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Alicia Dillard, </li><li class="list-inline-item cited-by__entry__author">Kemin Xu, </li><li class="list-inline-item cited-by__entry__author">Yichao Sun, </li><li class="list-inline-item cited-by__entry__author">Han-Hsuan Lin, </li><li class="list-inline-item cited-by__entry__author">Cong Shen, </li><li class="list-inline-item cited-by__entry__author">Eric Song, </li><li class="list-inline-item cited-by__entry__author">Ashish Saxena, </li><li class="list-inline-item cited-by__entry__author">Erika Hissong, </li><li class="list-inline-item cited-by__entry__author">Anna Yemelyanova, </li><li class="list-inline-item cited-by__entry__author">Neal I. Lindeman, </li><li class="list-inline-item cited-by__entry__author">Priya D. Velu, </li><li class="list-inline-item cited-by__entry__author">James P. Solomon, </li></ul><span class="cited-by__entry__title">Comparison of Targeted RNA-Sequencing Platforms for Oncogenic Fusion Detection in Non–Small-Cell Lung Cancer, </span><span class="cited-by__entry__series-title">The Journal of Molecular Diagnostics, </span><span class="cited-by__entry__volume"><strong>27</strong>, </span><span class="cited-by__entry__issue">6, </span><span class="cited-by__entry__page-range">(438-445), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.jmoldx.2025.02.007" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.jmoldx.2025.02.007</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.jmoldx.2025.02.007" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Zhenfang Du, </li><li class="list-inline-item cited-by__entry__author">Hongfei Kan, </li><li class="list-inline-item cited-by__entry__author">Jinghan Sun, </li><li class="list-inline-item cited-by__entry__author">Yue Liu, </li><li class="list-inline-item cited-by__entry__author">Jiahui Gu, </li><li class="list-inline-item cited-by__entry__author">Shugela Akemujiang, </li><li class="list-inline-item cited-by__entry__author">Yudi Zou, </li><li class="list-inline-item cited-by__entry__author">Lufan Jiang, </li><li class="list-inline-item cited-by__entry__author">Qinzhuo Wang, </li><li class="list-inline-item cited-by__entry__author">Chen Li, </li><li class="list-inline-item cited-by__entry__author">Lei Luo, </li><li class="list-inline-item cited-by__entry__author">Yunkai Zhang, </li><li class="list-inline-item cited-by__entry__author">Hong Fan, </li><li class="list-inline-item cited-by__entry__author">Pengfei Luo, </li><li class="list-inline-item cited-by__entry__author">Bo Wang, </li></ul><span class="cited-by__entry__title">Molecular mechanisms of acquired resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer, </span><span class="cited-by__entry__series-title">Drug Resistance Updates, </span><span class="cited-by__entry__page-range">(101266), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.drup.2025.101266" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.drup.2025.101266</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.drup.2025.101266" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Xiuning Le, </li><li class="list-inline-item cited-by__entry__author">Anna Eisert, </li><li class="list-inline-item cited-by__entry__author">Te-Chun Hsia, </li><li class="list-inline-item cited-by__entry__author">Nirmal Vivek Raut, </li><li class="list-inline-item cited-by__entry__author">Azura Ahmad, </li><li class="list-inline-item cited-by__entry__author">Oscar Siu Hong Chan, </li><li class="list-inline-item cited-by__entry__author">Charlotte De Bondt, </li><li class="list-inline-item cited-by__entry__author">David Farrugia, </li><li class="list-inline-item cited-by__entry__author">Patrizia Froesch, </li><li class="list-inline-item cited-by__entry__author">Maria González-Cao, </li><li class="list-inline-item cited-by__entry__author">Lizza Hendriks, </li><li class="list-inline-item cited-by__entry__author">Maximillian J. Hochmair, </li><li class="list-inline-item cited-by__entry__author">Julien Mazieres, </li><li class="list-inline-item cited-by__entry__author">Hazel O'Sullivan, </li><li class="list-inline-item cited-by__entry__author">Sanjay Popat, </li><li class="list-inline-item cited-by__entry__author">Jens Samol, </li><li class="list-inline-item cited-by__entry__author">Anthonie J. van der Wekken, </li><li class="list-inline-item cited-by__entry__author">Tsung-Ying Yang, </li><li class="list-inline-item cited-by__entry__author">Lye Mun Tho, </li><li class="list-inline-item cited-by__entry__author">Ulrike Himpe, </li><li class="list-inline-item cited-by__entry__author">Wei-Sen Lam, </li><li class="list-inline-item cited-by__entry__author">Kirsty Wai Chung Lee, </li><li class="list-inline-item cited-by__entry__author">Iacopo Petrini, </li><li class="list-inline-item cited-by__entry__author">Karin Berghoff, </li><li class="list-inline-item cited-by__entry__author">Niki Karachaliou, </li><li class="list-inline-item cited-by__entry__author">Kirti Joshi, </li><li class="list-inline-item cited-by__entry__author">Soetkin Vlassak, </li><li class="list-inline-item cited-by__entry__author">Gee-Chen Chang, </li></ul><span class="cited-by__entry__title">Tepotinib Plus an EGFR Tyrosine Kinase Inhibitor in Patients With EGFR-Mutant MET-Altered NSCLC: A Case Series, </span><span class="cited-by__entry__series-title">Clinical Lung Cancer, </span><span class="cited-by__entry__volume"><strong>26</strong>, </span><span class="cited-by__entry__issue">4, </span><span class="cited-by__entry__page-range">(338-346.e1), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.cllc.2025.02.013" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.cllc.2025.02.013</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.cllc.2025.02.013" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Dina Oksen, </li><li class="list-inline-item cited-by__entry__author">Emmanuelle Boutmy, </li><li class="list-inline-item cited-by__entry__author">Yuexi Wang, </li><li class="list-inline-item cited-by__entry__author">Christopher Stroh, </li><li class="list-inline-item cited-by__entry__author">Andreas Johne, </li><li class="list-inline-item cited-by__entry__author">Alnecia R. Nisbett, </li><li class="list-inline-item cited-by__entry__author">Alex Ryder, </li></ul><span class="cited-by__entry__title">Patients With Advanced Non–small Cell Lung Cancer Harboring MET Alterations: A Descriptive Cohort Study, </span><span class="cited-by__entry__series-title">Clinical Lung Cancer, </span><span class="cited-by__entry__volume"><strong>26</strong>, </span><span class="cited-by__entry__issue">4, </span><span class="cited-by__entry__page-range">(e259-e269.e5), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.cllc.2025.01.013" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.cllc.2025.01.013</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.cllc.2025.01.013" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Yu-Ra Choi, </li><li class="list-inline-item cited-by__entry__author">Mihwa Hwang, </li><li class="list-inline-item cited-by__entry__author">Jaemin Kim, </li><li class="list-inline-item cited-by__entry__author">Seog-Yun Park, </li><li class="list-inline-item cited-by__entry__author">Sunshin Kim, </li><li class="list-inline-item cited-by__entry__author">Jae J. Song, </li><li class="list-inline-item cited-by__entry__author">Youngjoo Lee, </li></ul><span class="cited-by__entry__title">Overcoming MET-targeted drug resistance in MET-amplified lung cancer by aurora kinase B inhibition, </span><span class="cited-by__entry__series-title">Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, </span><span class="cited-by__entry__page-range">(120001), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.bbamcr.2025.120001" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.bbamcr.2025.120001</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.bbamcr.2025.120001" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry--see-more"><a href="javascript:void(0)" data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2020.383.issue-10%3BrequestedJournal%3Ajournal%3Anejm%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3BpageGroup%3Astring%3APublication+Pages%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa2002787%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Bjournal%3Ajournal%3Anejms" class="cited-by__see-more">See more</a></li></ol></div><div class="cited-by__spinner justify-content-center align-items-center d-none"><div role="status" class="spinner-border text-gray"><span class="sr-only">Loading...</span></div></div></div></section>

        </div>
    

</section></section></div><div id="core-collateral-fulltext-options" role="tabpanel" data-core-tabs="core-collateral-fulltext-options" tabindex="-1" aria-labelledby="pane-core-collateral-fulltext-options"><header><h2 id="pane-core-collateral-fulltext-options"><i class="icon-eye" aria-hidden="true"></i>View Options</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div class="section--wrapper"><h3>View options</h3><section class="format--pdf"><h4> <abbr title="Portable Document Format">PDF</abbr></h4><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa2002787" class="btn btn--pdf" aria-label="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa2002787" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2002787.pdf"><i aria-hidden="true" class="icon-pdf"></i><span>View PDF</span></a></section></div><!-- Its needed to duplicate this for PB check Collateral.js as well--></div><div id="core-collateral-media" role="tabpanel" data-core-tabs="core-collateral-media" tabindex="-1" aria-labelledby="pane-core-collateral-media"><header><h2 id="pane-core-collateral-media"><i class="icon-photo" aria-hidden="true"></i>Media</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-figures" role="tab" id="tab-figures-label" aria-selected="true" class="active">Figures</button><button aria-controls="tab-other" role="tab" id="tab-other-label" tabindex="-1" aria-selected="false" class="inactive" aria-disabled="true">Other</button></div><section id="tab-figures" aria-labelledby="tab-figures-label" role="tabpanel" tabindex="0"><h3>Figures</h3><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#figures"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-f1"><figure class="graphic"><a class="open-in-viewer" href="#f1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2002787_f1.jpg"><img src="/cms/10.1056/NEJMoa2002787/asset/6bdb0b9c-7e03-4610-a745-acef42916681/assets/images/large/nejmoa2002787_f1.jpg" height="3438" width="2180" aria-labelledby="f1" loading="lazy"></a><figcaption><div class="caption">Study Design.</div><div class="notes"><div role="doc-footnote">Eligible patients with non–small-cell lung cancer (NSCLC) had to have an Eastern Cooperative Oncology Group (ECOG) performance-status score of 0 or 1 (on a scale from 0 [fully active] to 5 [death]; a score of 1 indicates that the patient is ambulatory but restricted from strenuous activity) and to have at least one measurable tumor, according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1. Patients were assigned to cohorts on the basis of <i>MET</i> status (<i>MET</i> exon 14 skipping mutation or <i>MET</i> amplification, as measured by gene copy number [GCN]) and previous lines of therapy. Enrollment in cohorts with a <i>MET</i> exon 14 skipping mutation was allowed regardless of concurrent <i>MET</i> amplification, but no concurrent <i>MET</i> exon 14 skipping mutation was permitted in cohorts with <i>MET</i> amplification. Previously treated patients had received systemic antineoplastic therapy for advanced NSCLC. Enrollment in cohort 5a was stopped early because of slow enrollment. Each cohort of the study, except the expansion cohorts, enrolled patients in parallel. Enrollment in cohort 6 was to be initiated only on completion of enrollments in cohort 1a or cohort 4 and included only patients who had received one line of therapy previously. Cohort 7 was added in a protocol amendment (on February 28, 2019); enrollment was ongoing at the data-cutoff date (January 6, 2020). The expansion cohorts allowed further data collection in the specified patient populations. <i>ALK</i> denotes anaplastic lymphoma kinase, and <i>EGFR</i> epidermal growth factor receptor.</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f1"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2002787_f1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-f2"><figure class="graphic"><a class="open-in-viewer" href="#f2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2002787_f2.jpg"><img src="/cms/10.1056/NEJMoa2002787/asset/69aa6840-a5e0-4ba5-ab13-693005a1f5c5/assets/images/large/nejmoa2002787_f2.jpg" height="1674" width="2640" aria-labelledby="f2" loading="lazy"></a><figcaption><div class="caption">Tumor Responses to Capmatinib.</div><div class="notes"><div role="doc-footnote">Assessments were conducted by an independent review committee whose members were unaware of the cohort assignments. Panel A shows the best percentage change from baseline in the sum of the longest diameters in patients with NSCLC with a <i>MET</i> exon 14 skipping mutation who had measurable disease at baseline and at least one valid postbaseline assessment; the analysis included 60 previously treated patients and 26 patients who had not received treatment previously. The line at 20% corresponds to a change indicating progressive disease; the line at −30% corresponds to a change indicating a partial response. Circles at the end of the bars indicate patients receiving ongoing treatment. Panel B shows the best percentage change from baseline in the sum of the longest diameters in patients with <i>MET</i>-amplified NSCLC (tumor tissue with a gene copy number [GCN] ≥10) who had measurable disease at baseline and at least one valid postbaseline assessment; the analysis included 55 previously treated patients and 14 patients who had not received treatment previously. Panel C shows progression-free survival among patients with NSCLC with a <i>MET</i> exon 14 skipping mutation; the analysis included 69 previously treated patients and 28 patients who had not received treatment previously. Diamonds at the end of the bars indicate censored data because the patient was still followed for efficacy and had not had disease progression or died, triangles indicate censored data because the patient was no longer followed for efficacy and had not had disease progression or died, and squares indicate death. Patients with no symbol at the end of the bar had progressive disease at the data-cutoff date (January 6, 2020). Panel D shows progression-free survival among patients with <i>MET</i>-amplified NSCLC (tumor tissue with a GCN ≥10); the analysis included 69 previously treated patients and 15 patients who had not received treatment previously.</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f2"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f2" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2002787_f2.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></section><section id="tab-other" aria-labelledby="tab-other-label" role="tabpanel" tabindex="-1"><h3>Other</h3></section></div><div id="core-collateral-tables" role="tabpanel" data-core-tabs="core-collateral-tables" tabindex="-1" aria-labelledby="pane-core-collateral-tables"><header><h2 id="pane-core-collateral-tables"><i class="icon-tables" aria-hidden="true"></i>Tables</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><!-- There is no content. --><div class="section--wrapper"><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#tables"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-t1"><figure class="table"><a class="open-in-viewer" href="#t1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2002787_t1.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2002787/asset/300b4740-aa3a-4dc7-8a38-d5d592183ef3/assets/images/large/nejmoa2002787_t1.jpg" height="2067" width="2615" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Characteristic</th><th class="txxx-borders" colspan="2"><span>NSCLC with <i>MET</i> Exon 14<br>Skipping Mutation</span></th><th class="txxr-borders" colspan="5"><span>NSCLC with <i>MET</i> Amplification</span></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">Cohort 4<br>(N=69)</th><th class="xxxx-borders">Cohort 5b<br>(N=28)</th><th class="xxxx-borders">Cohort 1a<br>(N=69)</th><th class="xxxx-borders">Cohort 5a<br>(N=15)</th><th class="xxxx-borders">Cohort 1b<br>(N=42)</th><th class="xxxx-borders">Cohort 2<br>(N=54)</th><th class="xxxr-borders">Cohort 3<br>(N=30)</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging02 shading">Age</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Median (range) — yr</td><td class="xxxx-borders">71 (49–90)</td><td class="xxxx-borders">71 (57–86)</td><td class="xxxx-borders">61 (33–76)</td><td class="xxxx-borders">70 (49–86)</td><td class="xxxx-borders">60 (36–76)</td><td class="xxxx-borders">64 (39–84)</td><td class="xxxr-borders">63 (38–78)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">≥65 yr — no. (%)</td><td class="xxxx-borders shading">55 (80)</td><td class="xxxx-borders shading">25 (89)</td><td class="xxxx-borders shading">28 (41)</td><td class="xxxx-borders shading">10 (67)</td><td class="xxxx-borders shading">13 (31)</td><td class="xxxx-borders shading">24 (44)</td><td class="xxxr-borders shading">14 (47)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Female sex — no. (%)</td><td class="xxxx-borders">40 (58)</td><td class="xxxx-borders">18 (64)</td><td class="xxxx-borders">15 (22)</td><td class="xxxx-borders">4 (27)</td><td class="xxxx-borders">21 (50)</td><td class="xxxx-borders">15 (28)</td><td class="xxxr-borders">11 (37)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">ECOG performance-status score — no. (%)<a href="#core-t1fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">0</td><td class="xxxx-borders">16 (23)</td><td class="xxxx-borders">7 (25)</td><td class="xxxx-borders">17 (25)</td><td class="xxxx-borders">4 (27)</td><td class="xxxx-borders">14 (33)</td><td class="xxxx-borders">23 (43)</td><td class="xxxr-borders">9 (30)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">≥1</td><td class="xxxx-borders shading">53 (77)</td><td class="xxxx-borders shading">21 (75)</td><td class="xxxx-borders shading">52 (75)</td><td class="xxxx-borders shading">11 (73)</td><td class="xxxx-borders shading">28 (67)</td><td class="xxxx-borders shading">31 (57)</td><td class="xxxr-borders shading">21 (70)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Smoking history — no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Never smoked</td><td class="xxxx-borders shading">40 (58)</td><td class="xxxx-borders shading">18 (64)</td><td class="xxxx-borders shading">5 (7)</td><td class="xxxx-borders shading">2 (13)</td><td class="xxxx-borders shading">7 (17)</td><td class="xxxx-borders shading">11 (20)</td><td class="xxxr-borders shading">7 (23)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Former smoking</td><td class="xxxx-borders">27 (39)</td><td class="xxxx-borders">9 (32)</td><td class="xxxx-borders">54 (78)</td><td class="xxxx-borders">8 (53)</td><td class="xxxx-borders">29 (69)</td><td class="xxxx-borders">34 (63)</td><td class="xxxr-borders">20 (67)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Current smoking</td><td class="xxxx-borders shading">2 (3)</td><td class="xxxx-borders shading">1 (4)</td><td class="xxxx-borders shading">10 (14)</td><td class="xxxx-borders shading">5 (33)</td><td class="xxxx-borders shading">6 (14)</td><td class="xxxx-borders shading">9 (17)</td><td class="xxxr-borders shading">3 (10)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Histologic findings — no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Adenocarcinoma</td><td class="xxxx-borders shading">53 (77)</td><td class="xxxx-borders shading">25 (89)</td><td class="xxxx-borders shading">57 (83)</td><td class="xxxx-borders shading">11 (73)</td><td class="xxxx-borders shading">35 (83)</td><td class="xxxx-borders shading">48 (89)</td><td class="xxxr-borders shading">22 (73)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Squamous-cell carcinoma</td><td class="xxxx-borders">6 (9)</td><td class="xxxx-borders">2 (7)</td><td class="xxxx-borders">7 (10)</td><td class="xxxx-borders">2 (13)</td><td class="xxxx-borders">2 (5)</td><td class="xxxx-borders">4 (7)</td><td class="xxxr-borders">5 (17)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Large-cell carcinoma</td><td class="xxxx-borders shading">1 (1)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">2 (3)</td><td class="xxxx-borders shading">1 (7)</td><td class="xxxx-borders shading">1 (2)</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">1 (3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Other</td><td class="xxxx-borders">9 (13)</td><td class="xxxx-borders">1 (4)</td><td class="xxxx-borders">3 (4)</td><td class="xxxx-borders">1 (7)</td><td class="xxxx-borders">4 (10)</td><td class="xxxx-borders">2 (4)</td><td class="xxxr-borders">2 (7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Brain metastases at baseline — no. (%)<a href="#core-t1fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders shading">11 (16)</td><td class="xxxx-borders shading">3 (11)</td><td class="xxxx-borders shading">26 (38)</td><td class="xxxx-borders shading">7 (47)</td><td class="xxxx-borders shading">14 (33)</td><td class="xxxx-borders shading">18 (33)</td><td class="xxxr-borders shading">6 (20)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">No. of previous lines of antineoplastic therapy — no. (%)<a href="#core-t1fn4" role="doc-noteref">§</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">1</td><td class="xxxx-borders shading">51 (74)</td><td class="xxxx-borders shading">NA</td><td class="xxxx-borders shading">41 (59)</td><td class="xxxx-borders shading">NA</td><td class="xxxx-borders shading">27 (64)</td><td class="xxxx-borders shading">28 (52)</td><td class="xxxr-borders shading">9 (30)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">2</td><td class="xxxx-borders">16 (23)</td><td class="xxxx-borders">NA</td><td class="xxxx-borders">27 (39)</td><td class="xxxx-borders">NA</td><td class="xxxx-borders">15 (36)</td><td class="xxxx-borders">26 (48)</td><td class="xxxr-borders">21 (70)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging12 shading" data-xml-align="left">3</td><td class="xbxx-borders shading">2 (3)</td><td class="xbxx-borders shading">NA</td><td class="xbxx-borders shading">1 (1)</td><td class="xbxx-borders shading">NA</td><td class="xbxx-borders shading">0</td><td class="xbxx-borders shading">0</td><td class="xbxr-borders shading">0</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t1fn1" role="paragraph" data-to-manipulate="true">Patients with non–small-cell lung cancer (NSCLC) with a <i>MET</i> exon 14 skipping mutation were assigned to study cohorts on the basis of receipt of previous treatment: cohort 4 included patients who had received treatment previously, and cohort 5b included those who had not received treatment previously. Patients with NSCLC with <i>MET</i> amplification were assigned to study cohorts on the basis of gene copy number (≥10, 6 to 9, 4 or 5, or &lt;4) and receipt of previous treatment (yes or no): among patients with a copy number of at least 10, cohort 1a included previously treated patients and cohort 5a included patients who had not received treatment previously; cohort 1b included patients with a gene copy number of 6 to 9, cohort 2 those with a gene copy number of 4 or 5, and cohort 3 those with a gene copy number of less than 4. All the patients with a gene copy number of less than 10 had received treatment previously. The data-cutoff date was January 6, 2020. Percentages may not total 100 because of rounding. NA denotes not applicable.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t1fn2" role="paragraph" data-to-manipulate="true">Eastern Cooperative Oncology Group (ECOG) performance-status scores are assessed on a scale from 0 (fully active) to 5 (death); a score of 1 indicates that the patient is ambulatory but restricted from strenuous activity. One patient in cohort 4, who had undergone randomization in error (protocol deviation), had an ECOG performance-status score of 2 (indicating that the patient was ambulatory and capable of self-care but unable to carry out any work activities).</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="core-t1fn3" role="paragraph" data-to-manipulate="true">Among patients with NSCLC with a <i>MET</i> exon 14 skipping mutation, 12 were identified from their medical history and 2 were identified on the basis of the baseline computed tomographic scan.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="core-t1fn4" role="paragraph" data-to-manipulate="true">The types of antineoplastic therapy that had been received by patients in the previously treated cohorts are shown in Table S1.</div></div></div></figcaption></a><figcaption><div class="caption">Characteristics of the Patients at Baseline.<a href="#core-t1fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t1"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2002787_t1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-t2"><figure class="table"><a class="open-in-viewer" href="#t2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2002787_t2.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2002787/asset/ebe1f72a-2669-4427-ae61-505f115b7a31/assets/images/large/nejmoa2002787_t2.jpg" height="1951" width="2615" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Response</th><th class="txxx-borders" colspan="2"><span>NSCLC with <i>MET</i> Exon 14<br>Skipping Mutation</span></th><th class="txxr-borders" colspan="5"><span>NSCLC with <i>MET</i> Amplification</span></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">Cohort 4<br>(N=69)</th><th class="xxxx-borders">Cohort 5b<br>(N=28)</th><th class="xxxx-borders">Cohort 1a<br>(N=69)</th><th class="xxxx-borders">Cohort 5a<br>(N=15)</th><th class="xxxx-borders">Cohort 1b<br>(N=42)</th><th class="xxxx-borders">Cohort 2<br>(N=54)</th><th class="xxxr-borders">Cohort 3<br>(N=30)</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging02 shading">Best response — no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Complete response</td><td class="xxxx-borders">0</td><td class="xxxx-borders">1 (4)</td><td class="xxxx-borders">1 (1)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Partial response</td><td class="xxxx-borders shading">28 (41)</td><td class="xxxx-borders shading">18 (64)</td><td class="xxxx-borders shading">19 (28)</td><td class="xxxx-borders shading">6 (40)</td><td class="xxxx-borders shading">5 (12)</td><td class="xxxx-borders shading">5 (9)</td><td class="xxxr-borders shading">2 (7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Stable disease</td><td class="xxxx-borders">25 (36)</td><td class="xxxx-borders">7 (25)</td><td class="xxxx-borders">28 (41)</td><td class="xxxx-borders">4 (27)</td><td class="xxxx-borders">17 (40)</td><td class="xxxx-borders">20 (37)</td><td class="xxxr-borders">14 (47)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Noncomplete response or nonprogressive disease</td><td class="xxxx-borders shading">1 (1)</td><td class="xxxx-borders shading">1 (4)</td><td class="xxxx-borders shading">1 (1)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">1 (2)</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Progressive disease</td><td class="xxxx-borders">6 (9)</td><td class="xxxx-borders">1 (4)</td><td class="xxxx-borders">12 (17)</td><td class="xxxx-borders">4 (27)</td><td class="xxxx-borders">15 (36)</td><td class="xxxx-borders">21 (39)</td><td class="xxxr-borders">6 (20)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Unknown or could not be evaluated</td><td class="xxxx-borders shading">9 (13)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">8 (12)</td><td class="xxxx-borders shading">1 (7)</td><td class="xxxx-borders shading">4 (10)</td><td class="xxxx-borders shading">8 (15)</td><td class="xxxr-borders shading">8 (27)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Overall response<a href="#core-t2fn2" role="doc-noteref">†</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">No. of patients with overall response</td><td class="xxxx-borders shading">28</td><td class="xxxx-borders shading">19</td><td class="xxxx-borders shading">20</td><td class="xxxx-borders shading">6</td><td class="xxxx-borders shading">5</td><td class="xxxx-borders shading">5</td><td class="xxxr-borders shading">2</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Percent of patients (95% CI)</td><td class="xxxx-borders">41 (29–53)</td><td class="xxxx-borders">68 (48–84)</td><td class="xxxx-borders">29 (19–41)</td><td class="xxxx-borders">40 (16–68)</td><td class="xxxx-borders">12 (4–26)</td><td class="xxxx-borders">9 (3–20)</td><td class="xxxr-borders">7 (1–22)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Disease control<a href="#core-t2fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">No. of patients with disease control</td><td class="xxxx-borders">54</td><td class="xxxx-borders">27</td><td class="xxxx-borders">49</td><td class="xxxx-borders">10</td><td class="xxxx-borders">23</td><td class="xxxx-borders">25</td><td class="xxxr-borders">16</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Percent of patients (95% CI)</td><td class="xxxx-borders shading">78 (67–87)</td><td class="xxxx-borders shading">96 (82–100)</td><td class="xxxx-borders shading">71 (59–81)</td><td class="xxxx-borders shading">67 (38–88)</td><td class="xxxx-borders shading">55 (39–70)</td><td class="xxxx-borders shading">46 (33–60)</td><td class="xxxr-borders shading">53 (34–72)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Duration of response</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">No. of events/no. of patients with response</td><td class="xxxx-borders shading">23/28</td><td class="xxxx-borders shading">11/19</td><td class="xxxx-borders shading">15/20</td><td class="xxxx-borders shading">6/6</td><td class="xxxx-borders shading">3/5</td><td class="xxxx-borders shading">4/5</td><td class="xxxr-borders shading">2/2</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Median duration of response (95% CI) — mo</td><td class="xxxx-borders">9.7<br>(5.6–13.0)</td><td class="xxxx-borders">12.6<br>(5.6–NE)</td><td class="xxxx-borders">8.3<br>(4.2–15.4)</td><td class="xxxx-borders">7.5<br>(2.6–14.3)</td><td class="xxxx-borders">24.9<br>(2.7–24.9)</td><td class="xxxx-borders">9.7<br>(4.2–NE)</td><td class="xxxr-borders">4.2<br>(4.2–4.2)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Progression-free survival</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Progression or death — no. of patients</td><td class="xxxx-borders">60</td><td class="xxxx-borders">17</td><td class="xxxx-borders">58</td><td class="xxxx-borders">15</td><td class="xxxx-borders">34</td><td class="xxxx-borders">50</td><td class="xxxr-borders">22</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging12 shading" data-xml-align="left">Median progression-free survival (95% CI) — mo</td><td class="xbxx-borders shading">5.4<br>(4.2–7.0)</td><td class="xbxx-borders shading">12.4<br>(8.2–NE)</td><td class="xbxx-borders shading">4.1<br>(2.9–4.8)</td><td class="xbxx-borders shading">4.2<br>(1.4–6.9)</td><td class="xbxx-borders shading">2.7<br>(1.4–3.1)</td><td class="xbxx-borders shading">2.7<br>(1.4–4.1)</td><td class="xbxr-borders shading">3.6<br>(2.2–4.2)</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t2fn1" role="paragraph" data-to-manipulate="true">The data-cutoff date was January 6, 2020, for cohorts 4, 5b, 1a, and 5a and April 15, 2019, for cohorts 1b, 2, and 3. Complete response required at least two determinations of complete response (according to the Response Evaluation Criteria in Solid Tumors, version 1.1) that were made at least 4 weeks apart before progression. Partial response required at least two determinations of partial response or better (not qualifying for complete response) that were made at least 4 weeks apart before progression. Stable disease required at least one assessment of stable disease or better (not qualifying for complete response) that was made more than 6 weeks after the start of capmatinib. A noncomplete response or nonprogressive disease was noted when neither complete response nor progressive disease was observed (for patients with nontarget lesions only at baseline). Progressive disease was noted when progression occurred 12 weeks or less after the start of capmatinib (and when the criteria for complete response, partial response, or stable disease were not met). Unknown status indicates all other cases (i.e., those not qualifying as a confirmed complete response or partial response and that did not involve stable disease after &gt;6 weeks after the start of capmatinib or progression within the first 12 weeks of therapy). Percentages may not total 100 because of rounding. NE denotes could not be estimated.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t2fn2" role="paragraph" data-to-manipulate="true">Overall response was defined as a complete response or partial response.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="core-t2fn3" role="paragraph" data-to-manipulate="true">Disease control was defined as a complete response, partial response, stable disease, or noncomplete response or nonprogressive disease.</div></div></div></figcaption></a><figcaption><div class="caption">Responses to Capmatinib Treatment, as Assessed by the Independent Review Committee.<a href="#core-t2fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t2"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t2" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2002787_t2.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-t3"><figure class="table"><a class="open-in-viewer" href="#t3" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2002787_t3.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2002787/asset/2fdac451-dafe-4867-98a3-df0979b5b06d/assets/images/large/nejmoa2002787_t3.jpg" height="2409" width="2615" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Variable</th><th class="txxx-borders" colspan="4"><span>NSCLC with <i>MET</i> Exon 14<br>Skipping Mutation</span></th><th class="txxx-borders" colspan="10"><span>NSCLC with <i>MET</i> Amplification</span></th><th class="txxr-borders" colspan="2"><span>All Cohorts<br>(N=364)</span></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders" colspan="2"><span>Cohort 4<br>(N=69)</span></th><th class="xxxx-borders" colspan="2"><span>Cohort 5b<br>(N=28)</span></th><th class="xxxx-borders" colspan="2"><span>Cohort 1a<br>(N=69)</span></th><th class="xxxx-borders" colspan="2"><span>Cohort 5a<br>(N=15)</span></th><th class="xxxx-borders" colspan="2"><span>Cohort 1b<br>(N=42)</span></th><th class="xxxx-borders" colspan="2"><span>Cohort 2<br>(N=54)</span></th><th class="xxxx-borders" colspan="2"><span>Cohort 3<br>(N=30)</span></th><th class="xxxx-borders">Total</th><th class="xxxr-borders">Grade<br>3 or 4</th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">Total</th><th class="xxxx-borders">Grade<br>3 or 4</th><th class="xxxx-borders">Total</th><th class="xxxx-borders">Grade<br>3 or 4</th><th class="xxxx-borders">Total</th><th class="xxxx-borders">Grade<br>3 or 4</th><th class="xxxx-borders">Total</th><th class="xxxx-borders">Grade<br>3 or 4</th><th class="xxxx-borders">Total</th><th class="xxxx-borders">Grade<br>3 or 4</th><th class="xxxx-borders">Total</th><th class="xxxx-borders">Grade<br>3 or 4</th><th class="xxxx-borders">Total</th><th class="xxxx-borders">Grade<br>3 or 4</th><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging02 shading"><b>Adverse events</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Any event — no. (%)</td><td class="xxxx-borders">68 (99)</td><td class="xxxx-borders">52 (75)</td><td class="xxxx-borders">28 (100)</td><td class="xxxx-borders">21 (75)</td><td class="xxxx-borders">67 (97)</td><td class="xxxx-borders">48 (70)</td><td class="xxxx-borders">15 (100)</td><td class="xxxx-borders">10 (67)</td><td class="xxxx-borders">42 (100)</td><td class="xxxx-borders">27 (64)</td><td class="xxxx-borders">54 (100)</td><td class="xxxx-borders">35 (65)</td><td class="xxxx-borders">28 (93)</td><td class="xxxx-borders">22 (73)</td><td class="xxxx-borders">355 (98)</td><td class="xxxr-borders">244 (67)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Most common events — no. (%)<a href="#core-t3fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Peripheral edema</td><td class="xxxx-borders">37 (54)</td><td class="xxxx-borders">10 (14)</td><td class="xxxx-borders">21 (75)</td><td class="xxxx-borders">3 (11)</td><td class="xxxx-borders">34 (49)</td><td class="xxxx-borders">5 (7)</td><td class="xxxx-borders">11 (73)</td><td class="xxxx-borders">3 (20)</td><td class="xxxx-borders">18 (43)</td><td class="xxxx-borders">3 (7)</td><td class="xxxx-borders">24 (44)</td><td class="xxxx-borders">3 (6)</td><td class="xxxx-borders">11 (37)</td><td class="xxxx-borders">1 (3)</td><td class="xxxx-borders">186 (51)</td><td class="xxxr-borders">33 (9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Nausea<a href="#core-t3fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders shading">32 (46)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">13 (46)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">32 (46)</td><td class="xxxx-borders shading">5 (7)</td><td class="xxxx-borders shading">9 (60)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">17 (40)</td><td class="xxxx-borders shading">3 (7)</td><td class="xxxx-borders shading">24 (44)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">15 (50)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">163 (45)</td><td class="xxxr-borders shading">9 (2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Vomiting<a href="#core-t3fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders">18 (26)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">7 (25)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">24 (35)</td><td class="xxxx-borders">5 (7)</td><td class="xxxx-borders">4 (27)</td><td class="xxxx-borders">1 (7)</td><td class="xxxx-borders">16 (38)</td><td class="xxxx-borders">1 (2)</td><td class="xxxx-borders">12 (22)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">9 (30)</td><td class="xxxx-borders">1 (3)</td><td class="xxxx-borders">102 (28)</td><td class="xxxr-borders">9 (2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Blood creatinine increased</td><td class="xxxx-borders shading">23 (33)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">10 (36)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">16 (23)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">3 (20)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">8 (19)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">14 (26)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">5 (17)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">89 (24)</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Dyspnea</td><td class="xxxx-borders">19 (28)</td><td class="xxxx-borders">7 (10)</td><td class="xxxx-borders">6 (21)</td><td class="xxxx-borders">2 (7)</td><td class="xxxx-borders">13 (19)</td><td class="xxxx-borders">4 (6)</td><td class="xxxx-borders">5 (33)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">16 (38)</td><td class="xxxx-borders">5 (12)</td><td class="xxxx-borders">14 (26)</td><td class="xxxx-borders">4 (7)</td><td class="xxxx-borders">7 (23)</td><td class="xxxx-borders">1 (3)</td><td class="xxxx-borders">84 (23)</td><td class="xxxr-borders">24 (7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Fatigue</td><td class="xxxx-borders shading">18 (26)</td><td class="xxxx-borders shading">6 (9)</td><td class="xxxx-borders shading">4 (14)</td><td class="xxxx-borders shading">1 (4)</td><td class="xxxx-borders shading">11 (16)</td><td class="xxxx-borders shading">1 (1)</td><td class="xxxx-borders shading">2 (13)</td><td class="xxxx-borders shading">1 (7)</td><td class="xxxx-borders shading">10 (24)</td><td class="xxxx-borders shading">2 (5)</td><td class="xxxx-borders shading">16 (30)</td><td class="xxxx-borders shading">2 (4)</td><td class="xxxx-borders shading">6 (20)</td><td class="xxxx-borders shading">3 (10)</td><td class="xxxx-borders shading">80 (22)</td><td class="xxxr-borders shading">16 (4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Decreased appetite<a href="#core-t3fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders">15 (22)</td><td class="xxxx-borders">1 (1)</td><td class="xxxx-borders">8 (29)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">15 (22)</td><td class="xxxx-borders">1 (1)</td><td class="xxxx-borders">4 (27)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">7 (17)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">12 (22)</td><td class="xxxx-borders">1 (2)</td><td class="xxxx-borders">8 (27)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">76 (21)</td><td class="xxxr-borders">3 (1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Constipation</td><td class="xxxx-borders shading">10 (14)</td><td class="xxxx-borders shading">2 (3)</td><td class="xxxx-borders shading">4 (14)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">16 (23)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">6 (40)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">9 (21)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">10 (19)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">7 (23)</td><td class="xxxx-borders shading">1 (3)</td><td class="xxxx-borders shading">66 (18)</td><td class="xxxr-borders shading">3 (1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Diarrhea</td><td class="xxxx-borders">12 (17)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">5 (18)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">19 (28)</td><td class="xxxx-borders">1 (1)</td><td class="xxxx-borders">4 (27)</td><td class="xxxx-borders">1 (7)</td><td class="xxxx-borders">6 (14)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">7 (13)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">8 (27)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">64 (18)</td><td class="xxxr-borders">2 (1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Cough</td><td class="xxxx-borders shading">10 (14)</td><td class="xxxx-borders shading">1 (1)</td><td class="xxxx-borders shading">7 (25)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">9 (13)</td><td class="xxxx-borders shading">1 (1)</td><td class="xxxx-borders shading">2 (13)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">9 (21)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">9 (17)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">5 (17)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">58 (16)</td><td class="xxxr-borders shading">2 (1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Back pain</td><td class="xxxx-borders">11 (16)</td><td class="xxxx-borders">2 (3)</td><td class="xxxx-borders">4 (14)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">8 (12)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">2 (13)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">7 (17)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">10 (19)</td><td class="xxxx-borders">1 (2)</td><td class="xxxx-borders">2 (7)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">54 (15)</td><td class="xxxr-borders">3 (1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Pyrexia</td><td class="xxxx-borders shading">9 (13)</td><td class="xxxx-borders shading">1 (1)</td><td class="xxxx-borders shading">2 (7)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">10 (14)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">3 (20)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">8 (19)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">8 (15)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">5 (17)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">50 (14)</td><td class="xxxr-borders shading">3 (1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">ALT increased</td><td class="xxxx-borders">8 (12)</td><td class="xxxx-borders">6 (9)</td><td class="xxxx-borders">4 (14)</td><td class="xxxx-borders">2 (7)</td><td class="xxxx-borders">12 (17)</td><td class="xxxx-borders">7 (10)</td><td class="xxxx-borders">5 (33)</td><td class="xxxx-borders">2 (13)</td><td class="xxxx-borders">4 (10)</td><td class="xxxx-borders">1 (2)</td><td class="xxxx-borders">5 (9)</td><td class="xxxx-borders">2 (4)</td><td class="xxxx-borders">3 (10)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">48 (13)</td><td class="xxxr-borders">23 (6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Asthenia</td><td class="xxxx-borders shading">6 (9)</td><td class="xxxx-borders shading">3 (4)</td><td class="xxxx-borders shading">4 (14)</td><td class="xxxx-borders shading">2 (7)</td><td class="xxxx-borders shading">6 (9)</td><td class="xxxx-borders shading">3 (4)</td><td class="xxxx-borders shading">2 (13)</td><td class="xxxx-borders shading">1 (7)</td><td class="xxxx-borders shading">8 (19)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">11 (20)</td><td class="xxxx-borders shading">3 (6)</td><td class="xxxx-borders shading">3 (10)</td><td class="xxxx-borders shading">1 (3)</td><td class="xxxx-borders shading">42 (12)</td><td class="xxxr-borders shading">13 (4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Pneumonia</td><td class="xxxx-borders">7 (10)</td><td class="xxxx-borders">4 (6)</td><td class="xxxx-borders">2 (7)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">12 (17)</td><td class="xxxx-borders">3 (4)</td><td class="xxxx-borders">1 (7)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">7 (17)</td><td class="xxxx-borders">3 (7)</td><td class="xxxx-borders">3 (6)</td><td class="xxxx-borders">3 (6)</td><td class="xxxx-borders">3 (10)</td><td class="xxxx-borders">1 (3)</td><td class="xxxx-borders">39 (11)</td><td class="xxxr-borders">17 (5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Weight loss</td><td class="xxxx-borders shading">9 (13)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">3 (11)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">7 (10)</td><td class="xxxx-borders shading">1 (1)</td><td class="xxxx-borders shading">3 (20)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">4 (10)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">2 (4)</td><td class="xxxx-borders shading">1 (2)</td><td class="xxxx-borders shading">4 (13)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">36 (10)</td><td class="xxxr-borders shading">2 (1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Noncardiac chest pain</td><td class="xxxx-borders">5 (7)</td><td class="xxxx-borders">1 (1)</td><td class="xxxx-borders">1 (4)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">10 (14)</td><td class="xxxx-borders">2 (3)</td><td class="xxxx-borders">3 (20)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">5 (12)</td><td class="xxxx-borders">1 (2)</td><td class="xxxx-borders">7 (13)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">1 (3)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">35 (10)</td><td class="xxxr-borders">4 (1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Serious adverse event — no. (%)</td><td class="xxxx-borders shading">36 (52)</td><td class="xxxx-borders shading">30 (43)</td><td class="xxxx-borders shading">14 (50)</td><td class="xxxx-borders shading">12 (43)</td><td class="xxxx-borders shading">42 (61)</td><td class="xxxx-borders shading">36 (52)</td><td class="xxxx-borders shading">9 (60)</td><td class="xxxx-borders shading">5 (33)</td><td class="xxxx-borders shading">21 (50)</td><td class="xxxx-borders shading">19 (45)</td><td class="xxxx-borders shading">30 (56)</td><td class="xxxx-borders shading">22 (41)</td><td class="xxxx-borders shading">15 (50)</td><td class="xxxx-borders shading">13 (43)</td><td class="xxxx-borders shading">184 (51)</td><td class="xxxr-borders shading">152 (42)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Event leading to discontinuation — no. (%)</td><td class="xxxx-borders">14 (20)</td><td class="xxxx-borders">8 (12)</td><td class="xxxx-borders">6 (21)</td><td class="xxxx-borders">5 (18)</td><td class="xxxx-borders">11 (16)</td><td class="xxxx-borders">8 (12)</td><td class="xxxx-borders">3 (20)</td><td class="xxxx-borders">2 (13)</td><td class="xxxx-borders">5 (12)</td><td class="xxxx-borders">5 (12)</td><td class="xxxx-borders">8 (15)</td><td class="xxxx-borders">1 (2)</td><td class="xxxx-borders">5 (17)</td><td class="xxxx-borders">2 (7)</td><td class="xxxx-borders">56 (15)</td><td class="xxxr-borders">35 (10)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading"><b>Exposure</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Median duration — wk</td><td class="xxxx-borders">22.1</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">48.2</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">17.6</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">15.3</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">11.8</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">8.8</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">6.6</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">15.3</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-type="row"><td class="xblx-borders hanging02 shading">Range — wk</td><td class="xbxx-borders shading" data-xml-align="center">0.4–<br>136.0</td><td class="xbxx-borders shading">&nbsp;</td><td class="xbxx-borders shading" data-xml-align="center">4.0–<br>117.4</td><td class="xbxx-borders shading">&nbsp;</td><td class="xbxx-borders shading" data-xml-align="center">0.9–<br>201.0</td><td class="xbxx-borders shading">&nbsp;</td><td class="xbxx-borders shading" data-xml-align="center">3.1–<br>61.1</td><td class="xbxx-borders shading">&nbsp;</td><td class="xbxx-borders shading" data-xml-align="center">1.0–<br>215.0</td><td class="xbxx-borders shading">&nbsp;</td><td class="xbxx-borders shading" data-xml-align="center">0.6–<br>195.0</td><td class="xbxx-borders shading">&nbsp;</td><td class="xbxx-borders shading" data-xml-align="center">1.6–<br>73.0</td><td class="xbxx-borders shading">&nbsp;</td><td class="xbxx-borders shading" data-xml-align="center">0.4–<br>215.0</td><td class="xbxr-borders shading">&nbsp;</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t3fn1" role="paragraph" data-to-manipulate="true">The data-cutoff date was January 6, 2020. The overall analysis included all patients from cohorts 1 through 7 who received at least one dose of capmatinib. ALT denotes alanine aminotransferase.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t3fn2" role="paragraph" data-to-manipulate="true">The most common adverse events were those reported in more than 20% of the patients in any cohort.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="core-t3fn3" role="paragraph" data-to-manipulate="true">Capmatinib was administered under fasting conditions; food restriction was removed in cohorts 6 (34 patients) and 7 (23 patients). Safety data for cohorts 6 and 7 are shown in Tables S8 and S9, and safety data for cohorts with fasting restrictions, as compared with those without fasting restrictions, are shown in Table S10.</div></div></div></figcaption></a><figcaption><div class="caption">Adverse Events, According to Grade, Regardless of Causality, and Exposure to Capmatinib.<a href="#core-t3fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t3"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t3" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2002787_t3.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></div></div><div id="core-collateral-share" role="tabpanel" data-core-tabs="core-collateral-share" tabindex="-1" aria-labelledby="pane-core-collateral-share"><header><h2 id="pane-core-collateral-share"><i class="icon-share" aria-hidden="true"></i>Share</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>Share</h3><div class="section--wrapper"><section><h4>CONTENT LINK</h4><div id="share-self"><p data-id="article-share-self-link" class="share-self__source">https://www.nejm.org/doi/full/10.1056/NEJMoa2002787</p><button data-id="article-share-access" aria-label="CONTENT LINK" class="share-self__action btn btn--inverse"><i aria-hidden="true" class="icon-copy-o"></i><span>Copy Link</span></button><div aria-live="polite" class="share-self__status"><p class="share-self__success"><i aria-hidden="true" class="icon-check_circle"></i><span>Copied!</span></p><p class="share-self__failed"><i aria-hidden="true" class="icon-x_btnclose"></i><span>Copying failed.</span></p></div></div></section><section data-location="share_tools_article"><h4>Share</h4><div class="share-buttons a2a a2a_kit" style="line-height: 16px;"><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i><span>Facebook</span></a><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i><span>X (formerly Twitter)</span></a><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i><span>LinkedIn</span></a><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i><span>email</span></a><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i><span>Bluesky</span></a></div></section></div></div><div data-location="references_article" id="core-collateral-references" role="tabpanel" aria-labelledby="pane-core-collateral-references" data-core-tabs="core-collateral-references" tabindex="-1"><header><h2 id="pane-core-collateral-references"><i aria-hidden="true" class="icon-references"></i>References</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>References</h3><div role="list" class="section--wrapper"><div role="listitem" data-has="label"><div class="label">1.</div><div id="core-r1" class="citations"><div class="citation"><div class="citation-content">Comoglio PM, Trusolino L, Boccaccio C. Known and novel roles of the MET oncogene in cancer: a coherent approach to targeted therapy. <em>Nat Rev Cancer</em> 2018;18:341-358.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r7-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41568-018-0002-y" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29674709/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000432926500005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Known+and+novel+roles+of+the+MET+oncogene+in+cancer%3A+a+coherent+approach+to+targeted+therapy.&amp;publication_year=2018&amp;journal=Nat+Rev+Cancer&amp;pages=341-358&amp;doi=10.1038%2Fs41568-018-0002-y&amp;pmid=29674709" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="core-r2" class="citations"><div class="citation"><div class="citation-content">Koch JP, Aebersold DM, Zimmer Y, Medová M. MET targeting: time for a rematch. <em>Oncogene</em> 2020;39:2845-2862.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r7-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41388-020-1193-8" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32034310/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000511752600005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=MET+targeting%3A+time+for+a+rematch.&amp;publication_year=2020&amp;journal=Oncogene&amp;pages=2845-2862&amp;doi=10.1038%2Fs41388-020-1193-8&amp;pmid=32034310" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="core-r3" class="citations"><div class="citation"><div class="citation-content">Awad MM, Oxnard GR, Jackman DM, et al. MET exon 14 mutations in non-small-cell lung cancer are associated with advanced age and stage-dependent MET genomic amplification and c-Met overexpression. <em>J Clin Oncol</em> 2016;34:721-730.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r3-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.2015.63.4600" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26729443/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000374333400018" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=MET+exon+14+mutations+in+non-small-cell+lung+cancer+are+associated+with+advanced+age+and+stage-dependent+MET+genomic+amplification+and+c-Met+overexpression.&amp;publication_year=2016&amp;journal=J+Clin+Oncol&amp;pages=721-730&amp;doi=10.1200%2FJCO.2015.63.4600&amp;pmid=26729443" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r3-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r7-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] mutations or from insertions or deletions. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r7-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] in the absence of other driver mutations, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r5-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] these patients are generally elderly </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="core-r4" class="citations"><div class="citation"><div class="citation-content">Frampton GM, Ali SM, Rosenzweig M, et al. Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. <em>Cancer Discov</em> 2015;5:850-859.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r4-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1158/2159-8290.CD-15-0285" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25971938/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000359317700018" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Activation+of+MET+via+diverse+exon+14+splicing+alterations+occurs+in+multiple+tumor+types+and+confers+clinical+sensitivity+to+MET+inhibitors.&amp;publication_year=2015&amp;journal=Cancer+Discov&amp;pages=850-859&amp;doi=10.1158%2F2159-8290.CD-15-0285&amp;pmid=25971938" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r4-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r7-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] mutations or from insertions or deletions. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r7-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] in the absence of other driver mutations, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r18-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] emerged as potential predictive biomarkers. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="core-r5" class="citations"><div class="citation"><div class="citation-content">Schrock AB, Frampton GM, Suh J, et al. Characterization of 298 patients with lung cancer harboring MET exon 14 skipping alterations. <em>J Thorac Oncol</em> 2016;11:1493-1502.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r5-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.jtho.2016.06.004" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27343443/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000382420200015" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Characterization+of+298+patients+with+lung+cancer+harboring+MET+exon+14+skipping+alterations.&amp;publication_year=2016&amp;journal=J+Thorac+Oncol&amp;pages=1493-1502&amp;doi=10.1016%2Fj.jtho.2016.06.004&amp;pmid=27343443" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r5-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r7-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] mutations or from insertions or deletions. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r7-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] in the absence of other driver mutations, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r5-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] these patients are generally elderly </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="core-r6" class="citations"><div class="citation"><div class="citation-content">Paik PK, Drilon A, Fan P-D, et al. Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping. <em>Cancer Discov</em> 2015;5:842-849.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r6-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1158/2159-8290.CD-14-1467" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25971939/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000359317700017" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Response+to+MET+inhibitors+in+patients+with+stage+IV+lung+adenocarcinomas+harboring+MET+mutations+causing+exon+14+skipping.&amp;publication_year=2015&amp;journal=Cancer+Discov&amp;pages=842-849&amp;doi=10.1158%2F2159-8290.CD-14-1467&amp;pmid=25971939" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r6-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r7-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] mutations or from insertions or deletions. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r18-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] emerged as potential predictive biomarkers. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="core-r7" class="citations"><div class="citation"><div class="citation-content">Tong JH, Yeung SF, Chan AWH, et al. MET amplification and exon 14 splice site mutation define unique molecular subgroups of non-small cell lung carcinoma with poor prognosis. <em>Clin Cancer Res</em> 2016;22:3048-3056.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r7-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1158/1078-0432.CCR-15-2061" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26847053/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000377958800024" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=MET+amplification+and+exon+14+splice+site+mutation+define+unique+molecular+subgroups+of+non-small+cell+lung+carcinoma+with+poor+prognosis.&amp;publication_year=2016&amp;journal=Clin+Cancer+Res&amp;pages=3048-3056&amp;doi=10.1158%2F1078-0432.CCR-15-2061&amp;pmid=26847053" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r7-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r7-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] mutations or from insertions or deletions. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r7-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] in the absence of other driver mutations, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r9" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] and are associated with a poor prognosis. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="core-r8" class="citations"><div class="citation"><div class="citation-content">Reungwetwattana T, Liang Y, Zhu V, Ou SI. The race to target MET exon 14 skipping alterations in non-small cell lung cancer: the why, the how, the who, the unknown, and the inevitable. <em>Lung Cancer</em> 2017;103:27-37.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r8"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.lungcan.2016.11.011" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28024693/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000392676900006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+race+to+target+MET+exon+14+skipping+alterations+in+non-small+cell+lung+cancer%3A+the+why%2C+the+how%2C+the+who%2C+the+unknown%2C+and+the+inevitable.&amp;publication_year=2017&amp;journal=Lung+Cancer&amp;pages=27-37&amp;doi=10.1016%2Fj.lungcan.2016.11.011&amp;pmid=28024693" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="core-r9" class="citations"><div class="citation"><div class="citation-content">Yeung SF, Tong JHM, Law PPW, et al. Profiling of oncogenic driver events in lung adenocarcinoma revealed MET mutation as independent prognostic factor. <em>J Thorac Oncol</em> 2015;10:1292-1300.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r9"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1097/JTO.0000000000000620" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26098749/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000360365400008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Profiling+of+oncogenic+driver+events+in+lung+adenocarcinoma+revealed+MET+mutation+as+independent+prognostic+factor.&amp;publication_year=2015&amp;journal=J+Thorac+Oncol&amp;pages=1292-1300&amp;doi=10.1097%2FJTO.0000000000000620&amp;pmid=26098749" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="core-r10" class="citations"><div class="citation"><div class="citation-content">Onozato R, Kosaka T, Kuwano H, Sekido Y, Yatabe Y, Mitsudomi T. Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers. <em>J Thorac Oncol</em> 2009;4:5-11.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r13"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1097/JTO.0b013e3181913e0e" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/19096300/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000262196500002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Activation+of+MET+by+gene+amplification+or+by+splice+mutations+deleting+the+juxtamembrane+domain+in+primary+resected+lung+cancers.&amp;publication_year=2009&amp;journal=J+Thorac+Oncol&amp;pages=5-11&amp;doi=10.1097%2FJTO.0b013e3181913e0e&amp;pmid=19096300" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="core-r11" class="citations"><div class="citation"><div class="citation-content">Okuda K, Sasaki H, Yukiue H, Yano M, Fujii Y. <i>Met</i> gene copy number predicts the prognosis for completely resected non-small cell lung cancer. <em>Cancer Sci</em> 2008;99:2280-2285.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r13"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/j.1349-7006.2008.00916.x" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/19037978/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000260730700025" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Met+gene+copy+number+predicts+the+prognosis+for+completely+resected+non-small+cell+lung+cancer.&amp;publication_year=2008&amp;journal=Cancer+Sci&amp;pages=2280-2285&amp;doi=10.1111%2Fj.1349-7006.2008.00916.x&amp;pmid=19037978" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="core-r12" class="citations"><div class="citation"><div class="citation-content">Cappuzzo F, Marchetti A, Skokan M, et al. Increased <i>MET</i> gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. <em>J Clin Oncol</em> 2009;27:1667-1674.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r13"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.2008.19.1635" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/19255323/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000266194100023" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Increased+MET+gene+copy+number+negatively+affects+survival+of+surgically+resected+non-small-cell+lung+cancer+patients.&amp;publication_year=2009&amp;journal=J+Clin+Oncol&amp;pages=1667-1674&amp;doi=10.1200%2FJCO.2008.19.1635&amp;pmid=19255323" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">13.</div><div id="core-r13" class="citations"><div class="citation"><div class="citation-content">Schildhaus HU, Schultheis AM, Rüschoff J, et al. <i>MET</i> amplification status in therapy-naïve adeno- and squamous cell carcinomas of the lung. <em>Clin Cancer Res</em> 2015;21:907-915.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r13"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1158/1078-0432.CCR-14-0450" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25492085/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000349851200029" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=MET+amplification+status+in+therapy-na%C3%AFve+adeno-+and+squamous+cell+carcinomas+of+the+lung.&amp;publication_year=2015&amp;journal=Clin+Cancer+Res&amp;pages=907-915&amp;doi=10.1158%2F1078-0432.CCR-14-0450&amp;pmid=25492085" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">14.</div><div id="core-r14" class="citations"><div class="citation"><div class="citation-content">Spigel DR, Edelman MJ, O’Byrne K, et al. Results from the phase III randomized trial of onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIB or IV non-small-cell lung cancer: METLung. <em>J Clin Oncol</em> 2017;35:412-420.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r14"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.2016.69.2160" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27937096/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000393182600006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Results+from+the+phase+III+randomized+trial+of+onartuzumab+plus+erlotinib+versus+erlotinib+in+previously+treated+stage+IIIB+or+IV+non-small-cell+lung+cancer%3A+METLung.&amp;publication_year=2017&amp;journal=J+Clin+Oncol&amp;pages=412-420&amp;doi=10.1200%2FJCO.2016.69.2160&amp;pmid=27937096" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">15.</div><div id="core-r15" class="citations"><div class="citation"><div class="citation-content">Jenkins RW, Oxnard GR, Elkin S, Sullivan EK, Carter JL, Barbie DA. Response to crizotinib in a patient with lung adenocarcinoma harboring a MET splice site mutation. <em>Clin Lung Cancer</em> 2015;16(5):e101-e104.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r18-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.cllc.2015.01.009" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25769807/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000360182100010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Response+to+crizotinib+in+a+patient+with+lung+adenocarcinoma+harboring+a+MET+splice+site+mutation.&amp;publication_year=2015&amp;journal=Clin+Lung+Cancer&amp;pages=e101-e104&amp;doi=10.1016%2Fj.cllc.2015.01.009&amp;pmid=25769807" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">16.</div><div id="core-r16" class="citations"><div class="citation"><div class="citation-content">Waqar SN, Morgensztern D, Sehn J. MET mutation associated with responsiveness to crizotinib. <em>J Thorac Oncol</em> 2015;10(5):e29-e31.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r18-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1097/JTO.0000000000000478" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25898962/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000354990100004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=MET+mutation+associated+with+responsiveness+to+crizotinib.&amp;publication_year=2015&amp;journal=J+Thorac+Oncol&amp;pages=e29-e31&amp;doi=10.1097%2FJTO.0000000000000478&amp;pmid=25898962" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">17.</div><div id="core-r17" class="citations"><div class="citation"><div class="citation-content">Schuler M, Berardi R, Lim W-T, et al. Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer: clinical and biomarker results from a phase I trial. <em>Ann Oncol</em> 2020;31:789-797.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r17-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.annonc.2020.03.293" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32240796/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000535705600012" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Molecular+correlates+of+response+to+capmatinib+in+advanced+non-small-cell+lung+cancer%3A+clinical+and+biomarker+results+from+a+phase+I+trial.&amp;publication_year=2020&amp;journal=Ann+Oncol&amp;pages=789-797&amp;doi=10.1016%2Fj.annonc.2020.03.293&amp;pmid=32240796" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r17-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r18-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] emerged as potential predictive biomarkers. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r24" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] -dysregulated NSCLC. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r17-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] the known safety profile of capmatinib. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">18.</div><div id="core-r18" class="citations"><div class="citation"><div class="citation-content">Drilon A, Clark JW, Weiss J, et al. Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration. <em>Nat Med</em> 2020;26:47-51.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r18-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41591-019-0716-8" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31932802/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000509831900025" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Antitumor+activity+of+crizotinib+in+lung+cancers+harboring+a+MET+exon+14+alteration.&amp;publication_year=2020&amp;journal=Nat+Med&amp;pages=47-51&amp;doi=10.1038%2Fs41591-019-0716-8&amp;pmid=31932802" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r18-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r18-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] emerged as potential predictive biomarkers. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r18-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] exon 14 skipping mutation, </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">19.</div><div id="core-r19" class="citations"><div class="citation"><div class="citation-content">Liu X, Wang Q, Yang G, et al. A novel kinase inhibitor, INCB28060, blocks c-MET-dependent signaling, neoplastic activities, and cross-talk with EGFR and HER-3. <em>Clin Cancer Res</em> 2011;17:7127-7138.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r21"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1158/1078-0432.CCR-11-1157" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21918175/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000297158500019" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+novel+kinase+inhibitor%2C+INCB28060%2C+blocks+c-MET-dependent+signaling%2C+neoplastic+activities%2C+and+cross-talk+with+EGFR+and+HER-3.&amp;publication_year=2011&amp;journal=Clin+Cancer+Res&amp;pages=7127-7138&amp;doi=10.1158%2F1078-0432.CCR-11-1157&amp;pmid=21918175" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">20.</div><div id="core-r20" class="citations"><div class="citation"><div class="citation-content">Baltschukat S, Engstler BS, Huang A, et al. Capmatinib (INC280) is active against models of non-small cell lung cancer and other cancer types with defined mechanisms of MET activation. <em>Clin Cancer Res</em> 2019;25:3164-3175.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r21"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1158/1078-0432.CCR-18-2814" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30674502/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000468064200025" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Capmatinib+%28INC280%29+is+active+against+models+of+non-small+cell+lung+cancer+and+other+cancer+types+with+defined+mechanisms+of+MET+activation.&amp;publication_year=2019&amp;journal=Clin+Cancer+Res&amp;pages=3164-3175&amp;doi=10.1158%2F1078-0432.CCR-18-2814&amp;pmid=30674502" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">21.</div><div id="core-r21" class="citations"><div class="citation"><div class="citation-content">Wolf J, Seto T, Han J-Y, et al. Capmatinib in METΔex14-mutated advanced non-small cell lung cancer (NSCLC): efficacy data from the phase II GEOMETRY mono-1 study. <em>J Clin Oncol.</em> 2019:37:15 Suppl:9004-9004. abstract.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r21"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Capmatinib+in+MET%CE%94ex14-mutated+advanced+non-small+cell+lung+cancer+%28NSCLC%29%3A+efficacy+data+from+the+phase+II+GEOMETRY+mono-1+study&amp;publication_year=2019&amp;pages=9004-9004" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">22.</div><div id="core-r22" class="citations"><div class="citation"><div class="citation-content">Heist RS, Seto T, Han J-Y, et al. Capmatinib (INC280) in METΔex14-mutated advanced non-small cell lung cancer (NSCLC): efficacy data from the phase 2 GEOMETRY mono-1 study. <em>Neuro Oncol</em> 2019;21:vi56-vi56. abstract.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r23"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/neuonc/noz175.223" target="_blank">Crossref</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000509478701080" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Capmatinib+%28INC280%29+in+MET%CE%94ex14-mutated+advanced+non-small+cell+lung+cancer+%28NSCLC%29%3A+efficacy+data+from+the+phase+2+GEOMETRY+mono-1+study&amp;publication_year=2019&amp;journal=Neuro+Oncol&amp;pages=vi56-vi56&amp;doi=10.1093%2Fneuonc%2Fnoz175.223" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">23.</div><div id="core-r23" class="citations"><div class="citation"><div class="citation-content">Shih K, Falchook GS, Becker K, et al. A phase Ib study evaluating the c-MET inhibitor INC280 in combination with bevacizumab in glioblastoma multiforme (GBM) patients. <em>Neuro Oncol</em> 2016;18:Suppl 6:vi11-vi12. abstract</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r23"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/neuonc/now212.043" target="_blank">Crossref</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000398604100045" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+phase+Ib+study+evaluating+the+c-MET+inhibitor+INC280+in+combination+with+bevacizumab+in+glioblastoma+multiforme+%28GBM%29+patients&amp;publication_year=2016&amp;journal=Neuro+Oncol&amp;pages=vi11-vi12&amp;doi=10.1093%2Fneuonc%2Fnow212.043" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">24.</div><div id="core-r24" class="citations"><div class="citation"><div class="citation-content">Wu Y-L, Zhang L, Kim D-W, et al. Phase Ib/II study of capmatinib (INC280) plus gefitinib after failure of epidermal growth factor receptor (EGFR) inhibitor therapy in patients with EGFR-mutated, MET factor-dysregulated non-small-cell lung cancer. <em>J Clin Oncol</em> 2018;36:3101-3109.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r24"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.2018.77.7326" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30156984/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000451439600007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Phase+Ib%2FII+study+of+capmatinib+%28INC280%29+plus+gefitinib+after+failure+of+epidermal+growth+factor+receptor+%28EGFR%29+inhibitor+therapy+in+patients+with+EGFR-mutated%2C+MET+factor-dysregulated+non-small-cell+lung+cancer.&amp;publication_year=2018&amp;journal=J+Clin+Oncol&amp;pages=3101-3109&amp;doi=10.1200%2FJCO.2018.77.7326&amp;pmid=30156984" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">25.</div><div id="core-r25" class="citations"><div class="citation"><div class="citation-content">Eisenhauer EA, Therasse P, Bogaerts J, et al. New Response Evaluation Criteria in Solid Tumours: revised RECIST guideline (version 1.1). <em>Eur J Cancer</em> 2009;45:228-247.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r25"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.ejca.2008.10.026" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/19097774/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000262948300002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=New+Response+Evaluation+Criteria+in+Solid+Tumours%3A+revised+RECIST+guideline+%28version+1.1%29.&amp;publication_year=2009&amp;journal=Eur+J+Cancer&amp;pages=228-247&amp;doi=10.1016%2Fj.ejca.2008.10.026&amp;pmid=19097774" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">26.</div><div id="core-r26" class="citations"><div class="citation"><div class="citation-content">de Marinis F, Grossi F. Clinical evidence for second- and third-line treatment options in advanced non-small cell lung cancer. <em>Oncologist</em> 2008;13:Suppl 1:14-20.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r27"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1634/theoncologist.13-S1-14" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/18263770/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000253047500003" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Clinical+evidence+for+second-+and+third-line+treatment+options+in+advanced+non-small+cell+lung+cancer.&amp;publication_year=2008&amp;journal=Oncologist&amp;pages=14-20&amp;doi=10.1634%2Ftheoncologist.13-S1-14&amp;pmid=18263770" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">27.</div><div id="core-r27" class="citations"><div class="citation"><div class="citation-content">Weiss JM, Stinchcombe TE. Second-line therapy for advanced NSCLC. <em>Oncologist</em> 2013;18:947-953.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r27"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1634/theoncologist.2013-0096" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23918070/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000324101200017" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Second-line+therapy+for+advanced+NSCLC.&amp;publication_year=2013&amp;journal=Oncologist&amp;pages=947-953&amp;doi=10.1634%2Ftheoncologist.2013-0096&amp;pmid=23918070" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">28.</div><div id="core-r28" class="citations"><div class="citation"><div class="citation-content">Zhou C, Wu Y-L, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. <em>Lancet Oncol</em> 2011;12:735-742.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r29"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S1470-2045(11)70184-X" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21783417/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000293272100024" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Erlotinib+versus+chemotherapy+as+first-line+treatment+for+patients+with+advanced+EGFR+mutation-positive+non-small-cell+lung+cancer+%28OPTIMAL%2C+CTONG-0802%29%3A+a+multicentre%2C+open-label%2C+randomised%2C+phase+3+study.&amp;publication_year=2011&amp;journal=Lancet+Oncol&amp;pages=735-742&amp;doi=10.1016%2FS1470-2045%2811%2970184-X&amp;pmid=21783417" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">29.</div><div id="core-r29" class="citations"><div class="citation"><div class="citation-content">Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. <em>J Clin Oncol</em> 2008;26:3543-3551.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r29"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.2007.15.0375" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/18506025/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000258050500015" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Phase+III+study+comparing+cisplatin+plus+gemcitabine+with+cisplatin+plus+pemetrexed+in+chemotherapy-naive+patients+with+advanced-stage+non-small-cell+lung+cancer.&amp;publication_year=2008&amp;journal=J+Clin+Oncol&amp;pages=3543-3551&amp;doi=10.1200%2FJCO.2007.15.0375&amp;pmid=18506025" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">30.</div><div id="core-r30" class="citations"><div class="citation"><div class="citation-content">Mok TS, Wu Y-L, Thongprasert S, et al. Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma. <em>N Engl J Med</em> 2009;361:947-957.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r32"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_31_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2002787&amp;key=10.1056%2FNEJMoa0810699&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/19692680/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000269480400004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Gefitinib+or+carboplatin%E2%80%93paclitaxel+in+pulmonary+adenocarcinoma.&amp;publication_year=2009&amp;journal=N+Engl+J+Med&amp;pages=947-957&amp;doi=10.1056%2FNEJMoa0810699&amp;pmid=19692680" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">31.</div><div id="core-r31" class="citations"><div class="citation"><div class="citation-content">Solomon BJ, Mok T, Kim D-W, et al. First-line crizotinib versus chemotherapy in <i>ALK</i>-positive lung cancer. <em>N Engl J Med</em> 2014;371:2167-2177.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r32"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_32_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2002787&amp;key=10.1056%2FNEJMoa1408440&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25470694/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000345976700005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=First-line+crizotinib+versus+chemotherapy+in+ALK-positive+lung+cancer.&amp;publication_year=2014&amp;journal=N+Engl+J+Med&amp;pages=2167-2177&amp;doi=10.1056%2FNEJMoa1408440&amp;pmid=25470694" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">32.</div><div id="core-r32" class="citations"><div class="citation"><div class="citation-content">Shaw AT, Ou S-HI, Bang Y-J, et al. Crizotinib in <i>ROS1</i>-rearranged non–small-cell lung cancer. <em>N Engl J Med</em> 2014;371:1963-1971.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r32"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_33_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2002787&amp;key=10.1056%2FNEJMoa1406766&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25264305/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000345002900005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Crizotinib+in+ROS1-rearranged+non%E2%80%93small-cell+lung+cancer.&amp;publication_year=2014&amp;journal=N+Engl+J+Med&amp;pages=1963-1971&amp;doi=10.1056%2FNEJMoa1406766&amp;pmid=25264305" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">33.</div><div id="core-r33" class="citations"><div class="citation"><div class="citation-content">Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non–small-cell lung cancer. <em>N Engl J Med</em> 2005;353:123-132.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r38"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_34_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2002787&amp;key=10.1056%2FNEJMoa050753&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/16014882/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000230438800004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Erlotinib+in+previously+treated+non%E2%80%93small-cell+lung+cancer.&amp;publication_year=2005&amp;journal=N+Engl+J+Med&amp;pages=123-132&amp;doi=10.1056%2FNEJMoa050753&amp;pmid=16014882" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">34.</div><div id="core-r34" class="citations"><div class="citation"><div class="citation-content">Garon EB, Ciuleanu T-E, Arrieta O, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. <em>Lancet</em> 2014;384:665-673.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r38"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(14)60845-X" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24933332/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000341359100024" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Ramucirumab+plus+docetaxel+versus+placebo+plus+docetaxel+for+second-line+treatment+of+stage+IV+non-small-cell+lung+cancer+after+disease+progression+on+platinum-based+therapy+%28REVEL%29%3A+a+multicentre%2C+double-blind%2C+randomised+phase+3+trial.&amp;publication_year=2014&amp;journal=Lancet&amp;pages=665-673&amp;doi=10.1016%2FS0140-6736%2814%2960845-X&amp;pmid=24933332" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">35.</div><div id="core-r35" class="citations"><div class="citation"><div class="citation-content">Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer. <em>N Engl J Med</em> 2015;373:123-135.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r38"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_36_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2002787&amp;key=10.1056%2FNEJMoa1504627&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26028407/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000357598600005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Nivolumab+versus+docetaxel+in+advanced+squamous-cell+non%E2%80%93small-cell+lung+cancer.&amp;publication_year=2015&amp;journal=N+Engl+J+Med&amp;pages=123-135&amp;doi=10.1056%2FNEJMoa1504627&amp;pmid=26028407" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">36.</div><div id="core-r36" class="citations"><div class="citation"><div class="citation-content">Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer. <em>N Engl J Med</em> 2015;373:1627-1639.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r38"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_37_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2002787&amp;key=10.1056%2FNEJMoa1507643&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26412456/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000363317800008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Nivolumab+versus+docetaxel+in+advanced+nonsquamous+non%E2%80%93small-cell+lung+cancer.&amp;publication_year=2015&amp;journal=N+Engl+J+Med&amp;pages=1627-1639&amp;doi=10.1056%2FNEJMoa1507643&amp;pmid=26412456" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">37.</div><div id="core-r37" class="citations"><div class="citation"><div class="citation-content">Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. <em>Lancet</em> 2017;389:255-265.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r38"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(16)32517-X" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27979383/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000392801200027" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Atezolizumab+versus+docetaxel+in+patients+with+previously+treated+non-small-cell+lung+cancer+%28OAK%29%3A+a+phase+3%2C+open-label%2C+multicentre+randomised+controlled+trial.&amp;publication_year=2017&amp;journal=Lancet&amp;pages=255-265&amp;doi=10.1016%2FS0140-6736%2816%2932517-X&amp;pmid=27979383" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">38.</div><div id="core-r38" class="citations"><div class="citation"><div class="citation-content">Herbst RS, Baas P, Kim D-W, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. <em>Lancet</em> 2016;387:1540-1550.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r38"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(15)01281-7" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26712084/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000373741600030" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Pembrolizumab+versus+docetaxel+for+previously+treated%2C+PD-L1-positive%2C+advanced+non-small-cell+lung+cancer+%28KEYNOTE-010%29%3A+a+randomised+controlled+trial.&amp;publication_year=2016&amp;journal=Lancet&amp;pages=1540-1550&amp;doi=10.1016%2FS0140-6736%2815%2901281-7&amp;pmid=26712084" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">39.</div><div id="core-r39" class="citations"><div class="citation"><div class="citation-content">Camidge DR, Otterson GA, Clark JW, et al. Crizotinib in patients (pts) with MET-amplified non-small cell lung cancer (NSCLC): updated safety and efficacy findings from a phase 1 trial. <em>J Clin Oncol</em> 2018;36:Suppl:36-36. abstract.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r39"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.2018.36.15_suppl.9062" target="_blank">Crossref</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000442916003235" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Crizotinib+in+patients+%28pts%29+with+MET-amplified+non-small+cell+lung+cancer+%28NSCLC%29%3A+updated+safety+and+efficacy+findings+from+a+phase+1+trial&amp;publication_year=2018&amp;journal=J+Clin+Oncol&amp;pages=36-36&amp;doi=10.1200%2FJCO.2018.36.15_suppl.9062" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">40.</div><div id="core-r40" class="citations"><div class="citation"><div class="citation-content">Noonan SA, Berry L, Lu X, et al. Identifying the appropriate FISH criteria for defining MET copy number-driven lung adenocarcinoma through oncogene overlap analysis. <em>J Thorac Oncol</em> 2016;11:1293-1304.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r40"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.jtho.2016.04.033" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27262212/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000381067300012" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Identifying+the+appropriate+FISH+criteria+for+defining+MET+copy+number-driven+lung+adenocarcinoma+through+oncogene+overlap+analysis.&amp;publication_year=2016&amp;journal=J+Thorac+Oncol&amp;pages=1293-1304&amp;doi=10.1016%2Fj.jtho.2016.04.033&amp;pmid=27262212" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">41.</div><div id="core-r41" class="citations"><div class="citation"><div class="citation-content">Paik PK, Felip E, Veillon R, et al. Tepotinib in non–small-cell lung cancer with <i>MET</i> exon 14 skipping mutations. <em>N Engl J Med</em> 2020;383:931-943.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r41"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_42_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2002787&amp;key=10.1056%2FNEJMoa2004407&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32469185/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000569841600013" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Tepotinib+in+non%E2%80%93small-cell+lung+cancer+with+MET+exon+14+skipping+mutations.&amp;publication_year=2020&amp;journal=N+Engl+J+Med&amp;pages=931-943&amp;doi=10.1056%2FNEJMoa2004407&amp;pmid=32469185" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">42.</div><div id="core-r42" class="citations"><div class="citation"><div class="citation-content">Lu S. Phase II study of savolitinib in patients (pts) with pulmonary sarcomatoid carcinoma (PSC) and other types of non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutations (METex14+). Presented at the 2020 American Society of Clinical Oncology Annual Meeting, Chicago, May 29–31, 2020. abstract.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r42"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Phase+II+study+of+savolitinib+in+patients+%28pts%29+with+pulmonary+sarcomatoid+carcinoma+%28PSC%29+and+other+types+of+non-small+cell+lung+cancer+%28NSCLC%29+harboring+MET+exon+14+skipping+mutations+%28METex14%2B%29&amp;publication_year=2020" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">43.</div><div id="core-r43" class="citations"><div class="citation"><div class="citation-content">Wolf J, Baik C, Heist RS, et al. Natural history, treatment (tx) patterns, and outcomes in MET dysregulated non-small cell lung cancer (NSCLC) patients (pts). Presented at the EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics, Dublin, November 13–16, 2018. abstract (<a href="https://stanfordhealthcare.org/publications/507/507112.html" target="_blank">https://stanfordhealthcare.org/publications/507/507112.html</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r45"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Natural+history%2C+treatment+%28tx%29+patterns%2C+and+outcomes+in+MET+dysregulated+non-small+cell+lung+cancer+%28NSCLC%29+patients+%28pts%29&amp;publication_year=2018" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">44.</div><div id="core-r44" class="citations"><div class="citation"><div class="citation-content">Sabari JK, Leonardi GC, Shu CA, et al. PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers. <em>Ann Oncol</em> 2018;29:2085-2091.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r45"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/annonc/mdy334" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30165371/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000455165100011" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=PD-L1+expression%2C+tumor+mutational+burden%2C+and+response+to+immunotherapy+in+patients+with+MET+exon+14+altered+lung+cancers.&amp;publication_year=2018&amp;journal=Ann+Oncol&amp;pages=2085-2091&amp;doi=10.1093%2Fannonc%2Fmdy334&amp;pmid=30165371" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">45.</div><div id="core-r45" class="citations"><div class="citation"><div class="citation-content">Reis H, Metzenmacher M, Goetz M, et al. MET expression in advanced non-small-cell lung cancer: effect on clinical outcomes of chemotherapy, targeted therapy, and immunotherapy. <em>Clin Lung Cancer</em> 2018;19(4):e441-e463.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r45"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.cllc.2018.03.010" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29631966/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000436644800010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=MET+expression+in+advanced+non-small-cell+lung+cancer%3A+effect+on+clinical+outcomes+of+chemotherapy%2C+targeted+therapy%2C+and+immunotherapy.&amp;publication_year=2018&amp;journal=Clin+Lung+Cancer&amp;pages=e441-e463&amp;doi=10.1016%2Fj.cllc.2018.03.010&amp;pmid=29631966" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">46.</div><div id="core-r46" class="citations"><div class="citation"><div class="citation-content">Ali A, Goffin JR, Arnold A, Ellis PM. Survival of patients with non-small-cell lung cancer after a diagnosis of brain metastases. <em>Curr Oncol</em> 2013;20(4):e300-e306.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r46"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.3747/co.20.1481" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23904768/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000322782400004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Survival+of+patients+with+non-small-cell+lung+cancer+after+a+diagnosis+of+brain+metastases.&amp;publication_year=2013&amp;journal=Curr+Oncol&amp;pages=e300-e306&amp;doi=10.3747%2Fco.20.1481&amp;pmid=23904768" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">47.</div><div id="core-r47" class="citations"><div class="citation"><div class="citation-content">Awad MM, Leonardi GC, Kravets S, et al. Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis. <em>Lung Cancer</em> 2019;133:96-102.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r47"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.lungcan.2019.05.011" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31200835/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000474326700016" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Impact+of+MET+inhibitors+on+survival+among+patients+with+non-small+cell+lung+cancer+harboring+MET+exon+14+mutations%3A+a+retrospective+analysis.&amp;publication_year=2019&amp;journal=Lung+Cancer&amp;pages=96-102&amp;doi=10.1016%2Fj.lungcan.2019.05.011&amp;pmid=31200835" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">48.</div><div id="core-r48" class="citations"><div class="citation"><div class="citation-content">Lepist E-I, Zhang X, Hao J, et al. Contribution of the organic anion transporter OAT2 to the renal active tubular secretion of creatinine and mechanism for serum creatinine elevations caused by cobicistat. <em>Kidney Int</em> 2014;86:350-357.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r48"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/ki.2014.66" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24646860/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000339987700020" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Contribution+of+the+organic+anion+transporter+OAT2+to+the+renal+active+tubular+secretion+of+creatinine+and+mechanism+for+serum+creatinine+elevations+caused+by+cobicistat.&amp;publication_year=2014&amp;journal=Kidney+Int&amp;pages=350-357&amp;doi=10.1038%2Fki.2014.66&amp;pmid=24646860" target="_blank">Google Scholar</a></div></div></div></div></div></div></div></div><aside data-core-aside="right-rail">



        
        <div id="DTM_Position_MedRectangle" class="ad">
 <!--emptycomment-->
</div>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="relatedArticlesWidget" data-widget-id="8206d5cd-cb8c-4ff9-8c46-3d22e0dee215" data-location="recirc_curatedRelated_article">
        



        
        <div class="ng-related-articles"><h3 class="ng-subsection-title"><span class="ng-subsection-title_text">Related articles</span></h3><ul class="ng-related-articles_list"><li class="ng-related-articles_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">May 28, 2020</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2004407" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Tepotinib in Non–Small-Cell Lung Cancer with <i>MET</i> Exon 14 Skipping Mutations</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">P.K. Paik and Others</span></div></div></div></div></div></li></ul></div>

        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <div id="nejm_jobs" class="nejm_jobs"> <!-- top red rectangle --><div id="nejm-widget" class="nejm-widget" style="display: block;"><div class="nejm-widget_logo">	<a target="nejm-win" href="https://www.nejmcareercenter.org/?query=fjw">		<img alt="CareerCenter" src="https://apps1.nejmcareercenter.org/images/nejmCCID-JobsWidget.gif" width="140" height="36">	</a></div><div class="nejm-widget_cont"> <!-- content --><div class="nejm-widget_title">PHYSICIAN JOBS</div><div class="nejm-widget_date">June 9, 2025</div><div class="nejm-widget_item"><div><span> Texas</span></div><div><span>Hematology / Oncology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/881397/hematologist-oncologist-texas-oncology-el-paso/?query=fjwp&amp;rid=5696">Hematologist/Oncologist - Texas Oncology El Paso</a></div></div><div class="nejm-widget_item"><div><span> Bozeman, Montana</span></div><div><span>Cardiology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/883924/yellowstone-big-sky-montana-mountains-plus-no-call-no-weekends/?query=fjwp&amp;rid=338868">Yellowstone, Big Sky, Montana Mountains, Plus No Call, No Weekends</a></div></div><div class="nejm-widget_item"><div><span> Raleigh, North Carolina</span></div><div><span>Obstetrics &amp; Gynecology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/883908/ob-gyn-physician-stable-group-/?query=fjwf&amp;rid=346908">OB/GYN Physician - Stable Group!</a></div></div><div class="nejm-widget_item"><div><span> Hartford, Connecticut</span></div><div><span>Physical Medicine &amp; Rehabilitation</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/880031/per-diem-physical-medicine-and-rehab-physician-hartford/?query=fjwf&amp;rid=33464">Per Diem Physical Medicine &amp; Rehab Physician- Hartford</a></div></div><div class="nejm-widget_item"><div><span> Fort Worth, Texas</span></div><div><span>Psychiatry</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/888442/outpatient-psychiatrist/?query=fjwf&amp;rid=377088">Outpatient Psychiatrist</a></div></div><div class="nejm-widget_item"><div><span> Florida</span></div><div><span>Cardiology / Interventional</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/890889/interventional-cardiology-in-sarasota-florida-partnership-track/?query=fjwf&amp;rid=5127">Interventional Cardiology in Sarasota, Florida - Partnership Track</a></div></div></div> <!-- content --> <!-- footer --></div> <!-- nejm-widget --></div><script src="https://apps1.nejmcareercenter.org/?width=300&amp;sp=all"></script>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="literatumAd" data-widget-id="001e4aa7-b6fe-4b21-9d5b-5bde81227c67" id="ad-article-right-rail-300x250-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <a href="/action/clickThrough?id=128129&amp;url=https%3A%2F%2Fstore.nejm.org%2Fsignup%2Fnejm%2Fregister%2Falerts%3Fpromo%3DONFQSR51%26query%3Dcm_rr%26utm_source%3Dnejm%26utm_medium%3Dcm%26utm_campaign%3Dalerts23&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2002787&amp;pubId=41288860&amp;placeholderId=101337&amp;productId=1035"><img src="/sda/128129/rightRail--SpecialtyUpdates23-001.jpg" width="300" height="250"></a>
            
        </div>
    

    

    



        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <script src="https://widgets.nejm.org/onepub-widgets/loader/webcomponents-loader.js" async="" nonce="94d6468482d1decb-SJC">
<script src="https://widgets.nejm.org/onepub-widgets/loader/polyfill-support.js"  nonce="94d6468482d1decb-SJC"></script>
<script src="https://widgets.nejm.org/onepub-widgets/more-like-this.js" type="module" nonce="94d6468482d1decb-SJC"></script>

<more-like-this class="onepub-widget" dataid="onepub-more-like-this" collections="catalyst-article, clinician-article, evidence-article, nejm-ai-article, nejm-article" headertitle="More Like This" maxitems="5"><!----><div class="more-like-this onepub-more-like-this_"><!--?lit$250839374$--><onepub-fonts><wc-fetch></wc-fetch><!--?lit$250839374$--><div class="mlt-wrapper"><div class="mlt-header-container"><div class="mlt-header-content-left"><div class="mlt-header-title-container"><span class="mlt-header-title">More Like This</span></div><!--?lit$250839374$--></div></div><div class="mlt-body"><!--?lit$250839374$--><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$250839374$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$250839374$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$250839374$-->Nov 30, 2023</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2306441?query=recirc_Semantic" target="_self">Amivantamab plus Chemotherapy in NSCLC with <em>EGFR</em> Exon 20 Insertions</a></div><div class="mlt-article-authors"><!--?lit$250839374$-->C. Zhou and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$250839374$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$250839374$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$250839374$-->Jul 14, 2022</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2204619?query=recirc_Semantic" target="_self">Adagrasib in Non–Small-Cell Lung Cancer Harboring a <em>KRAS<sup>G12C</sup></em> Mutation</a></div><div class="mlt-article-authors"><!--?lit$250839374$-->P.A. Jänne and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$250839374$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$250839374$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$250839374$-->Aug 24, 2023</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2303810?query=recirc_Semantic" target="_self">Single-Agent Divarasib (GDC-6036) in Solid Tumors with a <em>KRAS</em> G12C Mutation</a></div><div class="mlt-article-authors"><!--?lit$250839374$-->A. Sacher and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$250839374$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$250839374$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$250839374$-->Jan 09, 2025</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2408941?query=recirc_Semantic" target="_self">Clearance of Driver Mutations after Transplantation for Myelofibrosis</a></div><div class="mlt-article-authors"><!--?lit$250839374$-->N. Gagelmann and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$250839374$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$250839374$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$250839374$-->Apr 28, 2025</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2503704?query=recirc_Semantic" target="_self">Zongertinib in Previously Treated <em>HER2</em>-Mutant Non–Small-Cell Lung Cancer</a></div><div class="mlt-article-authors"><!--?lit$250839374$-->J.V. Heymach and Others</div></div><!----></div><div class="mlt-footer"></div></div></onepub-fonts><style>:host{display:block}@keyframes fadeIn{0%{opacity:0}100%{opacity:1}}.more-like-this{max-width:25rem}.more-like-this *{font-variant-numeric:lining-nums}.mlt-wrapper{animation:fadeIn 1s}.mlt-header-container{border-bottom:#4d4d4d solid .0625rem;border-top:#4d4d4d solid .125rem}.mlt-header-title{color:#1a1a1a;display:block;font-family:var(--sans-serif);font-size:1rem;font-weight:700;letter-spacing:.02rem;line-height:1.5rem;padding-bottom:.94rem;padding-top:.94rem;text-transform:uppercase}.mlt-header-description{color:#333;display:block;font-family:ff-scala-sans-pro;font-size:.75rem;letter-spacing:.05rem;margin-top:-.5rem;padding-bottom:1rem;text-transform:uppercase}.mlt-article-container{border-bottom:#e5e5e5 solid .0625rem;margin-top:1.38rem}.mlt-article-container-header{font-family:var(--sans-serif);font-size:.6875rem;letter-spacing:.04em;line-height:1.125rem;margin:0 0 1rem;text-transform:uppercase}.mlt-article-type{font-weight:700;line-height:1.25rem;letter-spacing:.04rem;text-decoration:none}.mlt-article-type:hover{text-decoration:underline}.nejm{color:#f30}.nejm-ai{color:#006197}.nejm-catalyst{color:#5708a6}.nejm-evidence{color:#69a323}.mlt-article-site-label::after,.mlt-article-type::after{border-right:1px solid #e5e5e5;content:'';display:inline;padding:.1875rem .375rem .125rem 0;margin:0 .375rem 0 0}.mlt-article-pubdate{color:#666;font-style:normal;font-weight:700;line-height:1.25rem;letter-spacing:.04em}.mlt-article-authors{color:#666;font-family:var(--sans-serif);font-size:1rem;font-style:normal;font-weight:400;letter-spacing:normal;line-height:1.5rem;margin-bottom:1.38rem}.mlt-article-site-label{color:#666;font-style:normal;font-weight:700;letter-spacing:.04em}.mlt-article-title{margin-bottom:.5rem}.mlt-article-title>a{background-image:linear-gradient(#f30,#f30);background-position:0 90%;background-repeat:no-repeat;background-size:0 0;color:#1a1a1a;font-family:var(--quadraat-web);font-size:1.25rem;font-style:normal;font-weight:700;letter-spacing:normal;line-height:1.8rem;margin:1.5rem 0 .35rem 0;text-decoration:none;transition:background .25s ease-in-out}.mlt-article-title>a:hover{background-position:0 98%;background-size:100% .125rem;text-decoration:none}.skeleton-card{box-shadow:0 0 4px 1px rgba(0,0,0,.1);margin:1rem 0;padding:1rem}</style></div></more-like-this>




        
        <div><div class="pb-dropzone" data-pb-dropzone="col-0" title="col-0"></div></div>










    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="ad06db99-f228-4c92-9ad7-c4ae0fdbdbf1" id="bc-web-rec">
        



        
        <!-- BlueConic TEST empty HTML widget with DIV wrapper with id=bc-web-rec -->

        </div>
    

</aside></article><div data-extent="article-wrapper"><div class="core-container"></div><div class="after-credits"><div class="core-container"><a href="/doi/pdf/10.1056/NEJMoa2002787?download=true" id="downloadPdfUrl" data-doi="10.1056/NEJMoa2002787" data-behavior="trackDownloadEvent" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2002787.pdf"><span>Download PDF</span></a></div></div></div><script id="axel-publication-metadata" type="application/json">{"doi":"10.1056/NEJMoa2002787"}
</script><script type="text/javascript" data-ot-ignore="data-ot-ignore" defer="defer" src="https://static.addtoany.com/menu/page.js" class="optanon-category-C0004 ot-vscat-C0004"></script><div class="articles-nav"></div><template id="figure_nav_template"><nav><a href="#" title="Open in viewer" class="open-in-viewer"><i aria-hidden="true" class="icon-expand"></i></a></nav></template><template id="fv_panel_template" data-sharesocial="Share"><div class="fv__panel js--hidden"><div class="fv__panel__text"><div class="fv__panel__contentTitle"></div><div class="fv__panel__contentText"></div></div></div></template>
<template id="fv_directory_template" data-overlay="View figure"><div class="fv__directory"><div class="fv__header"><nav class="tab__nav"></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"></div></div></template><template id="fv_directory_tabItem_template" data-figures="Figures" data-others="Others" data-tables="Tables"><button role="tab" data-toggle="tab" class="tab__nav__item"></button></template>
<template id="fv_lightbox_template" data-sr-back="Go to figure location within the article" data-sr-closealt="Close" data-sr-download="Toggle download panel" data-sr-download-pptx="Download PPT" data-sr-info="Toggle information panel" data-sr-panel="Close panel" data-sr-share="Toggle share panel" data-sr-zoom="Zoom" data-text-close="Back to article" data-text-nav-figures="All figures" data-text-nav-others="All others" data-text-nav-tables="All tables" data-text-viewall="View all material" data-title-back="Back to article" data-title-closealt="Close" data-title-download="Download" data-title-download-pptx="Download PPT" data-title-info="Info" data-title-share="Share" data-title-zoom="Zoom"></template>
<template id="fv_toolbar_template"><div class="fv__toolbar__info"><strong class="fv__toolbar__contentTitle uppercase"></strong><p class="fv__toolbar__contentText"></p></div></template><template id="toCitationLink" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></a></div></template><template id="toCitationButton" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><button class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></button></div></template><template id="toCitationAccordion" data-collapse-citation="Hide Citations" data-expand-citation="Show Citations" data-collapse-footnote="Hide Footnotes" data-expand-footnote="Show Footnotes"><div class="to-citation__wrapper"><button aria-controls="aria-controls" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="data-expand-title" data-collapsed-title="data-collapsed-title" class="accordion__toggle__title"></span></button><div role="menu" aria-label="links" class="to-citation__accordion no-separator"><ul></ul></div></div></template><template id="toCitationAccordionItem"><li><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span></span></a></li></template><template id="citations_truncate_template"><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary"><span>Show all references</span></button></div></template><template id="collateral_texts_template" data-references="References" data-figure="Go to Figure" data-media="Go to Media" data-more="More" data-original="Go to original" data-table="Go to Table" data-inviewer="Open in Viewer" data-allinviewer="Open all in viewer"><svg data-tags="copyright" viewBox="0 0 24 24"><path d="M12 20.016q3.281 0 5.648-2.368T20.016 12t-2.368-5.648T12 3.984 6.352 6.352 3.984 12t2.368 5.648T12 20.016zm0-18q4.125 0 7.055 2.93T21.985 12t-2.93 7.055T12 21.985t-7.055-2.93T2.015 12t2.93-7.055T12 2.015zm-.14 7.125q-1.876 0-1.876 2.718v.282q0 2.718 1.875 2.718.704 0 1.172-.398t.469-1.008h1.781q0 1.172-1.031 2.063-.984.843-2.39.843-1.876 0-2.86-1.125t-.984-3.093v-.282q0-1.921.937-3 1.125-1.265 2.906-1.265 1.547 0 2.438.89.984.985.984 2.297H13.5q0-.328-.14-.61-.235-.468-.329-.562-.469-.468-1.172-.468z"></path></svg><span>Request permissions</span><i aria-hidden="true" class="icon-open_in_new"></i></template><template id="collapsible_authors_template"><button aria-expanded="false" data-expandable="all" data-label-expand="Expand All" data-label-collapse="Collapse All" class="collateral-contributors-control"><span>Expand All</span></button></template>
<template id="collapsible_tables_collapse_template"><div class="collapsible-figure-btn__wrapper expanded"><button aria-expanded="true" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-up"></i><span class="text-uppercase">Collapse</span></button></div></template>
<template id="collapsible_tables_expand_template"><div class="collapsible-figure-btn__wrapper collapsed"><button aria-expanded="false" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-down"></i><span class="text-uppercase">Expand Table</span></button></div></template><template id="authorsAffiliationsLink"><a href="#tab-contributors" class="to-authors-affiliations">Authors Info &amp; Affiliations</a></template>

        <div role="navigation" aria-label="Sticky Navigation" class="st-header"><div class="st-header__content"><div class="st-header__item st-header__menu"></div><div class="st-header__current st-header__item"><div class="st-header__label">Now Reading:</div><div class="st-header__title">Capmatinib in <i>MET</i> Exon 14–Mutated or <i>MET</i>-Amplified Non–Small-Cell Lung Cancer</div></div><div class="st-header__share st-header__item"><div class="share-dropblock dropdown"><a id="sticky-header-dropBlock" href="#" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="dropdown-toggle"><span title="" data-toggle="tooltip" data-trigger="hover" data-original-title="Share options"><span class="sr-only">Share</span><i aria-hidden="true" class="icon-share"></i></span></a><div aria-labelledby="sticky-header-dropBlock" data-location="share_tools_article" class="dropdown-menu"><ul class="rlist--inline a2a a2a_kit" style="line-height: 16px;"><li><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i></a></li><li><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i></a></li><li><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i></a></li><li><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i></a></li><li><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i></a></li></ul></div></div></div><div class="st-header__nav st-header__item"><div class="content-navigation"><a href="/doi/full/10.1056/NEJMoa2004407" aria-label="Previous article" aria-disabled="false" class="content-navigation__prev"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>PREVIOUS ARTICLE</h6><div>Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations</div></div></div><i aria-hidden="true" class="icon-arrow-left"></i><span>Previous</span></a><a href="/doi/full/10.1056/NEJMra2005230" aria-label="Next article" aria-disabled="false" class="content-navigation__next"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>NEXT ARTICLE</h6><div>Spectrum of Fibrotic Lung Diseases</div></div></div><span>Next</span><i aria-hidden="true" class="icon-arrow-right"></i></a></div></div></div><div class="st-header__track"><div id="progress-tracker" class="st-header__tracker" style="width: 0px;"></div></div></div><div class="fv figureViewer js--has-focus-mode"><div class="fv__directory" data-core-tabs="default" style="display: flex;"><div class="fv__header"><nav class="tab__nav" role="tablist"><button role="tab" data-toggle="tab" class="tab__nav__item active" aria-controls="#tab-pane-figures" aria-selected="true">Figures</button><button role="tab" data-toggle="tab" class="tab__nav__item" aria-controls="#tab-pane-tables" tabindex="-1" aria-selected="false">Tables</button></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"><div class="tab__pane fv__list fv__list--figures" id="tab-pane-figures" aria-label="All figures" tabindex="0" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f1" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2002787_f1.jpg"><img src="/cms/10.1056/NEJMoa2002787/asset/6bdb0b9c-7e03-4610-a745-acef42916681/assets/images/large/nejmoa2002787_f1.jpg" height="3438" width="2180" aria-labelledby="f1" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 1</div><div class="fv__item__description"><figcaption><div class="caption">Study Design.</div><div class="notes"><div role="doc-footnote">Eligible patients with non–small-cell lung cancer (NSCLC) had to have an Eastern Cooperative Oncology Group (ECOG) performance-status score of 0 or 1 (on a scale from 0 [fully active] to 5 [death]; a score of 1 indicates that the patient is ambulatory but restricted from strenuous activity) and to have at least one measurable tumor, according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1. Patients were assigned to cohorts on the basis of <i>MET</i> status (<i>MET</i> exon 14 skipping mutation or <i>MET</i> amplification, as measured by gene copy number [GCN]) and previous lines of therapy. Enrollment in cohorts with a <i>MET</i> exon 14 skipping mutation was allowed regardless of concurrent <i>MET</i> amplification, but no concurrent <i>MET</i> exon 14 skipping mutation was permitted in cohorts with <i>MET</i> amplification. Previously treated patients had received systemic antineoplastic therapy for advanced NSCLC. Enrollment in cohort 5a was stopped early because of slow enrollment. Each cohort of the study, except the expansion cohorts, enrolled patients in parallel. Enrollment in cohort 6 was to be initiated only on completion of enrollments in cohort 1a or cohort 4 and included only patients who had received one line of therapy previously. Cohort 7 was added in a protocol amendment (on February 28, 2019); enrollment was ongoing at the data-cutoff date (January 6, 2020). The expansion cohorts allowed further data collection in the specified patient populations. <i>ALK</i> denotes anaplastic lymphoma kinase, and <i>EGFR</i> epidermal growth factor receptor.</div></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f2" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2002787_f2.jpg"><img src="/cms/10.1056/NEJMoa2002787/asset/69aa6840-a5e0-4ba5-ab13-693005a1f5c5/assets/images/large/nejmoa2002787_f2.jpg" height="1674" width="2640" aria-labelledby="f2" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 2</div><div class="fv__item__description"><figcaption><div class="caption">Tumor Responses to Capmatinib.</div><div class="notes"><div role="doc-footnote">Assessments were conducted by an independent review committee whose members were unaware of the cohort assignments. Panel A shows the best percentage change from baseline in the sum of the longest diameters in patients with NSCLC with a <i>MET</i> exon 14 skipping mutation who had measurable disease at baseline and at least one valid postbaseline assessment; the analysis included 60 previously treated patients and 26 patients who had not received treatment previously. The line at 20% corresponds to a change indicating progressive disease; the line at −30% corresponds to a change indicating a partial response. Circles at the end of the bars indicate patients receiving ongoing treatment. Panel B shows the best percentage change from baseline in the sum of the longest diameters in patients with <i>MET</i>-amplified NSCLC (tumor tissue with a gene copy number [GCN] ≥10) who had measurable disease at baseline and at least one valid postbaseline assessment; the analysis included 55 previously treated patients and 14 patients who had not received treatment previously. Panel C shows progression-free survival among patients with NSCLC with a <i>MET</i> exon 14 skipping mutation; the analysis included 69 previously treated patients and 28 patients who had not received treatment previously. Diamonds at the end of the bars indicate censored data because the patient was still followed for efficacy and had not had disease progression or died, triangles indicate censored data because the patient was no longer followed for efficacy and had not had disease progression or died, and squares indicate death. Patients with no symbol at the end of the bar had progressive disease at the data-cutoff date (January 6, 2020). Panel D shows progression-free survival among patients with <i>MET</i>-amplified NSCLC (tumor tissue with a GCN ≥10); the analysis included 69 previously treated patients and 15 patients who had not received treatment previously.</div></div></figcaption></div></div></div><div class="tab__pane fv__list fv__list--tables" id="tab-pane-tables" aria-label="All tables" tabindex="-1" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t1" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 1</div><div class="fv__item__description"><figcaption><div class="caption">Characteristics of the Patients at Baseline.<a href="#fv-t1fn1" role="doc-noteref">*</a></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t2" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 2</div><div class="fv__item__description"><figcaption><div class="caption">Responses to Capmatinib Treatment, as Assessed by the Independent Review Committee.<a href="#fv-t2fn1" role="doc-noteref">*</a></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t3" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 3</div><div class="fv__item__description"><figcaption><div class="caption">Adverse Events, According to Grade, Regardless of Causality, and Exposure to Capmatinib.<a href="#fv-t3fn1" role="doc-noteref">*</a></div></figcaption></div></div></div></div></div></div><div class="references-pop-up fade" aria-hidden="true"><div class="references-pop-up__heading text-dark d-flex align-items-center"><div class="references-pop-up__title flex-grow-1">Reference <span class="references-pop-up__heading-number">1</span></div><a class="references-pop-up__close text-dark" href="#" title="close pop-up" tabindex="-1" aria-hidden="true"><i class="icon-close" aria-hidden="true"></i></a></div><div class="references-pop-up__items citations to-citation__accordion external-links"></div></div></main>
    

</div>

                    
                        



        
        <div class="ng-page_layout ng-page_layout-fullWidth"><div class="container-fluid"><div class="row"><div class="col-12">



        
        




        
        <div class="ng-page_layout-contentSpacing"></div>










    
    
        <div data-widget-def="oneSearchMultiSearch" data-widget-id="778b3ad8-1a8d-43d8-8196-63b03df4a138" data-location="recirc_inIssue_bottom_article">
        



        
        <div class="os-ms os-ms-more-from-issue"><h3 class="ng-subsection-title"><a href="/toc/nejm/383/10" class="ng-subsection-title_link animation-icon-shift"><span class="ng-subsection-title_text">More from Vol. 383 No. 10</span><span class="ng-subsection-title_icon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-longArrowRight"></use></svg></span></span></a></h3><ul class="os-ms-more-from-issue_list"><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Sep 03, 2020</span></li><li data-toggle="tooltip" data-original-title="Video" class="issue-item_meta-item"><span role="img" aria-label="Video" tabindex="0" class="issue-item_video"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#tooltip-video"></use></svg></span></span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2007448" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Weight Loss in Underserved Patients — A Cluster-Randomized Trial</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">P.T. Katzmarzyk and Others</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Sep 03, 2020</span></li><li data-toggle="tooltip" data-original-title="Visual Abstract" class="issue-item_meta-item"><span role="img" aria-label="Visual Abstract" tabindex="0" class="issue-item_visualAbstract"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#tooltip-visual"></use></svg></span></span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa1916945" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Trial of Sodium Phenylbutyrate–Taurursodiol for Amyotrophic Lateral Sclerosis</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">S. Paganoni and Others</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/review-article" class="issue-item_type">Review Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Sep 03, 2020</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMra2005230" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Spectrum of Fibrotic Lung Diseases</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">M. Wijsenbeek and V. Cottin</span></div></div></div></div></div></li></ul></div>

        </div>
    

</div></div></div></div>

                    
                        



        
        <div class="ng-page_layout-bottomAd"><div class="container-fluid"><div class="row"><div class="col-12">









    
    
        <div data-widget-def="literatumAd" data-widget-id="7e022d0d-4a48-44a7-af66-033cf5c13eb8" id="ad-article-bottom-FULLx320-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <!-- START: Circulation Footer 3 -->
<aside class="g-cta-subscribe">
	<style>
.bads_footer-banner24-ONJQNRF1{background:url(/pb-assets/contextual_messaging/footer-yel-background-2x-1513629627453.jpg) center center no-repeat;padding:20px;display:block;margin:0;min-height:inherit;background-size:cover;text-decoration:none!important;color:#1a1a1a;text-align:left}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:42px;line-height:44px;letter-spacing:.2px;margin:0 0 20px;font-family:ff-quadraat-web-pro,sans-serif;font-weight:600}.bads_footer-banner24-ONJQNRF1-inner{max-width:1300px;margin:0 auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions .a-btn{width:130px;padding-left:12px}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{position:static;color:#000;font-size:18px;line-height:27px;border:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:20px 0 20px 0;list-style-type:none;padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login a{color:#0a68ad}.bads_clearfix:after{visibility:hidden;display:block;font-size:0;content:" ";clear:both;height:0}.bads_clearfix{display:block}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{float:left;width:50%;padding:30px 0}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{float:left;padding-left:30px;width:50%}.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{display:block;max-width:100%;height:auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:18px;text-transform:uppercase;line-height:24px;font-weight:600;margin:-15px 0 0;letter-spacing:.2px}@media only screen and (max-width:480px){.bads_footer-banner24-ONJQNRF1-inner .bads_device-img,.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{width:100%;float:none}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{padding-left:0}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:27px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding-top:0;padding-bottom:0}.bads_footer-banner24-ONJQNRF1{height:auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:0 0 12px;list-style-type:none}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{line-height:25px;font-size:15px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1 .bads_device-img{width:280px!important;margin:0 auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 3px;font-size:14px}}@media only screen and (min-width:480px) and (max-width:1024px){.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:30px;margin-bottom:15px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{font-size:14px}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:13px;margin-top:0}}@media only screen and (min-width:1025px) and (max-width:1200px){.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:10px 0}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 5px}}@media only screen and (min-width:1401px){.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{float:right}}
	</style>
	<div class="bads_footer-banner24-ONJQNRF1">
	  <div class="bads_footer-banner24-ONJQNRF1-inner bads_clearfix">
		 <div class="bads_subs-btn">
			<p class="g-cta-subscribe__title">Tap into groundbreaking research and clinically relevant insights</p>
			<ul class="g-cta-subscribe__actions">
				<li class="g-cta-subscribe__actions-primary">
				  <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dsubscribe%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa2002787%26promo%3DONFQNRF1&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2002787&amp;pubId=41288860&amp;placeholderId=101336&amp;productId=1035" class="ng-btn_primary ng-btn_iconRight"><span class="ng-btn_text">Subscribe </span><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#arrows-longArrowRight"></use></svg></span></a>
				</li>
			</ul>
			<p class="g-cta-subscribe__login">Already a subscriber? <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dactivate%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa2002787%26promo%3DONFQANR4&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2002787&amp;pubId=41288860&amp;placeholderId=101336&amp;productId=1035">Activate</a> your online access.</p>
		 </div>

		<div class="bads_device-img">
		   <img src="/sda/127716/footer-devices-2x.png" alt="Devices">
		</div>
	   </div>
	</div>
</aside>
<!--/END: Circulation Footer 3 -->
            
        </div>
    

    

    



        </div>
    

</div></div></div></div>

                    
                        



        
        <footer class="ng-footer footer__top" style="position: relative;"><div data-location="footer" class="ng-footer_columns"><div class="container-fluid"><div class="row"><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">ARTICLE CATEGORIES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item">
        <a href="/browse/nejm-article-category/research" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Research</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/review" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reviews</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/clinical-cases" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Clinical Cases</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/perspective" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Perspective</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/commentary" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Commentary</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/other" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Other</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/medical-article-index" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Browse all Articles</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/toc/nejm/current" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Current Issue</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/loi/nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Issue Index</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">RESOURCES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Authors &amp; Reviewers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Submit a Manuscript</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Subscribers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://tools.ovid.com/ovidtools/nejm.html" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Administrators</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/media" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Media</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/how-to-advertise" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertisers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/information-for-subscription-agents" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Agents</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/permissions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Permissions &amp; Licensing</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/reprints" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reprints</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a>
    </li>
</ul>
</div></div></div><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="About us">ABOUT US</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/about-nejm/about-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">About NEJM</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmgroup.org/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM Group</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Products &amp; Services</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/editors-and-publishers" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Editors &amp; Publishers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/advertising-policies" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertising Policies</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/contact-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text" aria-label="Contact us">Contact Us</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions?#Accessibility" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Accessibility</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">FAQs</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/help" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Help</span></a></li>
    <li class="ng-footer_column-list-item"><a href="mailto:sitefeedback@nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Site Feedback</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">SUBSCRIPTIONS</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Subscribe</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=renew&amp;product=nejm&amp;promo=ONFLNRR3&amp;prc=ONFARN52" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Renew</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=activate&amp;promo=ONFLNAA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Activate Subscription</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC4" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Manage Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=paybill&amp;product=nejm&amp;promo=BNFLPBA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Pay Bill</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.wolterskluwer.com/en/solutions/ovid/nejm-complete-collection" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Sales</span></a></li>    
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/special-content" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Special Content</span></a></li>
</ul>
</div></div></div><div class="col-lg-4 col-md-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">STAY CONNECTED</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/emails?section=NEJM" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Email Alerts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Apps</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Podcasts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">RSS Feed</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/institutional-access" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Remote Access</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="Follow us">FOLLOW US</h4>
<ul class="ng-footer_column-list">
<li class="ng-footer_column-list-item"><a href="https://www.facebook.com/TheNewEnglandJournalofMedicine" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-facebook"></use></svg></span></span><span class="ng-footer_column-link-text">Facebook</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://twitter.com/nejm" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-twitter"></use></svg></span></span><span class="ng-footer_column-link-text">X (formerly Twitter)</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.instagram.com/nejm/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-instagram"></use></svg></span></span><span class="ng-footer_column-link-text">Instagram</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.youtube.com/user/NEJMvideo" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-youtube"></use></svg></span></span><span class="ng-footer_column-link-text">Youtube</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.linkedin.com/company/nejm-group" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-linkedin"></use></svg></span></span><span class="ng-footer_column-link-text">LinkedIn</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://bsky.app/profile/nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-bluesky"></use></svg></span></span><span class="ng-footer_column-link-text">Bluesky</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.tiktok.com/@nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-tiktok"></use></svg></span></span><span class="ng-footer_column-link-text">TikTok</span></a></li>
</ul>
</div></div></div></div></div></div><div data-location="footer" class="ng-footer_journals"><div class="container-fluid"><div class="row"><div class="col-12">



        
        <h4 class="ng-footer_journals-label">JOURNALS</h4>
<ul class="ng-footer_journals-list">
<li class="ng-footer_journals-item"><a href="https://www.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">The New England Journal of Medicine</a></li>
<li class="ng-footer_journals-item"><a href="https://catalyst.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Catalyst Innovations in Care Delivery</a></li>
<li class="ng-footer_journals-item"><a href="https://evidence.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Evidence</a></li>
<li class="ng-footer_journals-item"><a href="https://ai.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM AI</a></li>
</ul>
</div></div></div></div><div data-location="legal" class="ng-footer_bottom"><div class="container-fluid"><div class="row"><div class="col-lg-7 col-md-6 ng-footer_bottom-left">



        
        <p>Copyright © 2025 <a href="https://www.massmed.org/" target="_blank" rel="noopener" class="ng-footer_bottom-link"><b>Massachusetts Medical Society</b></a>. All rights reserved, including those for text and data mining, AI training, and similar technologies. Electronic ISSN 1533-4406. Print ISSN 0028-4793.The content of this site is intended for health care professionals.</p>
</div><div class="col-lg-5 col-md-6 ng-footer_bottom-right">



        
        <style>
  #teconsent a {
    color: #666;
    text-decoration: none;
  }
  #teconsent a:hover {
    color: #666;
    text-decoration: underline;
  }
</style>
<ul class="ng-footer_bottom-list">
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/copyright-information.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Copyright</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/terms-of-use.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Terms</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/privacy-policy.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Privacy Policy</a></li>
<li class="ng-footer_bottom-list-item"><span id="teconsent" consent="undefined" aria-label="Open Cookie Preferences Modal" role="complementary"><a role="link" id="icon-id07788439541325353" tabindex="0" lang="en" aria-haspopup="dialog" aria-label="Cookie Preferences, opens a dedicated popup modal window" class="truste_cursor_pointer">Cookie Preferences</a></span></li>
</ul>
<a href="https://www.nejmgroup.org/" title="NEJM Group" target="_blank" rel="noopener" class="ng-footer_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/logo_group.svg" alt="NEJM Group logo" class="ng-footer_logo" loading="lazy" width="103" height="40"></a>
</div></div></div></div><div data-show-after="400" class="back-to-top back-to-top--align-right  "><button data-snap="footer__top" class="back-to-top__action position-relative p-0 m-0 border-0 d-flex flex-column align-items-center justify-content-center"><svg viewBox="0 0 36 36" class="position-relative"><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" class="back-to-top__action__ring-bg"></path><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" stroke-dasharray="0, 100" class="back-to-top__action__ring"></path></svg><span class="back-to-top__action-icon position-absolute d-flex"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-up"></use></svg></span></span><span class="sr-only">Back to top</span></button></div></footer>

                    
                        



        
        <!-- TrustArc: Banner -->
<div id="consent_blackbar"><style>  #consent_blackbar{    position:relative;    width:100%;    z-index: 999999;  }    #trustarc-banner-overlay {  background-color: rgb(0, 0, 0);   opacity: 0.3;   position: fixed;   z-index: 1000000;   width: 100%;  height: 100%;   top: 0px;   left: 0px;   overflow: hidden;}.truste-title {  /*font-family: "Source Sans Pro", sans-serif;  font-size: 23px;  font-style: normal;  font-stretch: normal;*/  color: #222;  margin-bottom: 20px;  text-align: center;/*  font-weight:bold;*/}.truste-footer {  margin: 0 auto;      }.truste-left {  margin: 0px 0px 15px 15px;/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;    */}.truste-banner { margin: 0 auto; }.truste-messageColumn {/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;*/  color: #666666;  margin: 0px;}#truste-consent-button, #truste-consent-required {    background-color: #FF1E00;    color: #F2F1F1;    padding: 5px 10px;    border: 1px solid #FF1E00;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }      #truste-show-consent {    background-color: #FF1E00;    color: #F2F1F1;    border: 1px solid #FF1E00;    padding: 5px 10px;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }div.truste-consent-track-class {  position: fixed;  z-index:9999999;   background: #666;   border: 1px solid #333;    /*padding: 10px 60px;*/    bottom:0px;    right:0px;    left:0px;    margin: 10px;}.truste-left {  margin: 0;}div.text-content {  display: flex;  flex-direction: column;  align-self: baseline;}#truste-consent-text {    /*font-family: "Source Sans Pro", sans-serif;    font-size: 16px;*/    color: #fff;    margin: 15px 0px;}.truste-footer {  padding-top: 15px;}#truste-consent-content {  margin: 0 auto;    padding: 0 10px;    max-width: 1366px;}.truste-consent-footer {  display: none;}.flex-container {  display: block;  align-items: center;  justify-content: space-between;}#truste-consent-buttons {  float: right;  margin: 10px 5px 10px 0px;}#truste-show-consent { background: #F30 !important;}#truste-consent-button, #truste-consent-required { background: #F30 !important; } /* MEDIA QUERIES */  @media screen and (max-width: 500px) {  #truste-consent-track {    padding: 5px 20px;  }  }@media screen and (max-width: 375px) {  .truste-buttonsColumn {    float: none;    margin: 0;  }  #truste-consent-button, #truste-consent-required, #truste-show-consent {    width: 100%;    margin-bottom: 5px;  }          #truste-consent-buttons {  float: none;  margin: 10px 0px 10px 0px;	}}</style><div id="truste-consent-track" style="display: block; opacity: 1;">  <div id="trustarc-banner-overlay"></div>  <div class="truste-consent-track-class">    <div id="truste-consent-content" class="truste-banner">        <div class="flex-container">          <div class="text-content">            <div id="truste-consent-text" class="truste-messageColumn">This site uses cookies and related technologies, as described in our privacy policy, for purposes that may include site operation, analytics, enhanced user experience, or advertising. You may choose to consent to our use of these technologies, or manage your own preferences.                       </div>          </div>          <div id="truste-consent-buttons" class="truste-buttonsColumn">            <button id="truste-show-consent" aria-haspopup="dialog">Manage Settings</button>      <button id="truste-consent-button">Accept</button>      <!-- <button id="truste-consent-required">Decline All</button> -->          </div>        </div>                <div style="clear:both;"></div>    </div>  </div></div><!--emptycomment--></div>
<!-- /TrustArc: Banner -->

                    
                        



        
        <link rel="stylesheet" href="https://cssjs.nejm.org/mmsWidgets.css"><script nonce="94d6468482d1decb-SJC" type="text/javascript" src="https://cssjs.nejm.org/mmsWidgets.js"></script><script nonce="94d6468482d1decb-SJC" type="text/javascript">var litSSO = {
    "ucid": null,
    "accessToken": null,
    "authState": null
};

var loginUri = '/action/doSsoLogin';
var logoutUri = '/action/doLogout';

displayAuthenticatedMessage();

mmsWidgets.init({
    clientId: 'qsra7g4d6jwdsgn3zbe6udp6r6278mr9',
    origin: 'NEJM',
    xdReceiver: 'http://www.nejm.org/pb-assets/sso/xd.html',
    isFullPageSignIn: isSignInPage(),
    debug: true,

    onReady: function (e) {
        console.log('<<<<<<<<<< client: received onReady event.');
        $("A.litSsoLogin").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0) {
                mmsWidgets.signIn(e);
                return false;
            }
        });
        $("A.litSsoLogout").click(function (e) {
            mmsWidgets.signOut(e);
            return false;
        });
        $("A.litSsoCreate").click(function (e) {
            mmsWidgets.showRegModal(e);
            return false;
        });
        $("A.litSsoSubscribe").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0)
                location.assign(e.currentTarget.href);
            return false;
        });
        if (window.doSSOLogin) {
            window.setTimeout(function () {
                mmsWidgets.signIn();
            }, 500);
        }
        ;
    },
    onLoginSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLoginSuccess event.' + JSON.stringify(e));

        const redirectUrl = getRedirectUri(window.location.search, location.href.replace(window.location.origin, ""));
        document.cookie = "skipSso=; expires=; path=/";
        if (!litSSO.ucid || e.ucid != litSSO.ucid || !litSSO.accessToken || e.accessToken != litSSO.accessToken) {
            location.assign(loginUri + "?ucid=" + e.profile.ucid
                + "&accessToken=" + e.accessToken
                + "&authState=" + e.authState
                + "&email=" + encodeURIComponent(e.profile.email)
                + "&givenNames=" + e.profile.givenName
                + "&surname=" + e.profile.familyName
                + "&redirectUri=" + redirectUrl
                + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                + "&rememberMe=" + e.rememberMe);
        }
    },
    onAuthStateReady: function (e) {
        console.log('<<<<<<<<<< client: received onAuthStateReady event.' + JSON.stringify(e))

        var isMmsSsoAuthenticated = (e.authState && e.authState !== "anonymous" && e.authState !== "lead" && e.ucid && e.accessToken) ? true : false;
        var isLitSsoAuthenticated = (litSSO.ucid && litSSO.accessToken && litSSO.authState) ? true : false;
        console.log('           isMmsSsoAuthenticated=' + isMmsSsoAuthenticated + ', isLitSsoAuthenticated=' + isLitSsoAuthenticated);

        if (isMmsSsoAuthenticated) {
            if (!isLitSsoAuthenticated || litSSO.ucid != e.ucid) {
                if (window.skipSso)
                    document.cookie = "skipSso=" + encodeURIComponent(e.ucid) + "; expires=; path=/";

                if (!window.skipSso && document.cookie.indexOf("skipSso=" + encodeURIComponent(e.ucid)) == -1) {
                    location.assign(loginUri + "?ucid=" + e.profile.ucid
                        + "&accessToken=" + e.accessToken
                        + "&authState=" + e.authState
                        + "&email=" + encodeURIComponent(e.profile.email)
                        + "&givenNames=" + e.profile.givenName
                        + "&surname=" + e.profile.familyName
                        + "&redirectUri=" + location.href.replace(window.location.origin, "")
                        + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                        + "&rememberMe=" + e.rememberMe);
                } else
                    console.log('**** client: Skip SSO ****');
            } else if (e.accessToken !== litSSO.accessToken)
                updateLitSession(e.ucid, e.accessToken);
        } else if (isLitSsoAuthenticated)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));

        if (document.getElementById("ssoerr-ucid"))
            document.getElementById("ssoerr-ucid").innerHTML = e.ucid;

    },
    onRegistrationSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onRegistrationSuccess event.' + JSON.stringify(e))
        document.cookie = "skipSso=; expires=; path=/";
        var uccLastUpdatedDate = '1812-01-01 00:00:00.1 +0000';
        location.assign(loginUri + "?ucid=" + e.profile.ucid
            + "&accessToken=" + e.accessToken
            + "&authState=" + e.authState
            + "&email=" + encodeURIComponent(e.profile.email)
            + "&givenNames=" + e.profile.givenName
            + "&surname=" + e.profile.familyName
            + "&redirectUri=" + location.href.replace(window.location.origin, "")
            + "&uccLastUpdatedDate=" + encodeURIComponent(uccLastUpdatedDate)
            + "&rememberMe=" + e.rememberMe);
    },
    onLogoutSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLogoutSuccess event.' + JSON.stringify(e))

        document.cookie = "skipSso=; expires=; path=/";
        location.assign(logoutUri);
    },
});

function updateLitSession(ucid, accessToken) {
    $.ajax({
        method: "GET",
        url: "/action/doSsoSessionUpdate",
        data: {ucid: ucid, accessToken: accessToken},
        success: function (callData, textStatus) {
            console.log("Session accessToken updated")
            litSSO.accessToken = accessToken
        },
        error: function (jqXHR, textStatus, errorThrown) {
            alert("Your website session has expired and will now be reset.")
            console.log("Session update failed: " + jqXHR.responseText)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));
        }
    });
}

function getRedirectUri(location, fallback) {
    const urlParams = new URLSearchParams(location);
    const uriUrlParam = urlParams.get('uri');
    if (uriUrlParam)
        return encodeURIComponent(uriUrlParam);
    else
        return encodeURIComponent(fallback);
}

function isSignInPage() {
    return document.querySelector('meta[name="pbContext"]').content.indexOf("customPage:string:/sign-in") > -1;
}

function displayAuthenticatedMessage() {
    if (isSignInPage()) {
        var div = document.getElementById('authMsg');
        if ("" === "PersonUser") {
            div.innerHTML += "You are already signed in to " + window.location.origin.replace("https://", "").replace("www.", "") + ". If you would like to sign in with a different email address, please use the form below.";
        } else {
            div.innerHTML = '';
        }
    }
}</script>

                    
                
            </div>
        </div><iframe name="trustarc_notice" id="trustarcNoticeFrame" title="Trustarc Cross-Domain Consent Frame" src="https://consent.trustarc.com/get?name=crossdomain.html&amp;domain=nejm.com" style="display: none;"></iframe><script src="https://consent.trustarc.com/asset/notice.js/v/v1.7-1576" async="async" crossorigin="" importance="high" nonce="94d6468482d1decb-SJC"></script>
        


        
        

            <script src="/products/mms-nextgen/mms/releasedAssets/js/build.lazyload.bundle-c8c4e7d20884f81951fb.js" nonce="94d6468482d1decb-SJC"></script>

        <script src="/products/mms-nextgen/mms/releasedAssets/js/main.bundle-3819a02ec7bc2aca01ec.js" nonce="94d6468482d1decb-SJC"></script>
        


<div id="adModal" tabindex="-1" aria-labelledby="exampleModalCenterTitle" class="ng-modal modal" style="display: none;" aria-hidden="true">
    <div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered ad-promoLayer">
        <div class="ng-modal_content modal-content p-0">
            <div class="ng-modal_body modal-body m-0">
                <div class="ng-modal_header modal-header">
                    <button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#close"></use></svg></span></span>
                    </button>
                </div>

            </div>
        </div>
    </div>
</div>
<script type="text/javascript" src="/wro/1125813~product.js" nonce="94d6468482d1decb-SJC"></script>








<input id="showLayers" type="hidden" value="true">

    <!-- placeholder id=null, description=ad-layer-config -->
    <!-- placeholder id=null, description=ad-lauchLayer-1 -->
    <!-- placeholder id=null, description=ad-layer-promo-1 -->

    <input id="firstAd" type="hidden" value="">
    <input id="secondAd" type="hidden" value="">

    
    
    

    
    
    <input id="IsInstitution" type="hidden" value="false">
    <input id="IsSubscriber" type="hidden" value="true">
    <input id="CustomerId" type="hidden" value="">


<script type="text/javascript" nonce="94d6468482d1decb-SJC">
  jQuery.extend(jQuery.mmsLayers.config, {
    rules: [{
      "name": "Launch Layer Ad",
      "frequency": 30,
      "showOnPage": 5,
      "enabled": false,
      "cookieName": "MarketingLaunchLayer",
      "styleClass": "launchLayer"
    },
    {
      "name": "Promo Layer Ad",
      "frequency": 14,
      "enabled": true,
      "cookieName": "PromoLayer",
      "styleClass": "promoLayer"
    },
    {
      "name": "Interstitial Ad",
      "frequency": 7,
      "enabled": false,
      "cookieName": "InterstitialAd"
    },
    {
      "name": "Iperceptions - Ion Layer Ad",
      "showOnPage": 1,
      "enabled": false,
      "test": false,
      "cookieName":"Iperceptions"
    }]
 });
</script>

















    <script type="text/javascript" nonce="94d6468482d1decb-SJC">
        $(document).ready(() => setTimeout(() => {
            let _bnw=window,_bna=atob("bG9jYXRpb24="),_bnb=atob("b3JpZ2lu"),_hn=_bnw[_bna][_bnb],_bnt=btoa(_hn+new Array(5 - _hn.length % 4).join(" "));
            $.get("/resource/lodash?t="+_bnt);
        },4000));
    </script>












    

    
    

    
    
    
    
        
            
                <script type="text/javascript" src="/wro/1125813~article-metrics.js" nonce="94d6468482d1decb-SJC"></script>
            
            
            
        
    




<script type="text/javascript" src="/wro/1125813~full-text-analytics.js" nonce="94d6468482d1decb-SJC"></script>


    


            <div style="display:none;" id="signInEmbedded" class="ucc-fullpage-signin ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Sign In</h1>
  </div>    
  <div class="capture_signin">
    {* #signInForm *}
    <div class="ucc-form-inner-wrapper">
      {* signInEmailAddress *}
      {* currentPassword *}
      <div style="padding-top:10px;">
          <div class="capture_form_item capture_form_rememberme">
          <label class="ucc-form-checkbox">                
            <input checked="checked" id="ucc-remember-me-cb-embedded" name="ucc-remember-me-cb-embedded" type="checkbox" value="true">
            <span>Remember Me</span>
          </label>                           
          </div>
          <div class="capture_form_item capture_form_forgotpwd">
            <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
          </div>
      </div>
      <div class="capture_form_item">      
        <button id="ucc-sign-in-submit-embedded" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
      </div>
      <div class="capture_form_item capture_form_footer">
        <div class="ucc-no-acct-msg">Don't have an account?</div>
        <div class="ucc-no-acct-msg-2">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
          <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
        </div>
      </div>
      <div class="capture_form_item capture_form_submit">
        
      </div>      
    </div>
    {* /signInForm *}
  </div>
</div><div style="display:none;" id="forgotPassword" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Forgot Password</h1>
  </div>   
  <div class="ucc-form-inner-wrapper">
  <p style="color:black">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
  </div> 
  <div class="capture_forgotpassword">
    {* #forgotPasswordForm *}      
      <div class="ucc-form-inner-wrapper">
        {* forgotPasswordEmailAddress *}
        {* captcha *}
        <div class="capture_form_item" style="padding-top: 20px;">        
          <input id="ucc-widget-forgotpwd-submit" value="Continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
        </div>
      </div>
    {* /forgotPasswordForm *}
  </div>
  </div><div style="display:none;" id="forgotPasswordSuccess" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Create New Password</h1>
  </div>    
  <div class="capture_forgotpassword">
      <div class="ucc-form-inner-wrapper">
        <p style="padding-top: 30px; padding-bottom: 30px;">We've sent an email with instructions to create a new password. Your existing password has not been changed.</p>        
        <div class="capture_form_item">      
          <button class="capture_btn capture_primary capture-full-width-btn" onclick="janrain.capture.ui.modal.close()">CLOSE</button>
        </div>
      </div>
  </div>
  </div><div style="display:none;" id="resetPassword" class="ucc-widgets-nejm-next">
      <div class="row">      
        <div class="col-md-8 col-md-offset-2 reset-pwd-info"><p>To reset your password, enter a new password twice and click the 'Reset Password' button.</p></div>
      </div>
      <div class="col-md-4 col-md-offset-4">
        {* #changePasswordFormNoAuth *}
          {* newPassword *}
          {* newPasswordConfirm *}     
          <div class="capture_form_item">
            <input value="RESET PASSWORD" type="submit" class="capture_btn capture_primary capture-full-width-btn">
          </div>
          {* /changePasswordFormNoAuth *}
      </div>
    </div><div style="display:none;" id="resetPasswordSuccess">
        <div class="reset-pwd-info">
          <div class="reset-pwd-success-welcome"></div>
          <p class="reset-pwd-success-msg">Your password has been reset. You will need to <a href="/signin" onclick="mmsWidgets.signIn(event)">sign in</a> again using your new password to access site content and features.</p>
          <p class="reset-pwd-success-nav"></p>
        </div>      
    </div><div style="display:none;" id="resetPasswordRequestCode" class="ucc-widgets-nejm-next">
        {* #resetPasswordForm *}
        <div class="capture_form_error">The link that you followed to reset your password has expired.</div>
          <div class="col-md-8 col-md-offset-2">
            <p class="reset-pwd-info">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
          </div>
          <div class="col-md-4 col-md-offset-4">
            {* signInEmailAddress *}
            <div class="capture_form_item">
              <input value="continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
            </div>
          </div>
        {* /resetPasswordForm *}
    </div><div style="display:none;" id="resetPasswordRequestCodeSuccess">
      <div class="reset-pwd-info">
        <p>If the address matches an existing account, you will receive an email with instructions to reset your password.</p>
        <p class="reset-pwd-success-nav"></p>
      </div>
  </div><script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'94d646847e23decb',t:'MTc0OTUzMTMxNi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script><iframe height="1" width="1" style="position: absolute; top: 0px; left: 0px; border: none; visibility: hidden;"></iframe><script defer="" src="https://static.cloudflareinsights.com/beacon.min.js/vcd15cbe7772f49c399c6a5babf22c1241717689176015" integrity="sha512-ZpsOmlRQV6y907TI0dKBHq9Md29nnaEIPlkf84rnaERnq6zvWvPUqr2ft8M1aS28oN72PdrCzSjY4U6VaAw1EQ==" data-cf-beacon="{&quot;rayId&quot;:&quot;94d646847e23decb&quot;,&quot;serverTiming&quot;:{&quot;name&quot;:{&quot;cfExtPri&quot;:true,&quot;cfEdge&quot;:true,&quot;cfOrigin&quot;:true,&quot;cfL4&quot;:true,&quot;cfSpeedBrain&quot;:true,&quot;cfCacheStatus&quot;:true}},&quot;version&quot;:&quot;2025.5.0&quot;,&quot;token&quot;:&quot;f55e150c7a5f4a4ab9ef82f4a1c9c43c&quot;}" crossorigin="anonymous"></script>

        
        
    

<div id="addtoany" style="position: static;"><div class="a2a_overlay" id="a2a_overlay"></div><div id="a2a_modal" class="a2a_modal a2a_hide" role="dialog" tabindex="-1" aria-label=""><div class="a2a_modal_body a2a_menu a2a_hide" id="a2a_copy_link"><label for="a2a_copy_link_text" id="a2a_copy_link_icon" class="a2a_svg a2a_s_link a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><title>Copy link</title><path fill="#FFF" d="M7.591 21.177c0-.36.126-.665.377-.917l2.804-2.804a1.235 1.235 0 0 1 .913-.378c.377 0 .7.144.97.43-.026.028-.11.11-.255.25-.144.14-.24.236-.29.29a2.82 2.82 0 0 0-.2.256 1.056 1.056 0 0 0-.177.344 1.43 1.43 0 0 0-.046.37c0 .36.126.666.377.918a1.25 1.25 0 0 0 .918.377c.126.001.251-.015.373-.047.125-.037.242-.096.345-.175.09-.06.176-.127.256-.2.1-.094.196-.19.29-.29.14-.142.223-.23.25-.254.297.28.445.607.445.984 0 .36-.126.664-.377.916l-2.778 2.79a1.242 1.242 0 0 1-.917.364c-.36 0-.665-.118-.917-.35l-1.982-1.97a1.223 1.223 0 0 1-.378-.9l-.001-.004Zm9.477-9.504c0-.36.126-.665.377-.917l2.777-2.79a1.235 1.235 0 0 1 .913-.378c.35 0 .656.12.917.364l1.984 1.968c.254.252.38.553.38.903 0 .36-.126.665-.38.917l-2.802 2.804a1.238 1.238 0 0 1-.916.364c-.377 0-.7-.14-.97-.418.026-.027.11-.11.255-.25a7.5 7.5 0 0 0 .29-.29c.072-.08.139-.166.2-.255.08-.103.14-.22.176-.344.032-.12.048-.245.047-.37 0-.36-.126-.662-.377-.914a1.247 1.247 0 0 0-.917-.377c-.136 0-.26.015-.37.046-.114.03-.23.09-.346.175a3.868 3.868 0 0 0-.256.2c-.054.05-.15.148-.29.29-.14.146-.222.23-.25.258-.294-.278-.442-.606-.442-.983v-.003ZM5.003 21.177c0 1.078.382 1.99 1.146 2.736l1.982 1.968c.745.75 1.658 1.12 2.736 1.12 1.087 0 2.004-.38 2.75-1.143l2.777-2.79c.75-.747 1.12-1.66 1.12-2.737 0-1.106-.392-2.046-1.183-2.818l1.186-1.185c.774.79 1.708 1.186 2.805 1.186 1.078 0 1.995-.376 2.75-1.13l2.803-2.81c.751-.754 1.128-1.671 1.128-2.748 0-1.08-.382-1.993-1.146-2.738L23.875 6.12C23.13 5.372 22.218 5 21.139 5c-1.087 0-2.004.382-2.75 1.146l-2.777 2.79c-.75.747-1.12 1.66-1.12 2.737 0 1.105.392 2.045 1.183 2.817l-1.186 1.186c-.774-.79-1.708-1.186-2.805-1.186-1.078 0-1.995.377-2.75 1.132L6.13 18.426c-.754.755-1.13 1.672-1.13 2.75l.003.001Z"></path></svg></label><input id="a2a_copy_link_text" type="text" title="Copy link" readonly=""><div id="a2a_copy_link_copied">✓</div></div><div class="a2a_modal_body a2a_menu a2a_thanks a2a_hide" id="a2a_thanks"><div class="a2a_localize" data-a2a-localize="inner,ThanksForSharing">Thanks for sharing!</div></div></div><div class="a2a_menu a2a_full a2a_localize" id="a2apage_full" role="dialog" tabindex="-1" aria-label="Share" data-a2a-localize="title,Share"><div class="a2a_full_header"><div id="a2apage_find_container" class="a2a_menu_find_container"><label for="a2apage_find" id="a2apage_find_icon" class="a2a_svg a2a_s_find"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" aria-hidden="true"><title>Find any service</title><path fill="#CCC" d="M19.7 18.2l-4.5-4.5c.7-1.1 1.2-2.3 1.2-3.6 0-3.5-2.8-6.3-6.3-6.3s-6.3 2.8-6.3 6.3 2.8 6.3 6.3 6.3c1.4 0 2.6-.4 3.6-1.2l4.5 4.5c.6.6 1.3.7 1.7.2.5-.4.4-1.1-.2-1.7zm-9.6-3.6c-2.5 0-4.5-2.1-4.5-4.5 0-2.5 2.1-4.5 4.5-4.5 2.5 0 4.5 2.1 4.5 4.5s-2 4.5-4.5 4.5z"></path></svg></label><input id="a2apage_find" class="a2a_menu_find a2a_localize" type="text" autocomplete="off" title="Find any service" data-a2a-localize="title,FindAnyServiceToAddTo"></div></div><div class="a2a_full_services" id="a2apage_full_services" role="presentation"></div><div class="a2a_full_footer"><a href="https://www.addtoany.com" title="Share Buttons" rel="noopener" target="_blank"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span>AddToAny</a></div></div><div id="a2apage_dropdown" class="a2a_menu a2a_mini a2a_localize a2a_hide" tabindex="-1" aria-label="Share" data-a2a-localize="label,Share"><div class="a2a_mini_services" id="a2apage_mini_services"></div><div id="a2apage_cols_container" class="a2a_cols_container"><div class="a2a_col1" id="a2apage_col1"></div><div id="a2apage_2_col1" class="a2a_hide"></div><div class="a2a_clear"></div></div><div class="a2apage_wide a2a_wide"><a href="#addtoany" id="a2apage_show_more_less" class="a2a_more a2a_localize" title="Show all" data-a2a-localize="title,ShowAll"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span><span class="a2a_localize" data-a2a-localize="inner,More">More…</span></a></div></div><div style="height: 1px; width: 1px; position: absolute; z-index: 100000; top: 0px; visibility: hidden;"><iframe id="a2a_sm_ifr" title="AddToAny Utility Frame" aria-hidden="true" src="https://static.addtoany.com/menu/sm.25.html#type=core&amp;event=load" style="height: 1px; width: 1px; border: 0px; left: 0px; top: 0px; position: absolute; z-index: 100000; display: none;"></iframe></div></div><akb-xfbqutvuueco></akb-xfbqutvuueco><div role="status" aria-live="assertive" aria-relevant="additions" class="ui-helper-hidden-accessible"></div><div id="janrainEngageEmbed" style="display: none;"><div class="janrainContent" style="width: 380px !important; height: 156px !important; padding-left: 5px !important; padding-right: 5px !important; box-sizing: content-box !important; background-color: rgb(255, 255, 255) !important; border: 1px solid rgb(192, 192, 192) !important; border-radius: 10px !important; overflow: hidden !important; position: relative !important;"><div id="janrainView"><div class="janrainHeader" style="background-color: rgb(255, 255, 255) !important; font-size: 14px !important; color: rgb(102, 102, 102) !important; position: relative !important; height: 20px !important; left: -5px !important; padding: 5px 5px 0px !important; white-space: nowrap !important; width: 380px !important; z-index: 100 !important; border-radius: 10px 10px 0px 0px !important; text-align: left !important;"><div style="padding-left: 1px !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important;">Sign in using your account with</div></div><div id="janrainProviderPages" style="padding-top: 5px; left: 5px; position: absolute;"><div class="janrainPage" pageindex="0"><ul class="providers" id="janrainProviders_0" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-aol" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="1" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-aol" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-aol" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">AOL</span></a></li><li id="janrain-openid" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="3" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-openid" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-openid" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">OpenID</span></a></li></ul><ul class="providers" id="janrainProviders_1" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-yahoo" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="2" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-yahoo" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-yahoo" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">Yahoo!</span></a></li></ul></div></div><div style="background-color: rgb(255, 255, 255) !important; width: 380px !important; height: 10px !important; position: absolute !important; left: 0px !important; padding-left: 5px !important; padding-right: 5px !important; padding-bottom: 5px !important; bottom: 0px !important; font-size: 10px !important; text-align: left !important; color: rgb(102, 102, 102) !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; border-radius: 0px 0px 10px 10px !important;"><div style="padding-left: 1px !important;"><a href="http://janrain.com/products/engage/social-login?utm_source=mms.rpxnow.com&amp;utm_medium=Partner&amp;utm_campaign=attribution" target="_blank">Social Login by Janrain</a></div></div></div></div></div><iframe name="captureIFrame_hdutjvs1li3fij389f528mlhhkhh8g16bkapde40" data-transactionid="hdutjvs1li3fij389f528mlhhkhh8g16bkapde40" id="captureIFrame_hdutjvs1li3fij389f528mlhhkhh8g16bkapde40" src="about:blank" class="" data-captureiframeloadeventbound="yes" style="display: none;"></iframe><div id="janrainModalOverlay" style="inset: 0px; position: fixed; background-color: rgb(0, 0, 0); opacity: 0.4; display: none; z-index: 1000;"></div><div id="janrainModal" style="width: 380px; height: 131px; position: absolute; z-index: 1000; display: none;"><a href="#" class="janrain_modal_closebutton" style="position: absolute; cursor: pointer; z-index: 1000;">X</a><div style="display: block;" id="signIn" class="ucc-widgets-nejm-next janrain-capture-ui capture-ui-content capture_screen_container" data-capturescreenname="signIn" data-captureventadded="true">
    <div class="capture_header">
      <h1>Sign In</h1>
    </div>    
    <div class="capture_signin">
      <form id="capture_signIn_signInForm" name="signInForm" data-capturefield="signInForm" action="https://mms.us.janraincapture.com/widget/traditional_signin.jsonp" class="capture_form capture_signInForm" method="POST" novalidate="novalidate" data-transactionid="hdutjvs1li3fij389f528mlhhkhh8g16bkapde40" target="captureIFrame_hdutjvs1li3fij389f528mlhhkhh8g16bkapde40" accept-charset="UTF-8" next="{&quot;noop&quot;:&quot;&quot;}"><div id="capture_signIn_signInForm_defaultSavedProfileMessage"></div><div id="capture_signIn_signInForm_errorMessages"></div><input id="capture_signIn_utf8" data-capturefield="undefined" value="✓" type="hidden" class="capture_utf8" name="utf8"><input id="capture_signIn_screen_hdutjvs1li3fij389f528mlhhkhh8g16bkapde40" data-capturefield="undefined" value="signIn" type="hidden" class="capture_screen_hdutjvs1li3fij389f528mlhhkhh8g16bkapde40" name="capture_screen"><input id="capture_signIn_js_version_hdutjvs1li3fij389f528mlhhkhh8g16bkapde40" data-capturefield="undefined" value="d445bf4" type="hidden" class="capture_js_version_hdutjvs1li3fij389f528mlhhkhh8g16bkapde40" name="js_version"><input id="capture_signIn_transactionId_hdutjvs1li3fij389f528mlhhkhh8g16bkapde40" data-capturefield="undefined" value="hdutjvs1li3fij389f528mlhhkhh8g16bkapde40" type="hidden" class="capture_transactionId_hdutjvs1li3fij389f528mlhhkhh8g16bkapde40" name="capture_transactionId"><input id="capture_signIn_form_hdutjvs1li3fij389f528mlhhkhh8g16bkapde40" data-capturefield="undefined" value="signInForm" type="hidden" class="capture_form_hdutjvs1li3fij389f528mlhhkhh8g16bkapde40" name="form"><input id="capture_signIn_flow_hdutjvs1li3fij389f528mlhhkhh8g16bkapde40" data-capturefield="undefined" value="standard" type="hidden" class="capture_flow_hdutjvs1li3fij389f528mlhhkhh8g16bkapde40" name="flow"><input id="capture_signIn_client_id_hdutjvs1li3fij389f528mlhhkhh8g16bkapde40" data-capturefield="undefined" value="qsra7g4d6jwdsgn3zbe6udp6r6278mr9" type="hidden" class="capture_client_id_hdutjvs1li3fij389f528mlhhkhh8g16bkapde40" name="client_id"><input id="capture_signIn_redirect_uri_hdutjvs1li3fij389f528mlhhkhh8g16bkapde40" data-capturefield="undefined" value="https://www.nejm.org" type="hidden" class="capture_redirect_uri_hdutjvs1li3fij389f528mlhhkhh8g16bkapde40" name="redirect_uri"><input id="capture_signIn_response_type_hdutjvs1li3fij389f528mlhhkhh8g16bkapde40" data-capturefield="undefined" value="code" type="hidden" class="capture_response_type_hdutjvs1li3fij389f528mlhhkhh8g16bkapde40" name="response_type"><input id="capture_signIn_flow_version_hdutjvs1li3fij389f528mlhhkhh8g16bkapde40" data-capturefield="undefined" value="20240514181256512029" type="hidden" class="capture_flow_version_hdutjvs1li3fij389f528mlhhkhh8g16bkapde40" name="flow_version"><input id="capture_signIn_settings_version_hdutjvs1li3fij389f528mlhhkhh8g16bkapde40" data-capturefield="undefined" value="" type="hidden" class="capture_settings_version_hdutjvs1li3fij389f528mlhhkhh8g16bkapde40" name="settings_version"><input id="capture_signIn_locale_hdutjvs1li3fij389f528mlhhkhh8g16bkapde40" data-capturefield="undefined" value="en-US" type="hidden" class="capture_locale_hdutjvs1li3fij389f528mlhhkhh8g16bkapde40" name="locale"><input id="capture_signIn_recaptcha_version_hdutjvs1li3fij389f528mlhhkhh8g16bkapde40" data-capturefield="undefined" value="2" type="hidden" class="capture_recaptcha_version_hdutjvs1li3fij389f528mlhhkhh8g16bkapde40" name="recaptchaVersion">
      <div class="ucc-form-inner-wrapper">
        <div id="capture_signIn_form_item_signInEmailAddress" class="capture_form_item capture_email capture_form_item_signInEmailAddress" data-capturefield="undefined"><label for="capture_signIn_signInEmailAddress">Email Address</label><input id="capture_signIn_signInEmailAddress" data-capturefield="signInEmailAddress" value="" type="email" class="capture_signInEmailAddress capture_required capture_text_input" placeholder="Email Address" name="signInEmailAddress"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="signInEmailAddress">Validating</div><div class="capture_tip_error" data-elementname="signInEmailAddress"></div></div>
        <div id="capture_signIn_form_item_currentPassword" class="capture_form_item capture_password capture_form_item_currentPassword" data-capturefield="undefined"><label for="capture_signIn_currentPassword">Password</label><input id="capture_signIn_currentPassword" data-capturefield="currentPassword" value="" type="password" class="capture_currentPassword capture_required capture_text_input" placeholder="Password" name="currentPassword"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="currentPassword">Validating</div><div class="capture_tip_error" data-elementname="currentPassword"></div></div>
        <div style="padding-top:10px;">
            <div class="capture_form_item capture_form_rememberme">
                <label class="ucc-form-checkbox">                
                    <input checked="checked" id="ucc-remember-me-cb" name="ucc-remember-me-cb" type="checkbox" value="true">
                    <span>Remember Me</span>
                </label>          
            </div>
            <div class="capture_form_item capture_form_forgotpwd">
              <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
            </div>
        </div>
        <div class="capture_form_item">
          <button id="ucc-sign-in-submit" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
        </div>
       
        <div class="capture_form_item">
          <div class="ucc-no-acct-msg">Don't have an account?</div>
          <div class="ucc-no-acct-msg-2" id="signInModalCreateAccountLink">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

          <div class="ucc-no-acct-msg-2" id="signInModalCloseLink" style="display:none">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

        </div>
     
        <div class="capture_form_item capture_form_submit">
          
        </div>      
      </div>
      </form>
    </div>
  </div></div><script type="text/javascript" src="https://api.altmetric.com/v1/internal-556fdf0f/doi/10.1056/nejmoa2002787?callback=_altmetric.embed_callback&amp;domain=www.nejm.org&amp;cache_until=1-10"></script></body></html>